SMILES,Conditions,Name,NCT_Number,Phases,Status,Gender,Age,Funded Bys,Study Designs,Locations,Patent_id,CPC,Gender_code_0,Gender_code_1,Gender_code_2,Gender_code_3,Age_code_0,Age_code_1,Age_code_2,Age_code_3,Age_code_4,Age_code_5,Allocation_Type_0,Allocation_Type_1,Allocation_Type_2,Allocation_Type_3,Intervention_Model_0,Intervention_Model_1,Intervention_Model_2,Intervention_Model_3,Intervention_Model_4,Intervention_Model_5,Country_0,Country_1,Country_2,Country_3,Country_4,Country_5,Funder_Type_0,Funder_Type_1,Funder_Type_2,Funder_Type_3,Funder_Type_4,Funder_Type_5,claims_#,Duration,Patent_#,PCT_code_0,PCT_code_1,CPC_code_0,CPC_code_2,CPC_code_3,CPC_code_4,CPC_code_5,PCT_code_2,CPC_code_1,logP,MW,PSA,HBA,HBD,Rings,Polarizability,Refractivity,Bond_#,Bioavailability_0,Bioavailability_1,Bioavailability_2,ECFP4.1,ECFP4.2,ECFP4.3,ECFP4.4,ECFP4.5,ECFP4.6,ECFP4.7,ECFP4.8,ECFP4.9,ECFP4.10,ECFP4.11,ECFP4.12,ECFP4.13,ECFP4.14,ECFP4.15,ECFP4.16,ECFP4.17,ECFP4.18,ECFP4.19,ECFP4.20,ECFP4.21,ECFP4.22,ECFP4.23,ECFP4.24,ECFP4.25,ECFP4.26,ECFP4.27,ECFP4.28,ECFP4.29,ECFP4.30,ECFP4.31,ECFP4.32,ECFP4.33,ECFP4.34,ECFP4.35,ECFP4.36,ECFP4.37,ECFP4.38,ECFP4.39,ECFP4.40,ECFP4.41,ECFP4.42,ECFP4.43,ECFP4.44,ECFP4.45,ECFP4.46,ECFP4.47,ECFP4.48,ECFP4.49,ECFP4.50,ECFP4.51,ECFP4.52,ECFP4.53,ECFP4.54,ECFP4.55,ECFP4.56,ECFP4.57,ECFP4.58,ECFP4.59,ECFP4.60,ECFP4.61,ECFP4.62,ECFP4.63,ECFP4.64,ECFP4.65,ECFP4.66,ECFP4.67,ECFP4.68,ECFP4.69,ECFP4.70,ECFP4.71,ECFP4.72,ECFP4.73,ECFP4.74,ECFP4.75,ECFP4.76,ECFP4.77,ECFP4.78,ECFP4.79,ECFP4.80,ECFP4.81,ECFP4.82,ECFP4.83,ECFP4.84,ECFP4.85,ECFP4.86,ECFP4.87,ECFP4.88,ECFP4.89,ECFP4.90,ECFP4.91,ECFP4.92,ECFP4.93,ECFP4.94,ECFP4.95,ECFP4.96,ECFP4.97,ECFP4.98,ECFP4.99,ECFP4.100,ECFP4.101,ECFP4.102,ECFP4.103,ECFP4.104,ECFP4.105,ECFP4.106,ECFP4.107,ECFP4.108,ECFP4.109,ECFP4.110,ECFP4.111,ECFP4.112,ECFP4.113,ECFP4.114,ECFP4.115,ECFP4.116,ECFP4.117,ECFP4.118,ECFP4.119,ECFP4.120,ECFP4.121,ECFP4.122,ECFP4.123,ECFP4.124,ECFP4.125,ECFP4.126,ECFP4.127,ECFP4.128
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,NEOPLASMS,_DOCETAXEL,NCT03693612,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada",4814470,C07D305/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,NEOPLASMS,_PACLITAXEL,NCT03693612,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,SOFT TISSUE SARCOMA,_DOCETAXEL,NCT03449901,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Medicine, Palo Alto, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States",4814470,C07D305/14,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,SOFT TISSUE SARCOMA,_GEMCITABINE,NCT03449901,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Medicine, Palo Alto, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
N=C(N)NCCC[C@H](N)C(=O)O,SOFT TISSUE SARCOMA,_ARGININE,NCT03449901,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Medicine, Palo Alto, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States",4271152.0,C07K14/672,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,PNEUMONIA,_METHYLPREDNISOLONE,NCT03852537,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Mayo Clinic in Rochester, Rochester, Minnesota, United States",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)N[C@@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@@H](CO)[C@@H](O)[C@@H]1O,CYSTIC FIBROSIS,_TEICOPLANIN,NCT04176328,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centro Ricerche Cliniche di Verona - Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0
CC(C)NCC(O)COc1cccc2ccccc12,OBSTRUCTIVE SLEEP APNEA,_PROPRANOLOL,NCT03049306,Phase 2,Enrolling by invitation,All,"20 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States",6500454,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,25.0,14.8832624899895,1234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,259.3434,41.49,3.0,2.0,2.0,29.98,76.83,6.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,OBSTRUCTIVE SLEEP APNEA,_MELATONIN,NCT02484300,Not Applicable,Recruiting,Male,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","University of California, San Diego, San Diego, California, United States",4309415,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,37.0,32.854884083862,1835.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.42,232.2783,54.12,2.0,2.0,2.0,25.65,66.28,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,CYSTIC FIBROSIS,_TRIMETHOPRIM,NCT03489629,Phase 2,Recruiting,All,"2 Years to 45 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Jewish Health, Denver, Colorado, United States|Indiana University, Indianapolis, Indiana, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|N.C. Memorial Hospital and N.C. Children's Hospital, Chapel Hill, North Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|University of Washington Medical Center and Seattle Children's, Seattle, Washington, United States",5763449.0,5,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,22.045627220271395,888.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.26,290.3177,105.51,7.0,2.0,2.0,29.71,81.51,5.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,CYSTIC FIBROSIS,_MINOCYCLINE,NCT03489629,Phase 2,Recruiting,All,"2 Years to 45 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Jewish Health, Denver, Colorado, United States|Indiana University, Indianapolis, Indiana, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|N.C. Memorial Hospital and N.C. Children's Hospital, Chapel Hill, North Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|University of Washington Medical Center and Seattle Children's, Seattle, Washington, United States",5908838,6,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,15.3432308671635,351.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.03,457.4764,164.63,9.0,5.0,4.0,45.9,122.54,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O,CYSTIC FIBROSIS,_MUPIROCIN,NCT03489629,Phase 2,Recruiting,All,"2 Years to 45 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Jewish Health, Denver, Colorado, United States|Indiana University, Indianapolis, Indiana, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|N.C. Memorial Hospital and N.C. Children's Hospital, Chapel Hill, North Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|University of Washington Medical Center and Seattle Children's, Seattle, Washington, United States",6013657.0,3,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,18.135896014291802,384.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.25,500.6222,146.05,8.0,4.0,2.0,55.5,129.39,17.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,CYSTIC FIBROSIS,_CHLORHEXIDINE,NCT03489629,Phase 2,Recruiting,All,"2 Years to 45 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Jewish Health, Denver, Colorado, United States|Indiana University, Indianapolis, Indiana, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|N.C. Memorial Hospital and N.C. Children's Hospital, Chapel Hill, North Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|University of Washington Medical Center and Seattle Children's, Seattle, Washington, United States",5538353,A45D34/04,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,CYSTIC FIBROSIS,_CHLORHEXIDINE_GLUCONATE,NCT03489629,Phase 2,Recruiting,All,"2 Years to 45 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Jewish Health, Denver, Colorado, United States|Indiana University, Indianapolis, Indiana, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|N.C. Memorial Hospital and N.C. Children's Hospital, Chapel Hill, North Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|University of Washington Medical Center and Seattle Children's, Seattle, Washington, United States",4199567,1,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,15.6389248239183,476.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,CYSTIC FIBROSIS,_SULFAMETHOXAZOLE,NCT03489629,Phase 2,Recruiting,All,"2 Years to 45 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Jewish Health, Denver, Colorado, United States|Indiana University, Indianapolis, Indiana, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|N.C. Memorial Hospital and N.C. Children's Hospital, Chapel Hill, North Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|University of Washington Medical Center and Seattle Children's, Seattle, Washington, United States",3983209,A61L15/64,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,20.008624407072002,118.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.79,253.278,98.22,4.0,2.0,2.0,24.99,64.5,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,PNEUMONIA,_CIPROFLOXACIN,NCT03177720,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Medical University of Vienna, Vienna, Austria",5286754,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,PNEUMONIA,_IMIPENEM,NCT03177720,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Medical University of Vienna, Vienna, Austria",8487093,C07D471/08,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,53.980574549785395,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.19,299.346,116.22,6.0,3.0,2.0,31.1,75.84,6.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,CYSTIC FIBROSIS,_SILDENAFIL,NCT04039087,Phase 2|Phase 3,Recruiting,All,"9 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","National Jewish Health, Denver, Colorado, United States|Augusta University, Augusta, Georgia, United States",5250534.0,C07D487/04,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,ASTHMA,_ROFLUMILAST,NCT04108377,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UC Davis, Sacramento, California, United States",5712298,C07C235/56,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,25.298260744573803,549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.47,403.207,60.45,4.0,1.0,3.0,35.9,93.92,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,_LEVOFLOXACIN,NCT02067780,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Emergency department of university hospital Fattouma Bourguiba of Monastir, Monastir, Tunisia",5053407,C07D413/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1,CYSTIC FIBROSIS,_CEPHALEXIN,NCT04553419,Phase 3,Recruiting,All,3 Years to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BC Children's Hospital, Vancouver, British Columbia, Canada",3931404,5,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,7.0,25.0682765559867,1218.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.55,347.389,112.73,5.0,3.0,3.0,32.52,88.97,4.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,NEOPLASMS,_CRIZOTINIB,NCT03194893,Phase 3,Recruiting,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chao Family Comprehensive Cancer Center; UC Irvine Medical Center, Orange, California, United States|Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Centre Francois Baclesse, Caen, France|Centre Georges François Leclerc; Service Pharmacie, Bp 77980, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Groupe Hospitalier Sud - Hôpital Haut Lévêque, Pessac, France|Hopital Pontchaillou - CHU de Rennes, Rennes, France|CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse cedex 9, France|Hopital Robert Schuman; Pneumologie, Vantoux, France|Queen Mary Hospital; Dept. of Clinical Oncology, Hong Kong, Hong Kong|Queen Elizabeth Hospital Department of Clinical Oncology, Kowloon, Hong Kong|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini - Unità Operativa Complessa di Pneumologia Oncologica 1, Roma, Lazio, Italy|Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia, Milano, Lombardia, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdańsk, Poland|University сlinic of headaches, Moscow, Moskovskaja Oblast, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Russian Federation|City Clinical Oncology Hospital, Moscow, Russian Federation|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Universitari Dexeus - Grupo Quironsalud; Servicio de Oncologia Medica, Barcelona, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Adana Acıbadem Hospital Oncology Department, Adana, Turkey|Istanbul Uni Capa Medical Faculty; Inst. of Oncology, Istanbul, Turkey|Ege University Medical Faculty; Chest Diseases, Izmir, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey",7230098,C07D413/12,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,39.49157066880221,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.82,450.337,77.99,5.0,2.0,4.0,45.44,128.43,5.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,NEOPLASMS,_ALECTINIB,NCT03194893,Phase 3,Recruiting,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chao Family Comprehensive Cancer Center; UC Irvine Medical Center, Orange, California, United States|Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Centre Francois Baclesse, Caen, France|Centre Georges François Leclerc; Service Pharmacie, Bp 77980, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Groupe Hospitalier Sud - Hôpital Haut Lévêque, Pessac, France|Hopital Pontchaillou - CHU de Rennes, Rennes, France|CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse cedex 9, France|Hopital Robert Schuman; Pneumologie, Vantoux, France|Queen Mary Hospital; Dept. of Clinical Oncology, Hong Kong, Hong Kong|Queen Elizabeth Hospital Department of Clinical Oncology, Kowloon, Hong Kong|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini - Unità Operativa Complessa di Pneumologia Oncologica 1, Roma, Lazio, Italy|Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia, Milano, Lombardia, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdańsk, Poland|University сlinic of headaches, Moscow, Moskovskaja Oblast, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Russian Federation|City Clinical Oncology Hospital, Moscow, Russian Federation|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Universitari Dexeus - Grupo Quironsalud; Servicio de Oncologia Medica, Barcelona, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Adana Acıbadem Hospital Oncology Department, Adana, Turkey|Istanbul Uni Capa Medical Faculty; Inst. of Oncology, Istanbul, Turkey|Ege University Medical Faculty; Chest Diseases, Izmir, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey",9126931,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,29.0,62.9828127887636,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.59,482.6166,72.36,5.0,1.0,6.0,56.56,155.11,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,PHARMACOKINETICS,_FLUTICASONE,NCT03739294,Phase 2,Recruiting,All,18 Years to 39 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Respiratory research unit, Bispebjerg University Hospital, Copenhagen, Denmark",5049389,5,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,PHARMACOKINETICS,_FLUTICASONE_FUROATE,NCT03739294,Phase 2,Recruiting,All,18 Years to 39 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Respiratory research unit, Bispebjerg University Hospital, Copenhagen, Denmark",5873360,A61M15/0043,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O,PHARMACOKINETICS,_VILANTEROL,NCT03739294,Phase 2,Recruiting,All,18 Years to 39 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Respiratory research unit, Bispebjerg University Hospital, Copenhagen, Denmark",5873360,A61M15/0043,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,44.61693258588471,29.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.39,486.43,91.18,6.0,4.0,2.0,53.67,129.09,16.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
OC[C@H]1O[C@H](O[C@]2(CO[C@]3(CO[C@]4(CO[C@]5(CO[C@]6(CO[C@]7(CO[C@]8(CO[C@]9(CO[C@]%10(CO[C@]%11(CO[C@]%12(CO[C@]%13(CO[C@]%14(CO[C@]%15(CO[C@]%16(CO[C@]%17(CO[C@]%18(CO[C@]%19(CO[C@]%20(CO[C@]%21(CO[C@]%22(CO[C@]%23(CO[C@]%24(CO[C@]%25(CO[C@]%26(CO[C@]%27(CO[C@]%28(CO[C@]%29(CO[C@]%30(CO[C@]%31(CO[C@]%32(CO[C@]%33(CO[C@]%34(CO[C@]%35(CO[C@]%36(CO[C@]%37(CO[C@]%38(CO)O[C@H](CO)[C@@H](O)[C@@H]%38O)O[C@H](CO)[C@@H](O)[C@@H]%37O)O[C@H](CO)[C@@H](O)[C@@H]%36O)O[C@H](CO)[C@@H](O)[C@@H]%35O)O[C@H](CO)[C@@H](O)[C@@H]%34O)O[C@H](CO)[C@@H](O)[C@@H]%33O)O[C@H](CO)[C@@H](O)[C@@H]%32O)O[C@H](CO)[C@@H](O)[C@@H]%31O)O[C@H](CO)[C@@H](O)[C@@H]%30O)O[C@H](CO)[C@@H](O)[C@@H]%29O)O[C@H](CO)[C@@H](O)[C@@H]%28O)O[C@H](CO)[C@@H](O)[C@@H]%27O)O[C@H](CO)[C@@H](O)[C@@H]%26O)O[C@H](CO)[C@@H](O)[C@@H]%25O)O[C@H](CO)[C@@H](O)[C@@H]%24O)O[C@H](CO)[C@@H](O)[C@@H]%23O)O[C@H](CO)[C@@H](O)[C@@H]%22O)O[C@H](CO)[C@@H](O)[C@@H]%21O)O[C@H](CO)[C@@H](O)[C@@H]%20O)O[C@H](CO)[C@@H](O)[C@@H]%19O)O[C@H](CO)[C@@H](O)[C@@H]%18O)O[C@H](CO)[C@@H](O)[C@@H]%17O)O[C@H](CO)[C@@H](O)[C@@H]%16O)O[C@H](CO)[C@@H](O)[C@@H]%15O)O[C@H](CO)[C@@H](O)[C@@H]%14O)O[C@H](CO)[C@@H](O)[C@@H]%13O)O[C@H](CO)[C@@H](O)[C@@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,_INULIN,NCT04459156,Not Applicable,Recruiting,All,"45 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","Texas A&M University-CTRAL, College Station, Texas, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-62.0,6179.3581,3038.93,191.0,116.0,38.0,44.7137,1251.4,149.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
NCCS.O=C(O)C(O)C(O)C(=O)O,ASTHMA,_CYSTEAMINE_BITARTRATE,NCT03883984,Phase 1,Recruiting,All,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",WO-2013062544-A1,1,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,22.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,_QUERCETIN,NCT03989271,Phase 1|Phase 2,Recruiting,All,"40 Years to 80 Years   (Adult, Older Adult)",Other|NIH|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nathaniel Marchetti, Philadelphia, Pennsylvania, United States",4211772,C07H17/07,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,9.0,25.232550976406003,3241.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.81,302.2357,127.45,7.0,5.0,3.0,28.54,76.86,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,OBSTRUCTIVE SLEEP APNEA,_BIA,NCT02666781,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"Toronto Western Hospital- UHN, Toronto, Ontario, Canada",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,3.7,439.3851,109.83,7.0,2.0,3.0,41.6,108.4,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
CCCCCCCC/C=C/CCCCCCCC(=O)O,CYSTIC FIBROSIS,_OLEIC_ACID,NCT04531410,Not Applicable,Enrolling by invitation,All,5 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Università degli Studi di Milan, Milan, Italy|Norwegian Resourse Center for Cystic Fibrosis, Oslo University Hospital, Oslo, Norway|Poznan University of Medical Sciences, Poznań, Poland",3937674,C09D11/108,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,28.0,40.7072013799051,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.68,282.4614,37.3,2.0,1.0,0.0,37.64,87.4,15.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,CYSTIC FIBROSIS,_LINOLEIC_ACID,NCT04531410,Not Applicable,Enrolling by invitation,All,5 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Università degli Studi di Milan, Milan, Italy|Norwegian Resourse Center for Cystic Fibrosis, Oslo University Hospital, Oslo, Norway|Poznan University of Medical Sciences, Poznań, Poland",3932476,C07C231/02,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,30.3907677775724,10757.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.06,280.4455,37.3,2.0,1.0,0.0,35.86,88.52,14.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
C[C@@H](N)[C@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]2O[C@H]([C@@H](C)O)[C@@H](O)[C@H](O)[C@H]2N)[C@H](O)[C@@H]1O,CYSTIC FIBROSIS,_ELX-02,NCT04135495,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Long Beach Memorial, Long Beach, California, United States|Stanford School of Medicine, Palo Alto, California, United States|National Jewish Health, Denver, Colorado, United States|Johns Hopkins, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-2.5,482.531,262.38,14.0,10.0,3.0,48.09,109.01,6.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,COVID-19,_PREDNISONE,NCT04451174,Phase 3,Recruiting,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Hospital Santiago Oriente, Santiago, Peñalolen, Chile",6488960,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,COVID-19,_METHYLPREDNISOLONE,NCT04329650,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitari Mútua de Terrassa, Terrassa, Spain",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,COVID-19 PNEUMONIA,_METHYLPREDNISOLONE,NCT04438980,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Sant Joan Despí Moisès Broggi, Sant Joan Despí, Barcelona, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,PNEUMONIA VENTILATOR ASSOCIATED,_AMIKACIN,NCT03149640,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Service de Réanimation Chirurgicale, Angers, France|Service de Réanimation Médicale - CH d'Angoulême, Angoulême, France|Service de Réanimation Polyvalente, Argenteuil, France|Service de Réanimation - CH Beauvais, Beauvais, France|Service de Réanimation Médicale - Hôpital Louis Mourier, Colombes, France|Service de Réanimation, Dijon, France|Service de Réanimation Médicale - CHD Les Oudairies, La Roche-sur-Yon, France|Service de Réanimation, Le Mans, France|Service de Réanimation Médicale - Hôpital La Croix-Rousse, Lyon, France|Service de Réanimation Médicale - CH de Montauban, Montauban, France|Service de Réanimation, Mulhouse, France|Service de Réanimation Médicale, Orléans, France|Service de Réanimation Médicale - Hôpital Pitié Salpêtrière, Paris, France|Service de Réanimation Médicale - CHU La Milétrie, Poitiers, France|Service de Réanimation Médicale, Poitiers, France|Service de Réanimation Médicale - CHU Pontchaillou, Rennes, France|Service de Réanimation Médicale - CHU Rouen, Rouen, France|Service de Réanimation Médicale - Hôpital Charles Nicolle, Rouen, France|Service de Réanimation - NHC, Strasbourg, France|Service de Réanimation Médicale - Hôpital de Hautepierre, Strasbourg, France|Service de Réanimation médicale, Hôpital Trousseau, Tours, France",7718189.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,79.0,57.95601552393271,878.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-3.2,585.6025,331.94,17.0,13.0,3.0,58.06,129.84,10.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12,"TUBERCULOSIS, PULMONARY",_MEROPENEM,NCT03174184,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Task Applied Science and Stellenbosch University, Stellenbosch, South Africa",4943569,C07F7/10,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,39.0,33.5119817655393,161.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.69,383.463,110.18,6.0,3.0,3.0,39.29,97.89,5.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,"TUBERCULOSIS, PULMONARY",_AMOXICILLIN,NCT03174184,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Task Applied Science and Stellenbosch University, Stellenbosch, South Africa",6878386,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,COVID-19,_SIROLIMUS,NCT04341675,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Loyola University Medical Center, Chicago, Illinois, United States|University of Cincinnati, Cincinnati, Ohio, United States",5212155,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,NON-CYSTIC FIBROSIS BRONCHIECTASIS,_MELPHALAN,NCT04278040,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kirill Zykov, Moscow, Russian Federation",8410077,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,COMMUNITY ACQUIRED PNEUMONIA,_HYDROCORTISONE,NCT02517489,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Service de Réanimation - Unité de Soins Continus, CH d'Angoulême, 'Angoulême, France|Service de Réanimation Polyvalente, CH d'Argenteuil, Argenteuil, France|Service de Réanimation, CHR Metz-Thionville, Ars-Laquenexy, France|Service de Réanimation, Aulnay-sous-Bois, France|Service de Réanimation, Belfort, France|Service de Réanimation, Bourg-en-Bresse, France|Service de Réanimation HIA Clermont-Tonnerre, Brest, France|Service de Réanimation Médicale, CHU de Brest, Brest, France|Service de Réanimation, CHU Côte de Nacre, Caen, France|Service de Réanimation Médicale, Hôpital Louis Pasteur, Chartres, Chartres, France|Service de Réanimation Médicale Polyvalente, Hôpital G Montpied, Clermont Ferrand, France|Service de Réanimation, Hôpital Louis Mourier, Colombes, France|Service de Réanimation Médicale, CHU de Dijon, Dijon, France|Service de Réanimation Médico-Chirurgicale, Hôpital Raymond Poincarré, APHP, Garches, France|Service de Réanimation Médicale, CHU de Grenoble, Grenoble, France|Service de Réanimation Polyvalente, CHD La Roche sur Yon, La Roche sur Yon, France|Service de Réanimation, CH Le Mans, Le Mans, France|Service de Réanimation Polyvalente, Hôpital Salengro, CHU de Lille, Lille, France|Service de Réanimation Polyvalente, CHU de Limoges, Limoges, France|Service de Réanimation Médicale, Hôpital Nord, Marseille, France|Service de Réanimation Polyvalente - Surveillance Continue, CH de Montauban, Montauban, France|Service de Réanimation Médicale, CHU de Nancy, Nancy, France|Service de Réanimation Polyvalente, Hôpital Hôtel Dieu, CHU de Nantes, Nantes, France|Service de Réanimation Médicale, CHR d'Orléans, Orléans, France|Service de Réanimation Médicale, Hôpital Cochin, APHP, Paris, France|Service de Réanimation et USC médico-chirurgicale, Hôpital Tenon, APHP, Paris, France|Service de Réanimation Médicale et Médecine Interne, CHU de Poitiers, Poitiers, France|Service des Maladies Infectieuses et Réanimation Médicale, CHU de Rennes, Rennes, France|Service de Réanimation Polyvalente, CH de Saint Malo, Saint Malo, France|Service de Réanimation, Saint-Brieuc, France|Service de Réanimation Médicale, Nouvel Hôpital Civil, CHU de Strasbourg, Strasbourg, France|Service de Réanimation Médicale, Hôpital de Hautepierre, CHU de Strasbourg, Strasbourg, France",5635497,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,ASTHMA IN CHILDREN,_PREDNISOLONE,NCT03962894,,Recruiting,All,"2 Years to 18 Years   (Child, Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"Lee County Public Safety & Emergency Services, Fort Myers, Florida, United States|Nassau County Fire Rescue Department, Yulee, Florida, United States",5178878,A61K9/0056,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,LOWER RESPIRATORY TRACT INFECTION,_AZITHROMYCIN,NCT03341273,Not Applicable,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Emory Vaccine Center - The Hope Clinic, Atlanta, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Texas Medical Center - Michael E. DeBakey Veterans Affairs, Houston, Texas, United States",5192535.0,A61K9/0048,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0
CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C,LOWER RESPIRATORY TRACT INFECTION,_PROCALCITONIN,NCT03341273,Not Applicable,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Emory Vaccine Center - The Hope Clinic, Atlanta, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Texas Medical Center - Michael E. DeBakey Veterans Affairs, Houston, Texas, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,COVID-19,_RUXOLITINIB,NCT04377620,Phase 3,Recruiting,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Georgetown University Hospital, Washington, District of Columbia, United States|Tampa General Hospital, Tampa, Florida, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Boston Medical Center, Boston, Massachusetts, United States|Lahey Clinic Inc., Burlington, Massachusetts, United States|UMass MMC - University Campus, Worcester, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Jefferson Hospital, Philadelphia, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States",7598257,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,CORONAVIRUS INFECTION,_RUXOLITINIB,NCT04348695,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Madrid Sanchinarro, Madrid, Spain",7598257,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,CORONAVIRUS INFECTION,_SIMVASTATIN,NCT04348695,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Madrid Sanchinarro, Madrid, Spain",RE42461,C07D205/08 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
N[C@@H](CS)C(=O)O,"TUBERCULOSIS, PULMONARY",_CYSTEINE,NCT03702738,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NIMR-Mbeya Medical Research Centre, Mbeya, Tanzania",10478453.0,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,22.0,11.0,4.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-2.6,121.15799999999999,63.32,3.0,3.0,0.0,11.41,28.22,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,_CHOLECALCIFEROL,NCT04011930,Phase 2,Recruiting,Male,"40 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"BSMMU, Dhaka, Bangladesh",5994329.0,6,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,COVID-19 PNEUMONIA,_IMATINIB,NCT04346147,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain",5521184,C07D409/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,COVID-19 PNEUMONIA,_LOPINAVIR,NCT04346147,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain",6037157,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,COVID-19 PNEUMONIA,_BARICITINIB,NCT04346147,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain",8158616,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,37.257438551099604,12.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.08,371.42,120.56,6.0,1.0,4.0,36.72,105.55,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,COVID-19,_LOSARTAN,NCT04335123,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Kansas Medical Center, Kansas City, Kansas, United States",5210079,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,INVASIVE PULMONARY ASPERGILLOSIS,_VORICONAZOLE,NCT03672292,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UC Davis Medical Center 4150 V St Ste G500, Sacramento, California, United States|Emory University Hospital 1364 Clifton Road NE, Atlanta, Georgia, United States|University of Chicago 5841 S. Maryland Avenue MC 5065, Chicago, Illinois, United States|St. Vincent Hospital Indianapolis 8402 Harcourt Rd Suite 806, Indianapolis, Indiana, United States|Brigham Womens Hospital INF 75 Francis Street PBB-A4, Boston, Massachusetts, United States|University of Michigan UH south F4005; 1500 E. Medical Center Drive SPC 5378, Ann Arbor, Michigan, United States|Wayne State University 3990 John R Detroit 48201 Site Supplies/Lab Kits Harper university Hospital 3990 John R # 5904, 5 Hudson, Detroit, Michigan, United States|UNIVERSITY OF MINNESOTA PHYSICIANS Mayo Memorial Building 420 Delaware St SE, Minneapolis, Minnesota, United States|Washington University School of Medicine Division of Infectious Disease 660 S Euclid Ave, Box 8051, Saint Louis, Missouri, United States|Duke University PO BOX 102359, Durham, North Carolina, United States|Wake Forest Baptist Medical Center 1 Medical Center Blvd., Winston-Salem, North Carolina, United States|Lowcountry Infectious Diseases P.A. 1938 Charlie Hall Blvd, Charleston, South Carolina, United States|Memorial Hermann Hospital Texas Medical Center Clinical Research Unit, Houston, Texas, United States|Hematology Department AZ Sint-Jan Brugge - Oostende AV Campus Brugge Ruddershove 10 8000, Brugge, Belgium|Hopital Erasme, Bruxelles, Belgium|Institut Jules Bordet Departement des Maladies Infectieuses Boulevard de Waterloo 121, 1000 Bruxelles, Bruxelles, Belgium|UZ Leuven campus Gasthuisberg Hematology Department Herestraat 49 B - 3000, Leuven, Belgium|Universitätsklinikum Bonn, Medizinische Klinik III Venusberg-Campus 1, Gebäude 20, Bonn, Germany|Universitaetsklinikum Koeln, Klinisches Studienzentrum 2 für Infektiologie, Klinik I für Innere Medizin Kerpener Str. 62, Bettenhaus Ebene 15 Raum 64, Köln, Germany|Universitätsklinikum Magdeburg A.ö.R., Zentrum für Innere Medizin, Universitätsklinik für Hämatologie und Onkologie Leipziger Str. 44, Magdeburg, Germany|Universitätsmedizin Mainz, III. Medizinische Klinik und Poliklinik Studienzentrale, Geb. 302, 2.OG, Mainz, Germany|Universitaetsmedizin Rostock, Medizinische Klinik III , Hämatologie, Onkologie, Palliativmedizin am Zentrum für Innere Medizin Ernst-Heydemann-Strasse 6, Rostock, Germany|Coral García Hospital Universitario Virgen de las Nieves. UGC Hematologia y Hemoterapia Avda. de las Fuerzas Armadas, 2., Granada, Spain|Aurora Rodríguez Ródenas Hospital Clínico de Valencia.Fundación Investigación Clínico de Valencia Instituto de Investigación Sanitaria INCLIVA .Pabellón Materno-Infantil, Planta 8ª (Ensayos clínicos) Si, Valencia, Spain",5116844,C07D233/56,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,33.4791268814554,78.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.65,349.3105,76.72,5.0,1.0,3.0,30.54,95.28,5.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=P(O)(O)O,COVID-19 PNEUMONIA,_CHLOROQUINE_PHOSPHATE,NCT04428268,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico",5021426,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,15.2118113308281,90.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,COVID-19 PNEUMONIA,_CHLOROQUINE,NCT04428268,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico",4181725,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C,PNEUMONIA,_PROCALCITONIN,NCT03711227,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"Lakeland Regional Healthcare, Saint Joseph, Michigan, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0
CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C,"INFLUENZA, HUMAN",_PROCALCITONIN,NCT02899065,Not Applicable,Recruiting,All,"up to 20 Years   (Child, Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"University of California, Davis Medical Center, Sacramento, California, United States",,,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,CORONAVIRUS INFECTION,_IVERMECTIN,NCT04431466,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Univeristário da Universidade Federal de São Carlos (HU-UFSCar), São Carlos, São Paulo, Brazil|Hospital Universitário da Universidade Federal de São Carlos (HU-UFSCar), São Carlos, São Paulo, Brazil",6103248,A01N53/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,26.809585412431396,1324.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.83,1736.1589,170.06,13.0,3.0,14.0,96.87,230.33,15.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,CORONAVIRUS INFECTIONS,_IVERMECTIN,NCT04384458,Not Applicable,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Drug Research and Development Center (NPDM), Federal University of Ceará (UFC), Fortaleza, Ceará, Brazil",6103248,A01N53/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,26.809585412431396,1324.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.83,1736.1589,170.06,13.0,3.0,14.0,96.87,230.33,15.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(c3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O,PULMONARY TUBERCULOSIS,_RIFABUTIN,NCT02256696,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Cape Town Lung Institute, Cape Town, South Africa",9050263,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,24.0,15.8360541284215,155.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.25,847.0047,205.55,13.0,5.0,6.0,90.72,232.64,5.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0
CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(=N)N)cc2)cc1,CORONA VIRUS INFECTION,_CAMOSTAT,NCT04321096,Phase 1|Phase 2,Recruiting,All,"18 Years to 110 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Infectious Diseases, Aalborg, Denmark|Department for Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark|Herning Regional Hospital, Herning, Denmark|Northzealands hospital - Hillerød, Hillerød, Denmark|Horsens Regional Hospital, Horsens, Denmark|Bispebjerg hospital, København, Denmark|Dept. of Infectious Diseases, Odense University Hospital, Odense, Denmark|Randers Regional Hospital, Randers, Denmark|Silkeborg Hospital, Silkeborg, Denmark",4990537,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,19.515801145814,104.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.88,398.4125,134.81,6.0,3.0,2.0,41.92,117.77,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CHRONIC SINUSITIS,_BUDESONIDE,NCT04163978,Phase 2,Recruiting,All,"19 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","St. Paul's Hospital, Vancouver, British Columbia, Canada",6123924,A61K9/008,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,SINUSITIS,_BUDESONIDE,NCT03584178,Not Applicable,Recruiting,All,"19 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"St Paul Hospital, Vancouver, British Columbia, Canada",6123924,A61K9/008,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0
CN(C)C(=O)Oc1ccc[n+](C)c1,COVID-19|SARS-COV-2,_PYRIDOSTIGMINE,NCT04343963,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Tlalpan, Mexico",3931205,C07D491/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,29.635105443643603,905.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-3.1,181.2117,33.42,1.0,0.0,1.0,19.38,49.66,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0
CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-],COVID-19|SARS-COV-2,_PYRIDOSTIGMINE_BROMIDE,NCT04343963,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Tlalpan, Mexico",5298504,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,22.505595597445502,96.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0
CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1,COVID-19,_NITAZOXANIDE,NCT04463264,Phase 2|Phase 3,Recruiting,All,18 Years to 59 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Hospital Universitario Austral, Presidente Derqui, Buenos Aires, Argentina, Argentina",5387598,4,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,18.0,9.856465225158619,123.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.14,307.282,114.11,5.0,1.0,2.0,27.54,73.89,5.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,CORONAVIRUS INFECTION,_COLCHICINE,NCT04363437,Phase 2,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Maimonides Medical Center, Brooklyn, New York, United States",7619004,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,11.466354545267803,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.59,399.43699999999995,83.09,6.0,1.0,3.0,42.41,111.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,CORONA VIRUS INFECTION,_COLCHICINE,NCT04322682,Phase 3,Recruiting,All,"40 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Mayo Clinic - Arizona, Phoenix, Arizona, United States|Yuma Regional Medical Center Cancer Center, Yuma, Arizona, United States|Centric Health Resources Inc., Bakersfield, California, United States|Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|Rancho Research Institute, Downey, California, United States|University of California, San Francisco - San Francisco General Hospital, San Francisco, California, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|South Florida Research Organization, Medley, Florida, United States|Miami Center for Advanced Cardiology, Miami Beach, Florida, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|North Mississippi Medical Clinics, Inc., Tupelo, Mississippi, United States|New York University School of Medecine, New York, New York, United States|Baylor Scott & White Research Institute - Pharmacy, Dallas, Texas, United States|University of Texas(UT) Southwestern Medical Center, Dallas, Texas, United States|Spring Clinical Research, Houston, Texas, United States|Heart Institute (inCor), Scholl of Medecine, University of Sao Paulo, São Paulo, Sao Paulo, Brazil|Montreal Heart Institute, Montreal, Quebec, Canada|Tread Research, Tygerberg Hospital, Cape Town, South Africa|Hospital Universitario La Paz, IdiPaz, La Paz, Madrid, Spain",7619004,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,8.0,11.466354545267803,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.59,399.43699999999995,83.09,6.0,1.0,3.0,42.41,111.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,SICKLE CELL DISEASE,_MOMETASONE,NCT03758950,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mount Sinai St Luke's, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",5394868,A61M15/0065,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,ASTHMA IN CHILDREN,_TRIAMCINOLONE,NCT04002362,Phase 2,Recruiting,All,8 Years to 17 Years   (Child),Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Healthcare of Altanta, Atlanta, Georgia, United States|Emory Children's Center, Atlanta, Georgia, United States",5976573,5,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,ASTHMA IN CHILDREN,_TRIAMCINOLONE_ACETONIDE,NCT04002362,Phase 2,Recruiting,All,8 Years to 17 Years   (Child),Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Healthcare of Altanta, Atlanta, Georgia, United States|Emory Children's Center, Atlanta, Georgia, United States",3962430,A61L2/0023,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,COVID-19,_MARAVIROC,NCT04441385,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clínic, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain",6586430,C07D401/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC,COVID-19,_PRAZOSIN,NCT04365257,Phase 2,Recruiting,All,"45 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins Hospital, Baltimore, Maryland, United States",4130647.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,17.380233680363,616.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.93,383.4011,106.95,7.0,1.0,4.0,40.49,104.5,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,COVID-19,_BARICITINIB,NCT04321993,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nova Scotia Health Authority, Halifax, Nova Scotia, Canada",8158616,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,3.0,37.257438551099604,12.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.08,371.42,120.56,6.0,1.0,4.0,36.72,105.55,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
NC(=O)c1nc(F)cnc1O,CORONAVIRUS INFECTION,_FAVIPIRAVIR,NCT04373733,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chelsea and Westminster Hospital, London, United Kingdom|West Middlesex University Hospital, London, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.49,157.10399999999996,89.1,4.0,2.0,1.0,12.12,33.98,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
COC(=O)OCOc1c2n(ccc1=O)N([C@@H]1c3ccccc3SCc3c1ccc(F)c3F)[C@@H]1COCCN1C2=O,INFLUENZA,_BALOXAVIR_MARBOXIL,NCT03969212,Phase 3,Recruiting,All,"5 Years to 64 Years   (Child, Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Central Alabama Research; Pediatrics, Birmingham, Alabama, United States|Cahaba Research, Inc., Birmingham, Alabama, United States|Cahaba Research, Inc, Pelham, Alabama, United States|Phoenix Clinical, Phoenix, Arizona, United States|Precision Trials, Phoenix, Arizona, United States|Alliance Urgent Care-Tolleson, Tolleson, Arizona, United States|Noble Clinical Research, Tucson, Arizona, United States|Marvel Research, LLC, Huntington Beach, California, United States|Long Beach Clinical Trials, Long Beach, California, United States|Downtown LA Research Center, Los Angeles, California, United States|MD Strategies Research Centers, San Diego, California, United States|Cherry Creek Family Practice, Denver, Colorado, United States|Canvas Clinical Research, Lake Worth, Florida, United States|Premier Research Associate, Inc, Miami, Florida, United States|Research Institute of South Florida Inc, Miami, Florida, United States|CNS Healthcare, Orlando, Florida, United States|Kendall South Medical Center Inc., South Miami, Florida, United States|Clinical Trials of Florida LLC, Tampa, Florida, United States|Clinical Research Prime, Idaho Falls, Idaho, United States|Medisphere Medical Research Center, Llc, Evansville, Indiana, United States|Mishawaka Osteopathic Clinic, Mishawaka, Indiana, United States|Claudia T Martorell MD LLC dba The Research Institute, Springfield, Massachusetts, United States|Burke Primary Care, Morganton, North Carolina, United States|Hometown Urgent Care and Occupational Health - Springdale, Cincinnati, Ohio, United States|Hometown Urgent Care and Occupational Health - Clintonville, Columbus, Ohio, United States|Dayton Clinical Research, Dayton, Ohio, United States|Tristar Clinical Investigations, Philadelphia, Pennsylvania, United States|Frontier Clinical Research, Smithfield, Pennsylvania, United States|AFC Urgent Care-Easley, Easley, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|AFC Urgent Care-Gunbarrell, Chattanooga, Tennessee, United States|Clinical Research Solutions PC, Knoxville, Tennessee, United States|City Doc Urgent Care-Dallas/Ft. Worth, Dallas, Texas, United States|Pioneer Research Solutions, Houston, Texas, United States|Vilo Research Group, Houston, Texas, United States|Mercury Clinical Research, Houston, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Sala Alberto Mignaburu, Berazategui, Argentina|Centro Médico Dra de Salvo, Buenos Aires, Argentina|Investigaciones en Patologias Respiratorias, San Miguel de Tucuman, Argentina|CEMER Centro Medico de Enfermedades Respiratorias, Vicente López, Argentina|Santa Casa de Misericordia; de Belo Horizonte, Belo Horizonte, MG, Brazil|Centro Integrado de Oncologia de Curitiba, Curitiba, PR, Brazil|Hospital Moinhos de Vento, Porto Alegre, RS, Brazil|Dr. Consulta, Sao Paulo, SP, Brazil|Beijing Ditan Hospital, Beijing, China|Beijing You An Hospital; Digestive Dept, Beijing, China|China-Japan Friendship Hospital, Beijing, China|Beijing Hospital of Ministry of Health, Beijing, China|Capital Medical University Beijing Hospital of Traditional Chinese Medicine, Beijing, China|West China Hospital, Sichuan University, Chengdu, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|Nanjing 1st Hospital; Endocrinology Dept., Nanjing, China|The Third People's Hospital of Hainan Province, Sanya, China|Huashan Hospital Affiliated to Fudan University, Shanghai City, China|Zhongshan Hospital Fudan University, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, China|Shenzhen People's Hospital, Shenzhen, China|First Affiliated Hospital of Soochow University, Suzhou, China|Taizhou Hospital of Zhejiang Province, Taizhou, China|The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China|General Hospital of Ningxia Medical University, Yinchuan, China|Henan Provincial People's Hospital, Zhengzhou, China|ICIMED Instituto de Investigación en Ciencias Médicas, San Jose, Costa Rica|Laiko General Hospital - Uni of Athens; 1St Dept. of Internal Medicine, Athens, Greece|Sotiria General Hospital of Athens; 3rd Department of Internal Medicine, Athens, Greece|Attikon University General Hospital; 4th Academic Department of Internal Medicine, Chaidari, Greece|Queen Mary Hospital; Uni Dept of Medicine, Division of Gastroenterology, Hong Kong, Hong Kong|Sir Gangaram Hospital, New Delhi, Delhi, India|Sterling Hospital; Clinical Research Department, Ahmedabad, Gujarat, India|Kanoria Hospital & Research Centre, Gandhi Nagar, Gujarat, India|M S Ramaiah Medical College and Hospitals; Department of Internal Medicine,, Bengaluru, Karnataka, India|Mazumdar Shaw Medical Centre- A unit of Narayana Hrudayalaya, Bengaluru, Karnataka, India|JSS Hospital; Deprt of Pulmonology, Mysuru, Karnataka, India|Kasturba Medical College and Hospital; Department of Medicine, Udupi, Karnataka, India|GT Hospital, Mumbai, Maharashtra, India|Criticare Hospital & Research Institute, Nagpur, Maharashtra, India|Jehangir Clinical development Centre Pvt Ltd., Pune, Maharashtra, India|MTES's Sanjeevan Hospital, Pune, Maharashtra, India|Lifepoint Multispeciality Hospital; Research Department, Pune, Maharashtra, India|JLN Medical College and Hospital; TB and Chest Department, Ajmer, Rajasthan, India|Sawai Man Singh Medical College; Institute of Respiratory Disease, Jaipur, Rajasthan, India|AIG Hospitals, Hyderabad, Telangana, India|M.V Hospital and Research Centre, Lucknow, Uttar Pradesh, India|Ajanta Research centre, Lucknow, Uttar Pradesh, India|Medical College and Hospital- Kolkata, Kolkata, WEST Bengal, India|Krishna Institute of Medical Science, Secunderabad, India|Siaal Research Center for Family Medicine and Primary Care; Faculty of Health Sciences, Beer-Sheva, Israel|Siaal Research Center for Family Medicine and Primary Care; Clalit Neve Zeev, Beer-Sheva, Israel|Siaal Research Center for Family Medicine and Primary Care; Clalit Tet Clinic, Beer-Sheva, Israel|Clalit Health Services- Pediatric Ambulatory Clinic; Pediatric Ambulatory Clinic, Petach Tikva, Israel|Maccabi health services - Moked Hashalom; Maccabi health services - Moked Ramat Hasharon, Ramat Hasharon, Israel|Maccabi health services - Moked Hashalom, Tel Aviv, Israel|Toda Internal medicine & Rehabilitation Clinic, Akashi, Japan|Medical Corporation Houmankai Umezu Clinic, Chikushino, Japan|Kashinoki Internal Medicine Clinic, Date, Japan|Shin Komonji Hospital, Fukuoka, Japan|Fukuoka Shin Mizumaki Hospital, Fukuoka, Japan|Hatakeyama Internal Medicine and Gastroenterology Clinic, Fukuoka, Japan|Fukuoka Wajiro Hospital, Fukuoka, Japan|Irie Naika Syounika Iin, Fukuoka, Japan|Kimura Siro Clinic, Fukuoka, Japan|Kunisaki Makoto Clinic, Fukuoka, Japan|Iguchi Clinic, Fukuyama, Japan|Shimada Ear, Nose and Throat Clinic, Habikino, Japan|Mashiba Clinic, Hanno, Japan|Fujimaki Ent Clinic, Ichikawa, Japan|Nakamura Cardiovascular Clinic, Itoshima, Japan|Moriyama Otolaryngology, Kagoshima, Japan|Kamoike ENT Allergy Clinic, Kagoshima, Japan|Clinic Kashiwanoha, Kashiwa, Japan|Kamezawa Clinic, Kasugai, Japan|Oishi Clinic, Kasuyagun, Japan|Takahashi naika, Kawasaki, Japan|Kanagawa Himawari Clinic, Kawasaki, Japan|Osaki Internal and Respiratory Clinic,, Kitakyushu, Japan|Sato ENT Clinic, Kitakyushu, Japan|Kiheibashi Otolaryngology, Kodaira, Japan|Medical Corporation Association KANWAKAI Musashikoganei Clinic, Koganei, Japan|Medical corporation Shirayurikai Swing Nozaki Clinic, Musashino, Japan|Tanigawa Clinic, Nagasaki, Japan|Yaesu Clinic, Naha, Japan|Horikawa Clinic, Nonoichi, Japan|Funai Ear Nose Throat Clinic, Oita, Japan|Lee's Clinic, Osaka, Japan|Manabe Clinic, Osaka, Japan|Kitada Clinic, Osaka, Japan|Sunami Internal medicine Clinic, Osaka, Japan|Kikumori Ear, Nose and Throat Clinic, Osaka, Japan|Saga Memorial Hospital, Saga, Japan|Medical Corporation Saitadayoshikai Saikatsu Clinic, Saitama, Japan|Segawa Hospital, Saitama, Japan|Okuda Ent Clinic, Sakai, Japan|Uehara Clinic, Sapporo, Japan|Aiiku Hospital, Sapporo, Japan|Matsuo Kenko Clinic, Sendai, Japan|Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai, Shinagawa, Japan|Wakasa Clinic, Tokorozawa, Japan|Yamaichi Building Medical Clinic, Tokyo, Japan|Seiwa Clinic, Tokyo, Japan|Miyazaki RC Clinic, Tokyo, Japan|Sakayori Clinic, Tokyo, Japan|Sato Medical Clinic, Tokyo, Japan|Denenchofu Family Clinic, Tokyo, Japan|Sato Clinic, Tokyo, Japan|Suzuki internal & circulatory Medical Clinic, Tokyo, Japan|Sekino Hospital, Toshima, Japan|Tsuchiura Beryl Clinic, Tsuchiura, Japan|Medical corporation Seijinkai Takei Clinic, Tsuru, Japan|Gushiken-Cardiology and Internal medicine, Urasoe, Japan|Uranishi Clinic, Urasoe, Japan|Mizoguchi Clinic, YAO, Japan|Tamura Medical Clinic, Yokohama, Japan|Yotsukaido Tokushukai Medical Center, Yotsukaido, Japan|Centro de Estudios Clinicos de Queretaro (CECLIQ), Querétaro, Queretaro, Mexico|Centro de Desarrollo Biomédico SCP, Mérida, Yucatan, Mexico|Merida   Investigacion Clinica, Mérida, Yucatan, Mexico|Centro de Investigacion Medico Biologico y Terapia Avanzada, S.C., Guadalajara, Mexico|Centro de Investigacion Clínica GRAMEL S.C, Mexico, Mexico|Centro Respiratorio de México, Mexico, Mexico|National University Hospital, Singapore, Singapore|National Healthcare Group Polyclinics- Yishun, Singapore, Singapore|Somerset West Clinical Trial Unit, Cape Town, South Africa|TREAD Research, Cape Town, South Africa|CRISMO; Clinical Research, Germiston, South Africa|Into Research; Life Groenkloof Hospital Medical Centre, Groenkloof, South Africa|Newtown Clinical Research, Johannesburg, South Africa|Peermed Clinical Trial Centre, Kempton Park, South Africa|Trident Clinical, Kimberley, South Africa|Langeberg Clinical Trials, Kraaifontein, South Africa|Metropolitan Medical Center, Polokwane, South Africa|Emmed Research, Pretoria, South Africa|Setshaba Research Centre; Clinical Research, Pretoria, South Africa|Dr As'ad Ebrahim Bhorat; Soweto Clinical Trial Centre, Soweto, South Africa|Wits Clinical Research, Soweto, South Africa|Limpopo Clinical Research Initiative; Tamboti Medical Centre, Tabazimbi, South Africa|Welkom Clinical Trial Centre, Welkom, South Africa|Centro de Salud Las Aguilas; Medicina General, Madrid, Spain|Ankara University Medical Faculty, Ankara, Turkey|Hacettepe University Medical Faculty; Infectious Diseases, Ankara, Turkey|Hacettepe University Medical Faculty; Infectious Diseases, Ankara, Turkey|Ankara City Hospital, Ankara, Turkey|Gazi University Medical Faculty, Ankara, Turkey|Akdeniz University Medical Faculty, Antalya, Turkey|Istanbul Uni Istanbul Medical Faculty, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Dokuz Eylul University Medical Faculty; Infection, Izmir, Turkey|Koc University Medical Faculty; Department of Gynecology & Obstetrics, Topkapi, Turkey|Karadeniz Technical Uni School of Medicine; Infection Diseases & Clinical Mikrobiology Dept, Trabzon, Turkey|The Haven Surgery, Durham, United Kingdom|Staploe Medical Centre, Ely, United Kingdom|Preston Hill Surgery, Harrow, United Kingdom|Knowle House Surgery, Plymouth, United Kingdom|The Village Practice; Thornton Medical Centre, Thornton-Cleveleys, United Kingdom",8927710,5,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,23.0,54.7690917677981,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.12,571.55,97.85,8.0,0.0,6.0,53.87,140.76,6.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
O=C1c2c(O)c(=O)ccn2N([C@@H]2c3ccccc3SCc3c2ccc(F)c3F)[C@@H]2COCCN12,INFLUENZA,_BALOXAVIR,NCT03969212,Phase 3,Recruiting,All,"5 Years to 64 Years   (Child, Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Central Alabama Research; Pediatrics, Birmingham, Alabama, United States|Cahaba Research, Inc., Birmingham, Alabama, United States|Cahaba Research, Inc, Pelham, Alabama, United States|Phoenix Clinical, Phoenix, Arizona, United States|Precision Trials, Phoenix, Arizona, United States|Alliance Urgent Care-Tolleson, Tolleson, Arizona, United States|Noble Clinical Research, Tucson, Arizona, United States|Marvel Research, LLC, Huntington Beach, California, United States|Long Beach Clinical Trials, Long Beach, California, United States|Downtown LA Research Center, Los Angeles, California, United States|MD Strategies Research Centers, San Diego, California, United States|Cherry Creek Family Practice, Denver, Colorado, United States|Canvas Clinical Research, Lake Worth, Florida, United States|Premier Research Associate, Inc, Miami, Florida, United States|Research Institute of South Florida Inc, Miami, Florida, United States|CNS Healthcare, Orlando, Florida, United States|Kendall South Medical Center Inc., South Miami, Florida, United States|Clinical Trials of Florida LLC, Tampa, Florida, United States|Clinical Research Prime, Idaho Falls, Idaho, United States|Medisphere Medical Research Center, Llc, Evansville, Indiana, United States|Mishawaka Osteopathic Clinic, Mishawaka, Indiana, United States|Claudia T Martorell MD LLC dba The Research Institute, Springfield, Massachusetts, United States|Burke Primary Care, Morganton, North Carolina, United States|Hometown Urgent Care and Occupational Health - Springdale, Cincinnati, Ohio, United States|Hometown Urgent Care and Occupational Health - Clintonville, Columbus, Ohio, United States|Dayton Clinical Research, Dayton, Ohio, United States|Tristar Clinical Investigations, Philadelphia, Pennsylvania, United States|Frontier Clinical Research, Smithfield, Pennsylvania, United States|AFC Urgent Care-Easley, Easley, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|AFC Urgent Care-Gunbarrell, Chattanooga, Tennessee, United States|Clinical Research Solutions PC, Knoxville, Tennessee, United States|City Doc Urgent Care-Dallas/Ft. Worth, Dallas, Texas, United States|Pioneer Research Solutions, Houston, Texas, United States|Vilo Research Group, Houston, Texas, United States|Mercury Clinical Research, Houston, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Sala Alberto Mignaburu, Berazategui, Argentina|Centro Médico Dra de Salvo, Buenos Aires, Argentina|Investigaciones en Patologias Respiratorias, San Miguel de Tucuman, Argentina|CEMER Centro Medico de Enfermedades Respiratorias, Vicente López, Argentina|Santa Casa de Misericordia; de Belo Horizonte, Belo Horizonte, MG, Brazil|Centro Integrado de Oncologia de Curitiba, Curitiba, PR, Brazil|Hospital Moinhos de Vento, Porto Alegre, RS, Brazil|Dr. Consulta, Sao Paulo, SP, Brazil|Beijing Ditan Hospital, Beijing, China|Beijing You An Hospital; Digestive Dept, Beijing, China|China-Japan Friendship Hospital, Beijing, China|Beijing Hospital of Ministry of Health, Beijing, China|Capital Medical University Beijing Hospital of Traditional Chinese Medicine, Beijing, China|West China Hospital, Sichuan University, Chengdu, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|Nanjing 1st Hospital; Endocrinology Dept., Nanjing, China|The Third People's Hospital of Hainan Province, Sanya, China|Huashan Hospital Affiliated to Fudan University, Shanghai City, China|Zhongshan Hospital Fudan University, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, China|Shenzhen People's Hospital, Shenzhen, China|First Affiliated Hospital of Soochow University, Suzhou, China|Taizhou Hospital of Zhejiang Province, Taizhou, China|The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China|General Hospital of Ningxia Medical University, Yinchuan, China|Henan Provincial People's Hospital, Zhengzhou, China|ICIMED Instituto de Investigación en Ciencias Médicas, San Jose, Costa Rica|Laiko General Hospital - Uni of Athens; 1St Dept. of Internal Medicine, Athens, Greece|Sotiria General Hospital of Athens; 3rd Department of Internal Medicine, Athens, Greece|Attikon University General Hospital; 4th Academic Department of Internal Medicine, Chaidari, Greece|Queen Mary Hospital; Uni Dept of Medicine, Division of Gastroenterology, Hong Kong, Hong Kong|Sir Gangaram Hospital, New Delhi, Delhi, India|Sterling Hospital; Clinical Research Department, Ahmedabad, Gujarat, India|Kanoria Hospital & Research Centre, Gandhi Nagar, Gujarat, India|M S Ramaiah Medical College and Hospitals; Department of Internal Medicine,, Bengaluru, Karnataka, India|Mazumdar Shaw Medical Centre- A unit of Narayana Hrudayalaya, Bengaluru, Karnataka, India|JSS Hospital; Deprt of Pulmonology, Mysuru, Karnataka, India|Kasturba Medical College and Hospital; Department of Medicine, Udupi, Karnataka, India|GT Hospital, Mumbai, Maharashtra, India|Criticare Hospital & Research Institute, Nagpur, Maharashtra, India|Jehangir Clinical development Centre Pvt Ltd., Pune, Maharashtra, India|MTES's Sanjeevan Hospital, Pune, Maharashtra, India|Lifepoint Multispeciality Hospital; Research Department, Pune, Maharashtra, India|JLN Medical College and Hospital; TB and Chest Department, Ajmer, Rajasthan, India|Sawai Man Singh Medical College; Institute of Respiratory Disease, Jaipur, Rajasthan, India|AIG Hospitals, Hyderabad, Telangana, India|M.V Hospital and Research Centre, Lucknow, Uttar Pradesh, India|Ajanta Research centre, Lucknow, Uttar Pradesh, India|Medical College and Hospital- Kolkata, Kolkata, WEST Bengal, India|Krishna Institute of Medical Science, Secunderabad, India|Siaal Research Center for Family Medicine and Primary Care; Faculty of Health Sciences, Beer-Sheva, Israel|Siaal Research Center for Family Medicine and Primary Care; Clalit Neve Zeev, Beer-Sheva, Israel|Siaal Research Center for Family Medicine and Primary Care; Clalit Tet Clinic, Beer-Sheva, Israel|Clalit Health Services- Pediatric Ambulatory Clinic; Pediatric Ambulatory Clinic, Petach Tikva, Israel|Maccabi health services - Moked Hashalom; Maccabi health services - Moked Ramat Hasharon, Ramat Hasharon, Israel|Maccabi health services - Moked Hashalom, Tel Aviv, Israel|Toda Internal medicine & Rehabilitation Clinic, Akashi, Japan|Medical Corporation Houmankai Umezu Clinic, Chikushino, Japan|Kashinoki Internal Medicine Clinic, Date, Japan|Shin Komonji Hospital, Fukuoka, Japan|Fukuoka Shin Mizumaki Hospital, Fukuoka, Japan|Hatakeyama Internal Medicine and Gastroenterology Clinic, Fukuoka, Japan|Fukuoka Wajiro Hospital, Fukuoka, Japan|Irie Naika Syounika Iin, Fukuoka, Japan|Kimura Siro Clinic, Fukuoka, Japan|Kunisaki Makoto Clinic, Fukuoka, Japan|Iguchi Clinic, Fukuyama, Japan|Shimada Ear, Nose and Throat Clinic, Habikino, Japan|Mashiba Clinic, Hanno, Japan|Fujimaki Ent Clinic, Ichikawa, Japan|Nakamura Cardiovascular Clinic, Itoshima, Japan|Moriyama Otolaryngology, Kagoshima, Japan|Kamoike ENT Allergy Clinic, Kagoshima, Japan|Clinic Kashiwanoha, Kashiwa, Japan|Kamezawa Clinic, Kasugai, Japan|Oishi Clinic, Kasuyagun, Japan|Takahashi naika, Kawasaki, Japan|Kanagawa Himawari Clinic, Kawasaki, Japan|Osaki Internal and Respiratory Clinic,, Kitakyushu, Japan|Sato ENT Clinic, Kitakyushu, Japan|Kiheibashi Otolaryngology, Kodaira, Japan|Medical Corporation Association KANWAKAI Musashikoganei Clinic, Koganei, Japan|Medical corporation Shirayurikai Swing Nozaki Clinic, Musashino, Japan|Tanigawa Clinic, Nagasaki, Japan|Yaesu Clinic, Naha, Japan|Horikawa Clinic, Nonoichi, Japan|Funai Ear Nose Throat Clinic, Oita, Japan|Lee's Clinic, Osaka, Japan|Manabe Clinic, Osaka, Japan|Kitada Clinic, Osaka, Japan|Sunami Internal medicine Clinic, Osaka, Japan|Kikumori Ear, Nose and Throat Clinic, Osaka, Japan|Saga Memorial Hospital, Saga, Japan|Medical Corporation Saitadayoshikai Saikatsu Clinic, Saitama, Japan|Segawa Hospital, Saitama, Japan|Okuda Ent Clinic, Sakai, Japan|Uehara Clinic, Sapporo, Japan|Aiiku Hospital, Sapporo, Japan|Matsuo Kenko Clinic, Sendai, Japan|Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai, Shinagawa, Japan|Wakasa Clinic, Tokorozawa, Japan|Yamaichi Building Medical Clinic, Tokyo, Japan|Seiwa Clinic, Tokyo, Japan|Miyazaki RC Clinic, Tokyo, Japan|Sakayori Clinic, Tokyo, Japan|Sato Medical Clinic, Tokyo, Japan|Denenchofu Family Clinic, Tokyo, Japan|Sato Clinic, Tokyo, Japan|Suzuki internal & circulatory Medical Clinic, Tokyo, Japan|Sekino Hospital, Toshima, Japan|Tsuchiura Beryl Clinic, Tsuchiura, Japan|Medical corporation Seijinkai Takei Clinic, Tsuru, Japan|Gushiken-Cardiology and Internal medicine, Urasoe, Japan|Uranishi Clinic, Urasoe, Japan|Mizoguchi Clinic, YAO, Japan|Tamura Medical Clinic, Yokohama, Japan|Yotsukaido Tokushukai Medical Center, Yotsukaido, Japan|Centro de Estudios Clinicos de Queretaro (CECLIQ), Querétaro, Queretaro, Mexico|Centro de Desarrollo Biomédico SCP, Mérida, Yucatan, Mexico|Merida   Investigacion Clinica, Mérida, Yucatan, Mexico|Centro de Investigacion Medico Biologico y Terapia Avanzada, S.C., Guadalajara, Mexico|Centro de Investigacion Clínica GRAMEL S.C, Mexico, Mexico|Centro Respiratorio de México, Mexico, Mexico|National University Hospital, Singapore, Singapore|National Healthcare Group Polyclinics- Yishun, Singapore, Singapore|Somerset West Clinical Trial Unit, Cape Town, South Africa|TREAD Research, Cape Town, South Africa|CRISMO; Clinical Research, Germiston, South Africa|Into Research; Life Groenkloof Hospital Medical Centre, Groenkloof, South Africa|Newtown Clinical Research, Johannesburg, South Africa|Peermed Clinical Trial Centre, Kempton Park, South Africa|Trident Clinical, Kimberley, South Africa|Langeberg Clinical Trials, Kraaifontein, South Africa|Metropolitan Medical Center, Polokwane, South Africa|Emmed Research, Pretoria, South Africa|Setshaba Research Centre; Clinical Research, Pretoria, South Africa|Dr As'ad Ebrahim Bhorat; Soweto Clinical Trial Centre, Soweto, South Africa|Wits Clinical Research, Soweto, South Africa|Limpopo Clinical Research Initiative; Tamboti Medical Centre, Tabazimbi, South Africa|Welkom Clinical Trial Centre, Welkom, South Africa|Centro de Salud Las Aguilas; Medicina General, Madrid, Spain|Ankara University Medical Faculty, Ankara, Turkey|Hacettepe University Medical Faculty; Infectious Diseases, Ankara, Turkey|Hacettepe University Medical Faculty; Infectious Diseases, Ankara, Turkey|Ankara City Hospital, Ankara, Turkey|Gazi University Medical Faculty, Ankara, Turkey|Akdeniz University Medical Faculty, Antalya, Turkey|Istanbul Uni Istanbul Medical Faculty, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Dokuz Eylul University Medical Faculty; Infection, Izmir, Turkey|Koc University Medical Faculty; Department of Gynecology & Obstetrics, Topkapi, Turkey|Karadeniz Technical Uni School of Medicine; Infection Diseases & Clinical Mikrobiology Dept, Trabzon, Turkey|The Haven Surgery, Durham, United Kingdom|Staploe Medical Centre, Ely, United Kingdom|Preston Hill Surgery, Harrow, United Kingdom|Knowle House Surgery, Plymouth, United Kingdom|The Village Practice; Thornton Medical Centre, Thornton-Cleveleys, United Kingdom",,,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.01,483.49,73.32,6.0,1.0,6.0,45.53,124.13,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
N[C@@H](CSCC(=O)O)C(=O)O,BRONCHIECTASIS,_CARBOCYSTEINE,NCT04140214,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, United Kingdom|Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, Brompton, United Kingdom|Altnagelvin Area Hospital, Western Health and Social Care Trust, Derry, United Kingdom|Ninewells Hospital and Medical School, NHS Tayside, Dundee, United Kingdom|Royal Infirmary Edinburgh, NHS Lothian, Edinburgh, United Kingdom|Royal Free Hospital, Royal Free London NHS Foundation Trust, Hamstead, United Kingdom|Princess Alexandra Hospital, The Princess Alexandra Hospital NHS Trust, Harlow, United Kingdom|Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom|Freeman Hospital, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom|Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom|Southampton General Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom|Royal Gwent Hospital, Aneurin Bevan University Health Board, Wales, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.2,179.19400000000005,100.62,5.0,3.0,0.0,16.69,39.11,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,CARCINOMA|NON-SMALL-CELL LUNG,_PEMETREXED,NCT03952403,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cancer Hospital Chinese Academy of Medical Sciences (CAMS), Beijing, Beijing, China",5344932,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
[Cl-].[Na+],EPISTAXIS,_SODIUM_CHLORIDE,NCT02930941,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, Davis Medical Center, Sacramento, California, United States",6248726,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
NC[C@H]1CC[C@H](C(=O)O)CC1,EPISTAXIS,_TRANEXAMIC_ACID,NCT02930941,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, Davis Medical Center, Sacramento, California, United States",8273795.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,NON SMALL CELL LUNG CANCER,_EXEMESTANE,NCT02666105,Phase 2,Recruiting,Female,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic Health System, Albert Lea, Minnesota, United States|Mayo Clinic Health System, Mankato, Minnesota, United States|Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States|Sanford Thief River Falls Medical Center, Thief River Falls, Minnesota, United States|Sanford Worthington Medical Center, Worthington, Minnesota, United States",4808616,C07J1/0011,0.0,1.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,NON-SMALL CELL LUNG CANCER METASTATIC,_DOCETAXEL,NCT04154956,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 8400007, Bakersfield, California, United States|Investigational Site Number 8400015, Newnan, Georgia, United States|Investigational Site Number 8400004, Tinley Park, Illinois, United States|Investigational Site Number 8400016, Grand Rapids, Michigan, United States|Investigational Site Number 8400014, Greenville, South Carolina, United States|Investigational Site Number 8400003, Nashville, Tennessee, United States|Investigational Site Number 8400013, The Woodlands, Texas, United States|Investigational Site Number 0320004, Buenos Aires, Argentina|Investigational Site Number 0320009, Caba, Argentina|Investigational Site Number 0320012, Capital Federal, Argentina|Investigational Site Number 0320008, Pergamino, Argentina|Investigational Site Number 0320005, Rosario, Argentina|Investigational Site Number 0320002, Salta, Argentina|Investigational Site Number 0320003, Viedma, Argentina|Investigational Site Number 0360002, Blacktown, Australia|Investigational Site Number 0360003, Waratah, Australia|Investigational Site Number 0360001, Woolloongabba, Australia|Investigational Site Number 0560005, Brugge, Belgium|Investigational Site Number 0560002, Bruxelles, Belgium|Investigational Site Number 0560004, Edegem, Belgium|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 0560003, Liège, Belgium|Investigational Site Number 0760023, Blumenau, Brazil|Investigational Site Number 0760008, Curitiba, Brazil|Investigational Site Number 0760002, Fortaleza, Brazil|Investigational Site Number 0760012, Porto Alegre, Brazil|Investigational Site Number 0760022, Sao Paulo, Brazil|Investigational Site Number 0760020, Sao Paulo, Brazil|Investigational Site Number 0760007, Sao Paulo, Brazil|Investigational Site Number 0760001, São José Do Rio Preto, Brazil|Investigational Site Number 0760010, São Paulo, Brazil|Investigational Site Number 1000008, Burgas, Bulgaria|Investigational Site Number 1000007, Plovdiv, Bulgaria|Investigational Site Number 1000004, Sofia, Bulgaria|Investigational Site Number 1000003, Sofia, Bulgaria|Investigational Site Number 1000001, Sofia, Bulgaria|Investigational Site Number 1240003, Greenfield Park, Canada|Investigational Site Number 1240004, Montreal, Canada|Investigational Site Number 1520007, Santiago, Chile|Investigational Site Number 1520006, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520009, Santiago, Chile|Investigational Site Number 1520002, Santiago, Chile|Investigational Site Number 1520005, Temuco, Chile|Investigational Site Number 1520001, Viña Del Mar, Chile|Investigational Site Number 1560026, Beijing, China|Investigational Site Number 1560010, Changchun, China|Investigational Site Number 1560024, Fuzhou, China|Investigational Site Number 1560001, Guangzhou, China|Investigational Site Number 1560037, Guangzhou, China|Investigational Site Number 1560017, Guangzhou, China|Investigational Site Number 1560034, Guangzhou, China|Investigational Site Number 1560025, Hangzhou, China|Investigational Site Number 1560033, Hangzhou, China|Investigational Site Number 1560021, Hangzhou, China|Investigational Site Number 1560018, Hangzhou, China|Investigational Site Number 1560011, Hangzhou, China|Investigational Site Number 1560014, Hefei, China|Investigational Site Number 1560028, Jinan, China|Investigational Site Number 1560035, Nanchang, China|Investigational Site Number 1560019, Nanjing, China|Investigational Site Number 1560006, Wuhan, China|Investigational Site Number 1560016, Zhanjiang, China|Investigational Site Number 1560041, Zhengzhou, China|Investigational Site Number 1560040, Zhengzhou, China|Investigational Site Number 2500010, Bordeaux Cedex, France|Investigational Site Number 2500008, Caen Cedex 05, France|Investigational Site Number 2500006, Creteil, France|Investigational Site Number 2500001, Marseille Cedex 20, France|Investigational Site Number 2500003, Rennes Cedex 09, France|Investigational Site Number 2500002, Saint-Mande, France|Investigational Site Number 2500004, Villejuif Cedex, France|Investigational Site Number 2760001, Heidelberg, Germany|Investigational Site Number 2760003, Oldenburg, Germany|Investigational Site Number 3480002, Budapest, Hungary|Investigational Site Number 3480003, Budapest, Hungary|Investigational Site Number 3480004, Budapest, Hungary|Investigational Site Number 3480007, Budapest, Hungary|Investigational Site Number 3480001, Debrecen, Hungary|Investigational Site Number 3480008, Farkasgyepü, Hungary|Investigational Site Number 3480005, Kaposvár, Hungary|Investigational Site Number 3760005, Jerusalem, Israel|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800003, Orbassano, Italy|Investigational Site Number 3920011, Bunkyo-Ku, Japan|Investigational Site Number 3920012, Fukuoka-Shi, Japan|Investigational Site Number 3920017, Himeji-Shi, Japan|Investigational Site Number 3920001, Hirakata-Shi, Japan|Investigational Site Number 3920006, Kanazawa-Shi, Japan|Investigational Site Number 3920008, Kurume-Shi, Japan|Investigational Site Number 3920002, Nagoya-Shi, Japan|Investigational Site Number 3920015, Nagoya-Shi, Japan|Investigational Site Number 3920009, Natori-Shi, Japan|Investigational Site Number 3920013, Osaka Sayama-Shi, Japan|Investigational Site Number 3920003, Osaka-Shi, Japan|Investigational Site Number 3920014, Sakai-Shi, Japan|Investigational Site Number 3920016, Sapporo-Shi, Japan|Investigational Site Number 3920004, Sunto-Gun, Japan|Investigational Site Number 3920010, Ube-Shi, Japan|Investigational Site Number 3920007, Wakayama-Shi, Japan|Investigational Site Number 3920005, Yokohama-Shi, Japan|Investigational Site Number 4100008, Busan-gwangyeoksi, Korea, Republic of|Investigational Site Number 4100005, Cheongju-Si, Korea, Republic of|Investigational Site Number 4100006, Seoul, Korea, Republic of|Investigational Site Number 4100007, Seoul, Korea, Republic of|Investigational Site Number 4100003, Seoul, Korea, Republic of|Investigational Site Number 4100001, Seoul, Korea, Republic of|Investigational Site Number 4100004, Seoul, Korea, Republic of|Investigational Site Number 4840002, Cdmx, Mexico|Investigational Site Number 4840004, Guadalajara, Mexico|Investigational Site Number 4840003, México, Mexico|Investigational Site Number 5280003, 'S Hertogenbosch, Netherlands|Investigational Site Number 5280004, Breda, Netherlands|Investigational Site Number 5280005, Utrecht, Netherlands|Investigational Site Number 6160004, Olsztyn, Poland|Investigational Site Number 6160003, Radom, Poland|Investigational Site Number 6160001, Warsaw, Poland|Investigational Site Number 6200002, Almada, Portugal|Investigational Site Number 6200001, Lisboa, Portugal|Investigational Site Number 6200004, Lisboa, Portugal|Investigational Site Number 6200006, Porto, Portugal|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430003, Saint -Petersburg, Russian Federation|Investigational Site Number 7240007, Barcelona, Spain|Investigational Site Number 7240005, Barcelona, Spain|Investigational Site Number 7240001, Hospitalet De Llobregat, Spain|Investigational Site Number 7240009, Madrid / Madrid, Spain|Investigational Site Number 7240106, Madrid, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240010, Majadahonda, Spain|Investigational Site Number 7240004, Málaga, Spain|Investigational Site Number 7240006, Pamplona, Spain|Investigational Site Number 7240011, Sevilla, Spain|Investigational Site Number 7240008, Valencia, Spain|Investigational Site Number 7920008, Adana, Turkey|Investigational Site Number 7920002, Adana, Turkey|Investigational Site Number 7920004, Ankara, Turkey|Investigational Site Number 7920003, Edirne, Turkey|Investigational Site Number 7920005, Istanbul, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920006, Istanbul, Turkey|Investigational Site Number 7920007, Izmir, Turkey|Investigational Site Number 7920009, Malatya, Turkey",4814470,C07D305/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,LUNG CANCER,_NIRAPARIB,NCT03891615,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess, Boston, Massachusetts, United States",8859562,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
O=P1(N(CCCl)CCCl)NCCCO1,RHABDOMYOSARCOMA,_CYCLOPHOSPHAMIDE,NCT04388839,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moffitt Cancer Center, Tampa, Florida, United States",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,RHABDOMYOSARCOMA,_VINCRISTINE,NCT04388839,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moffitt Cancer Center, Tampa, Florida, United States",6723338,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,OSTEOSARCOMA,_CYCLOPHOSPHAMIDE,NCT03063983,Phase 2,Recruiting,All,"up to 30 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grupo de Apoio ao Adolescente e a Criança com Câncer, Sao Paulo, Brazil",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,OSTEOSARCOMA,_METHOTREXATE,NCT03063983,Phase 2,Recruiting,All,"up to 30 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grupo de Apoio ao Adolescente e a Criança com Câncer, Sao Paulo, Brazil",6746429,A61M5/2425,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,LUNG CANCER,_PALBOCICLIB,NCT03170206,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",6936612,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,LUNG CANCER,_BINIMETINIB,NCT03170206,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",7777050,C07D235/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,9.0,28.9780077619663,11.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,441.233,88.41,5.0,3.0,3.0,38.55,98.02,6.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,LUNG ADENOCARCINOMA,_VINORELBINE,NCT03891173,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Europejskie Centrum Zdrowia Otwock, Otwock, Poland|Dnipropetrovsk City Multi-field Clinical Hospital #4, Dnipro, Ukraine|Sumy Regional Clinical Oncological Centre, Sumy, Ukraine|Vinnytsya Regional Clinical Oncological Centre, Vinnytsia, Ukraine",4307100.0,C07D519/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,LUNG CANCER,_GEMCITABINE,NCT02428764,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,NON SMALL CELL LUNG CANCER,_PACLITAXEL,NCT02477826,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Southern Cancer Center, Inc., Mobile, Alabama, United States|Local Institution, La Jolla, California, United States|California Pacific Medical Center, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Emory University Hospital, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Southfield, Michigan, United States|Local Institution, Rochester, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Medical Group, Pc, Sayre, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Greenville Health System, Greenville, South Carolina, United States|St Francis Hospital, Greenville, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|The University Of Texas, Dallas, Texas, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|Huntsman Cancer Institute At The Univ. Of Utah, Salt Lake City, Utah, United States|Kadlec Clinical Hematology and Oncology, Kennewick, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Instituto Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Fundacion Investigar, Ciudad de Buenos Aires, Buenos Aires, Argentina|Hospital Privado De Comunidad, Mar Del Plata, Buenos Aires, Argentina|Hospital Privado Centro Medico De Cordoba, Córdoba, Cordoba, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|Local Institution, Garran, Australian Capital Territory, Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Local Institution, Gosford, New South Wales, Australia|Tamworth Hospital, Tamworth, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Clayton, Victoria, Australia|St Vincent's Hospital, Fitzroy, Victoria, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Murdoch, Australia|Medizinische Universitatsklinik, Graz, Austria|Akh Wien, Vienna, Austria|Klinikum Wels-Grieskirchen Gmbh, Wels, Austria|Local Institution, Charleroi, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Hasselt, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Sint Niklaas, Belgium|Local Institution, Salvador, Bahia, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Dr. H.Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada|London Regional Cancer Program, London, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivieres, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec - Universite Laval, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Instituto Oncologico, Vina Del Mar, Valparaiso, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Haikou, Hainan, China|Local Institution, Haerbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Xi'an, Shaanxi, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Qingdao, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Hanghzou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Changsha, China|Local Institution, Chongqing, China|Local Institution, Chongqing, China|Local Institution, Hangzhou, China|Local Institution, Hangzhou, China|Local Institution, Kunming, China|Local Institution, Shanghai, China|Oncologos Del Occidente Sa, Pereira, Risaralda, Colombia|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Hospital Universitario San Ignacio, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Plicni klinika, Hradec Kralove, Czechia|Klinika plicnich nemoci a tuberkulozy, Olomouc, Czechia|Pneumologicka klinika 1. LF a TN, Praha 4, Czechia|Oddeleni Onkologie, Pribram, Czechia|Local Institution, Oulu, Finland|Local Institution, Turku, Finland|Local Institution, ANGERS Cedex 2, France|Local Institution, Besançon Cedex, France|Local Institution, Bron Cedex, France|Local Institution, Caen, France|Local Institution, Creteil, France|Local Institution, Limoges cedex, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Pessac, France|Local Institution, Rennes Cedex 9, France|Local Institution, Rouen, France|Local Institution, Saint Herblain, France|Local Institution, Saint Priest En Jarez, France|Local Institution, Strasbourg, France|Local Institution, Toulon, France|Zentralklinik Bad Berka Gmbh, Bad Berka, Thuringen, Germany|Local Institution, Berlin, Germany|Universitaetsklinikum Essen, Essen, Germany|Universitatsklinikum Frankfurt, Frankfurt, Germany|SRH WALD KLINIKUM GERA gGmbH, Gera, Germany|Klinik Schillerhoehe, Gerlingen, Germany|Krankenhaus Grosshansdorf, Grosshansdorf, Germany|Stadtisches Krankenhaus Martha Maria Halle-Dolau, Halle, Germany|Thoraxklinik-Heidelberg Ggmbh, Heidelberg, Germany|Lungenklinik Hemer, Hemer, Germany|Klinikverbund Kempten-Oberallgau, Immenstadt, Germany|Universitaetsklinikum Magdeburg A. o. R., Magdeburg, Germany|Klinikum Bogenhausen, Muenchen, Germany|Hsk Dr.-Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany|Local Institution, Athens, Greece|Local Institution, Heraklio, Greece|Local Institution, Neo Faliro, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Matrahaza, Hungary|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Limerick, Ireland|Local Institution, Jerusalem, Israel|Local Institution, Kfar-saba, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Tel-hashomer, Israel|Local Institution, Zerifin, Israel|Local Institution, Avellino, Italy|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Livorno, Italy|Local Institution, Messina, Italy|Local Institution, Milano, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Local Institution, Ravenna, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, S.Andrea Fratte PG, Italy|Local Institution, Terni, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Ota-shi, Gunma, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osakasayama-shi, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Wakayama-shi, Wakayama, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Cheongju-si, Chungcheonbuk-do, Korea, Republic of|Local Institution, Seongnam-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Beirut, Lebanon|Local Institution, Beirut, Lebanon|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Phylasis Clinicas Research S de R. L. de C. V., Cuautitlan, Estado DE Mexico, Mexico|Local Institution, Toluca, Estado DE Mexico, Mexico|Instituto Jalisciense De Cancerologia, Guadalajara, Jalisco, Mexico|Local Institution, Morelia, Michoacan, Mexico|Axis Heilsa S de Rl de Cv, Monterrey, Nuevo LEON, Mexico|Medical Care & Research, Merida, Yucatan, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, San Luis Potosi, Mexico|Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi S.C., San Luis Potosi, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|Local Institution, Breda, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Veldhoven, Netherlands|Clinica Ricardo Palma, Lima, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Clinica San Felipe- Unidad de Oncologia Medica, Lima, Peru|Instituto Oncologico Miraflores, Lima, Peru|Oncocenter Peru SAC - Oncosalud, Lima, Peru|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Oddzial Onkologii I Radioterapii Szpital Morski Im. Pck, Gdynia, Poland|Centrum Onkologii-Inst.Im.M.Sklodowskiej-Curie O.W Gliwicach, Gliwice, Poland|Regionalny Osrodek Onkologiczny, Lodz, Poland|Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|ORTHOS Szpital Wielospecjalistyczny Sp. z o.o., Wroclaw, Poland|Institute Of Oncology ""Prof.Dr.Alexandru Trestioreanu"" Bucha, Bucharest, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|S.C. Radiotherapy Center Cluj S.R.L., Floresti, Romania|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep, Romania, Romania|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Ufa, Russian Federation|Local Institution, Riyadh 11426, Saudi Arabia|Local Institution, Riyadh-11211, Saudi Arabia|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Saxonwold, Johannesburg, Gauteng, South Africa|Local Institution, Vereeniging, South Africa|Local Institution, Majadahonda, Madrid, Spain|Local Institution, Badalona (Barcelona), Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Klinik Fur Onkologie, Basel, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|Local Institution, Winterthur, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Tao-Yuan County, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Kayseri, Turkey|Local Institution, Al Ain, United Arab Emirates|Local Institution, Middlesborough, Cleveland, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Leicester, Leicestershire, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, Cambridgeshire, United Kingdom|Local Institution, Edinburgh, United Kingdom|Local Institution, Surrey, United Kingdom",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,SMALL CELL LUNG CANCER,_PACLITAXEL,NCT04210037,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Flinders Medical Centre, Bedford Park, South Australia, Australia",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER,_PACLITAXEL,NCT04416035,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Anhui Provincial Center Hospital, Hefei, Anhui, China|Chinese Academy of Medical Sciences, Cancer Hospital, Beijing, Beijing, China|Beijing Hospital, Beijing, Beijing, China|The Second Affiliated Hospital of Xingtai Medical College, Xingtai, Hebei, China|Wuhan Fourth Hospital, Wuhan, Hubei, China|The Second Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China|FAW General Hospital of Jilin Province, Changchun, Jilin, China|Jinan Central Hospital, Jinan, Shandong, China|Shanghai East Hospital, Shanghai, Shanghai, China|Shanghai Fifth People's Hospital, Fudan University, Shanghai, Shanghai, China|Nanchong Central Hospital, Nanchong, Sichuan, China",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,ADVANCED NON-SQUAMOUS NSCLC,_PACLITAXEL,NCT04325698,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China|Dongguan People's Hospital, Dongguan, Guangdong, China|Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China|Affiliated Hospital of Hebei University, Baoding, Hebei, China|Henan Cancer Hostipal, Zhengzhou, Henan, China|Xuzhou Central Hospital/ Medical Oncology Department, Xuzhou, Jiangsu, China|Jinan Central Hospital, Jinan, Shandong, China|Linyi Cancer Hospital, Linyi, Shandong, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, China|Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology, Hangzhou, Zhejiang, China",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,NON SMALL CELL LUNG CANCER,_OLAPARIB,NCT03334617,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Duarte, California, United States|Research Site, Fullerton, California, United States|Research Site, La Jolla, California, United States|Research Site, Santa Monica, California, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Edmonton, Alberta, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Bordeaux, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Villejuif, France|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Grosshansdorf, Germany|Research Site, Haifa, Israel|Research Site, Kfar Saba, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of",7151102,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1,NON SMALL CELL LUNG CANCER,_VISTUSERTIB,NCT03334617,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Duarte, California, United States|Research Site, Fullerton, California, United States|Research Site, La Jolla, California, United States|Research Site, Santa Monica, California, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Edmonton, Alberta, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Bordeaux, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Villejuif, France|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Grosshansdorf, Germany|Research Site, Haifa, Israel|Research Site, Kfar Saba, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of",US-20090099174-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,12.0,32.7488,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.22,462.55400000000003,92.71,8.0,1.0,5.0,51.35,133.06,4.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,NON SMALL CELL LUNG CANCER,_CEDIRANIB,NCT03334617,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Duarte, California, United States|Research Site, Fullerton, California, United States|Research Site, La Jolla, California, United States|Research Site, Santa Monica, California, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Edmonton, Alberta, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Bordeaux, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Villejuif, France|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Grosshansdorf, Germany|Research Site, Haifa, Israel|Research Site, Kfar Saba, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of",WO-2001074360-A1,A61K45/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,11.0,32.7488,26.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.77,450.5053,72.5,5.0,1.0,5.0,48.77,125.16,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,NON SMALL CELL LUNG CANCER,_METHYLPREDNISOLONE,NCT03661567,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)[CH]CC2=O)C(C)C)cc1)C(C)C,NON SMALL CELL LUNG CANCER,_VEDOTIN,NCT03539536,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of South Alabama /ID# 212939, Mobile, Alabama, United States|Mayo Clinic Arizona /ID# 218550, Phoenix, Arizona, United States|Highlands Oncology Group /ID# 215600, Fayetteville, Arkansas, United States|UCSD Moores Cancer Center - LaJolla /ID# 218258, La Jolla, California, United States|University of California, Los Angeles /ID# 203219, Los Angeles, California, United States|Sutter Medical Center Sacramen /ID# 203299, Sacramento, California, United States|Univ of Colorado Cancer Center /ID# 203212, Aurora, Colorado, United States|Rocky Mountain Cancer Centers - Denver Midtown /ID# 215789, Denver, Colorado, United States|Mayo Clinic /ID# 218488, Jacksonville, Florida, United States|Straub Clinic and Hospital /ID# 217905, Honolulu, Hawaii, United States|Northwestern University Feinberg School of Medicine /ID# 203239, Chicago, Illinois, United States|University of Chicago /ID# 203216, Chicago, Illinois, United States|NorthShore University HealthSystem - Evanston Hospital /ID# 215583, Evanston, Illinois, United States|Ingalls Memorial Hosp /ID# 203228, Harvey, Illinois, United States|Joliet Oncology-Hematology Associates, LTD /ID# 203238, Joliet, Illinois, United States|Goshen Center for Cancer Care /ID# 215584, Goshen, Indiana, United States|Univ Kansas Med Ctr /ID# 216804, Kansas City, Kansas, United States|Cancer Center of Kansas /ID# 203235, Wichita, Kansas, United States|Baptist Health /ID# 203283, Lexington, Kentucky, United States|Norton Cancer Institute /ID# 203284, Louisville, Kentucky, United States|Central Maine Medical Center /ID# 216583, Lewiston, Maine, United States|Massachusetts General Hospital /ID# 203215, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center /ID# 208124, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 203248, Boston, Massachusetts, United States|University of Michigan Hospitals /ID# 215646, Ann Arbor, Michigan, United States|Henry Ford Hospital - West Bloomfield /ID# 203220, West Bloomfield, Michigan, United States|Mayo Clinic - Rochester /ID# 215603, Rochester, Minnesota, United States|Washington University-School of Medicine /ID# 203217, Saint Louis, Missouri, United States|St. Vincent Frontier Cancer Center /ID# 203292, Billings, Montana, United States|Univ Nebraska Med Ctr /ID# 203388, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center /ID# 203350, Lebanon, New Hampshire, United States|Atlantic Health System /ID# 203404, Morristown, New Jersey, United States|Overlook Medical Center /ID# 211160, Summit, New Jersey, United States|University of New Mexico /ID# 208339, Albuquerque, New Mexico, United States|Univ Hosp Cleveland /ID# 215648, Cleveland, Ohio, United States|Providence Cancer Center Oncology and Hematology Care - Westside Portland /ID# 203301, Portland, Oregon, United States|Penn State University and Milton S. Hershey Medical Center /ID# 221844, Hershey, Pennsylvania, United States|Allegheny General Hospital /ID# 215585, Pittsburgh, Pennsylvania, United States|Veterans Healthcare System /ID# 215602, Pittsburgh, Pennsylvania, United States|Vanderbilt University Med Ctr /ID# 203281, Nashville, Tennessee, United States|Houston Methodist Hospital - Scurlock Tower /ID# 213268, Houston, Texas, United States|Baylor Scott & White Medical Center- Temple /ID# 216578, Temple, Texas, United States|Virginia Cancer Specialists /ID# 203224, Fairfax, Virginia, United States|University of Washington /ID# 206056, Seattle, Washington, United States|Medical College of Wisconsin /ID# 210062, Milwaukee, Wisconsin, United States|The Kinghorn Cancer Centre /ID# 207666, Darlinghurst, New South Wales, Australia|Newcastle Private Hospital /ID# 206600, Lambton Heights, New South Wales, Australia|The Tweed Hospital /ID# 206601, Tweed Heads, New South Wales, Australia|UZ Antwerp /ID# 217430, Edegem, Belgium|AZ Groeninge /ID# 217431, Kortrijk, Belgium|Cross Cancer Institute /ID# 204540, Edmonton, Alberta, Canada|The Ottawa Hospital /ID# 205579, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre /ID# 204423, Toronto, Ontario, Canada|CISSS de la Monteregie /ID# 211356, Greenfield Park, Quebec, Canada|Anhui Provincial Hospital /ID# 212096, Hefei, Anhui, China|Fujian Provincial Cancer Hospital /ID# 210808, Fuzhou, Fujian, China|Jilin Cancer Hosptial /ID# 210563, Changchun, Jilin, China|Fudan University Shanghai Cancer Center /Id# 210084, Shanghai, Shanghai, China|The First Affiliated Hospital,College of Medicine, Zhejiang University /ID# 211154, Hangzhou, Zhejiang, China|Zhejiang Cancer hospital /ID# 210085, Hangzhou, Zhejiang, China|Beijing Cancer Hospital /ID# 210133, Beijing, China|West China Hospital, Sichuan University /ID# 210022, Chengdu, China|Shanghai Chest Hospital /ID# 210930, Shanghai, China|Henan Cancer Hospital /ID# 210961, Zhengzhou Henan, China|CHU Hopital Nord /ID# 209854, Marseille, Bouches-du-Rhone, France|Institut Bergonie /ID# 216207, Bordeaux, Gironde, France|Institut Curie /ID# 207046, Paris CEDEX 05, Ile-de-France, France|Centre Leon Berard /ID# 205107, Lyon CEDEX 08, Rhone, France|Institut Gustave Roussy /ID# 205149, Villejuif, Val-de-Marne, France|Hopital Louis Pradel /ID# 216209, Bron, France|CHRU de Lille - Hopital Albert Calmette /ID# 205105, Lille, France|Nouvel Hopital Civil (NHC) /ID# 208080, Strasbourg, France|KH Martha-Maria Halle Dolau /ID# 205442, Halle (Saale), Sachsen-Anhalt, Germany|Vivantes Klinikum Neukolln /ID# 205928, Berlin, Germany|Asklepios Fachkliniken M. Gaut /ID# 207789, Gauting, Germany|Evangelisches Krankenhaus Hamm /ID# 208043, Hamm, Germany|Klinikum Kassel /ID# 205443, Kassel, Germany|Pius Hospital Oldenburg /ID# 211615, Oldenburg, Germany|General Hospital of Chest Diseases of Athens SOTIRIA /ID# 205528, Athens, Greece|Metropolitan Hospital /ID# 205529, Athens, Greece|University General Hospital of Heraklion PA.G.N.I /ID# 205530, Heraklion, Greece|CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 204878, Miskolc, Borsod-Abauj-Zemplen, Hungary|Torokbalinti Tudogyogyintezet /ID# 204883, Budapest, Pest, Hungary|Semmelweis Egyetem /ID# 204434, Budapest, Hungary|Veszprem Megyei Tudogyogyintez /ID# 213950, Farkasgyepu, Hungary|Matrahaza Gyogyintezet /ID# 204432, Kékesteto, Hungary|St. James's Hospital /ID# 205104, Dublin 8, Dublin, Ireland|Cork University Hospital /ID# 205103, Cork, Ireland|St Vincent's University Hosp /ID# 205102, Dublin, Ireland|Soroka Medical Center /ID# 204898, Be'er Sheva, HaDarom, Israel|Rabin Medical Center /ID# 215322, Petakh Tikva, Tel-Aviv, Israel|Rambam Health Care Campus /ID# 204866, Haifa, Israel|Meir Medical Center /ID# 204255, Kfar Saba, Israel|Sheba Medical Center /ID# 204254, Ramat Gan, Israel|IRST IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori /ID# 205601, Meldola, Emilia-Romagna, Italy|Policlinico Universitario Campus Bio-Medico /ID# 215918, Rome, Lazio, Italy|Azienda Ospedaliera San Camillo Forlanini /ID# 205163, Rome, Lazio, Italy|AO San Giuseppe Moscati /ID# 204707, Avellino, Italy|A.O.U. San Luigi Gonzaga /ID# 204706, Orbassano, Italy|Azienda Ospedaliero Uni Parma /ID# 204983, Parma, Italy|National Hospital Organization Kyushu Cancer Center /ID# 206061, Fukuoka-shi, Fukuoka, Japan|Kinki-Chuo Chest Medical Center /ID# 216461, Kita-ku, Osaka, Japan|Shizuoka Cancer Center /ID# 205065, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital /ID# 205066, Chuo-ku, Tokyo, Japan|The Cancer Institute Hospital Of JFCR /ID# 216463, Koto-ku, Tokyo, Japan|Hiroshima Citizens Hospital /ID# 218087, Hiroshima, Japan|Niigata Cancer Center Hospital /ID# 216462, Niigata-shi, Japan|Osaka Inter. Cancer Institute /ID# 210735, Osaka, Japan|Sendai Kousei Hospital /ID# 216460, Sendai, Japan|Kanagawa Cancer Center /ID# 205068, Yokohama, Japan|National Cancer Center /ID# 204241, Goyang, Gyeonggido, Korea, Republic of|Seoul National Univ Bundang ho /ID# 204237, Seongnam, Gyeonggido, Korea, Republic of|Chungbuk National Univ Hosp /ID# 205680, Cheongju, Korea, Republic of|Chonnam National University Hwasun Hospital /ID# 206951, Jeonnam, Korea, Republic of|Asan Medical Center /ID# 204236, Seoul, Korea, Republic of|Antoni van Leeuwenhoek /ID# 216657, Amsterdam, Noord-Holland, Netherlands|Meander Medisch Centrum /ID# 217756, Amersfoort, Netherlands|Ziekenhuis St. Jansdal /ID# 216658, Harderwijk, Netherlands|VA Caribbean Healthcare System /ID# 206336, San Juan, Puerto Rico|Puerto Rico Hematology Oncolog /ID# 206337, San Juan, Puerto Rico|Institutul Oncologic /ID# 206320, Cluj Napoca, Romania|Oncomed SRL /ID# 205616, Timisoara, Romania|""Avicenna"" medical center /ID# 212397, Novosibirsk, Novosibirskaya Oblast, Russian Federation|Tatarstan Cancer Center /ID# 206463, Kazan, Tatarstan, Respublika, Russian Federation|Volgograd Regional Clinical Oncology Dispensary /ID# 206520, Volgograd, Volgogradskaya Oblast, Russian Federation|Arkhangelsk clinical oncology /ID# 216418, Arkhangelsk, Russian Federation|LLC Evimed /ID# 216473, Chelyabinsk, Russian Federation|Univercity Headache Clynic,LTD /ID# 212080, Moscow, Russian Federation|PMI Euromedservice /ID# 206390, Pushkin, Russian Federation|LLC Novaya Clinica /ID# 216262, Pyatigorsk, Russian Federation|OOO Centre of Palliative Medicine De Vita /ID# 212900, Saint Petersburg, Russian Federation|St.Petersburg City Cancer Center /ID# 206405, Sankt-Peterburg, Russian Federation|Hospital Clínico Universitario de Santiago /ID# 204367, Santiago de Compostela, A Coruna, Spain|Instituto Catalan de Oncologia (ICO) Badalona /ID# 216106, Badalona, Barcelona, Spain|Hospital Regional Universitario de Malaga /ID# 216081, Málaga, Malaga, Spain|Hospital Universitario y Politecnico La Fe /ID# 203862, Valencia, Valenciana, Spain|Hospital Vall d'Hebron /ID# 206997, Barcelona, Spain|Hospital Univ Ramon y Cajal /ID# 203922, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 203913, Madrid, Spain|Hosp Univ Virgen del Rocio /ID# 216058, Sevilla, Spain|National Cheng Kung University Hospital /ID# 205307, Tainan City, Tainan, Taiwan|National Taiwan University Hospital /ID# 205100, Taipei City, Taipei, Taiwan|Dalin Tzu Chi General Hospital /ID# 205309, Dalin Township, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 205831, Kaohsiung, Taiwan|Taipei Med Univ Shuang Ho Hosp /ID# 215356, New Taipei City, Taiwan|Taichung Veterans General Hosp /ID# 205308, Taichung City, Taiwan|Linkou Chang Gung Memorial Ho /ID# 205424, Taoyuan City, Taiwan|Adana Sehir Egitim ve Arastirma Hastanesi /ID# 206000, Adana, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi /ID# 205243, Ankara, Turkey|Akdeniz Universitesi Tip Fakul /ID# 205238, Antalya, Turkey|Trakya University Medical Facu /ID# 205242, Edirne, Istanbul, Turkey|Istanbul Medeniyet Universites /ID# 215082, Istanbul, Turkey|Dr. Suat Seren Gogus Has /ID# 215083, Izmir, Turkey|Heart of England NHS Foundation Trust /ID# 206209, Birmingham, United Kingdom|Oxford Univ Hosp NHS Trust /ID# 205890, Oxford, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,NON SMALL CELL LUNG CANCER,_ETOPOSIDE,NCT03840902,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California Irvine Medical Center, Orange, California, United States|UCLA Hematology Oncology - Main Site - 2020 Santa Monica, Santa Monica, California, United States|University of Colorado Health - Memorial Hospital - Memorial Hospital, Colorado Springs, Colorado, United States|Lynn Cancer Institute Center, Boca Raton, Florida, United States|Holy Cross Hospital - Michael and Dianne Bienes CCC, Fort Lauderdale, Florida, United States|Sylvester Comprehensive Cancer Center - University of Miami Health System, Miami, Florida, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|American Health Network of Indiana, LLC, Indianapolis, Indiana, United States|Baptist Health Lexington Oncology Associates, Lexington, Kentucky, United States|University of Maryland - DUPLICATE/Pediatric Surgery, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Columbia University Medical Center, New York, New York, United States|Hematology Oncology Center of Nyack Hospital, Nyack, New York, United States|FirstHealth of the Carolinas, Inc., Pinehurst, North Carolina, United States|The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|University of Texas MD Anderson Cancer Center - Unit 432 Thoracic Head and Neck Medical Oncology, Houston, Texas, United States|Centro Polivalente de Asistencia e Inv. Clinica CER, San Juan, Argentina|Bendigo Hospital, Bendigo, Australia|The Townsville Hospital, Douglas, Australia|Calvary Central Districts Hospital, Elizabeth Vale, Australia|St Vincent's Hospital Melbourne - PARENT, Fitzroy, Australia|Austin Health, Heidelberg Heights, Australia|Centro de Investigacion Pergamino SA, Pergamino, Australia|Prince of Wales Hospital, Randwick, Australia|Sunshine Hospital, St Albans, Australia|South West Healthcare - South West Oncology, Warrnambool, Australia|UZ Leuven, Leuven, Belgium|Clinique et Maternite St Elisabeth Namur, Namur, Belgium|CHU Mont-Godinne, Yvoir, Belgium|Hospital de Câncer de Barretos - Fundação Pio XII, Barretos, Brazil|HGB - Hospital Giovanni Battista - Mãe de Deus Center - Centro de Pesquisa Clínica - Instituto do Câncer, Porto Alegre, Brazil|Hospital São Lucas da PUCRS, Porto Alegre, Brazil|COI - Clínicas Oncológicas Integradas, Rio de Janeiro, Brazil|A. C. Camargo Cancer Center - Fundação Antônio Prudente, São Paulo, Brazil|ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira, São Paulo, Brazil|BC Cancer Agency Center for the Southern Interior, Kelowna, Canada|Fakultni nemocnice Olomouc - Dept of Onkologicka klinika, Olomouc, Czechia|Hôpital Nord - AP-HM Marseille# - Service d'Oncologie Multidisciplinaire, Marseille cedex 20, France|Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris - Service d'Oncologie Médicale, Paris Cedex 05, France|CHU Nantes - Hôpital Guillaume et René Laënnec - Service de Pneumologie, Saint Herblain, France|Nippon Medical School Hospital - Dept of Respiratory Medicine, Bunkyo-ku, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital - Dept of Respiratory Medicine, Bunkyo-ku, Japan|Saitama Medical University International Medical Center - Dept of Respiratory Medicine, Hidaka-shi, Japan|National Cancer Center Hospital East - Dept of Respiratory Medicine, Kashiwa-shi, Japan|Kobe City Hospital Organization Kobe City Medical Center General Hospital - Dept of Respiratory Medicine, Kobe-shi, Japan|Cancer Institute Hospital of JFCR - Dept of Respiratory Medicine, Koto-ku, Japan|Kurume University Hospital - Dept of Lung Cancer Center, Kurume-shi, Japan|Aichi Cancer Center Hospital - Dept of Respiratory Medicine, Nagoya-shi, Japan|Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka-shi, Japan|Kindai University Hospital (13859), Osakasayama-shi, Japan|Shizuoka Cancer Center, Sunto-gun, Japan|Kanagawa Cancer Center - Dept of Respiratory Medicine, Yokohama-shi, Japan|Keimyung University Dongsan Hospital, Daegu, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Jeroen Bosch Ziekenhuis, 's Hertogenbosch, Netherlands|Meander Medisch Centrum - Dep of Pulmonology, Amersfoort, Netherlands|Amphia Ziekenhuis - PARENT - Parent, Breda, Netherlands|Martini ziekenhuis, Groningen, Netherlands|Ziekenhuis St. Jansdal, Harderwijk, Netherlands|St. Antonius Ziekenhuis - Dept Pulmonology - Nieuwegein, Nieuwegein, Netherlands|St. Elisabeth Ziekenhuis - Parent, Tilburg, Netherlands|ISALA Klinieken Locatie Sophia, Zwolle, Netherlands|Hospital del Mar - Servicio de Oncologia, Barcelona, Spain|Hospital Universitari Vall d'Hebron - Dept of Oncology, Barcelona, Spain|ICO l´Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia, L'Hospitalet de Llobregat, Spain|Hospital Universitario HM Madrid Sanchinarro - Servicio de Oncologia, Madrid, Spain|Clinica Universidad de Navarra (MAD) - Oncology Service, Madrid, Spain|Hospital Universitario 12 de Octubre - Servicio de Oncologia, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Nuestra Señora de Valme - Servicio de Oncologia, Sevilla, Spain|Hospital Universitario Virgen del Rocio - Servicio de Oncologia, Sevilla, Spain|Hospital Universitario Virgen Macarena - Servicio de Oncologia, Sevilla, Spain|Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica, Valencia, Spain|Taichung Veterans General Hospital, Taichung, Taiwan|Chi Mei Medical Center, Liou Ying, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan",4701327,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0
CC(=O)Nc1ccc(O)cc1,"CARCINOMA, NON-SMALL-CELL LUNG",_ACETAMINOPHEN,NCT04165096,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona, United States|City of Hope ( Site 0014), Duarte, California, United States|University of Kentucky Markey Cancer Center ( Site 0019), Lexington, Kentucky, United States|MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland, United States|Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031), Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon, New Hampshire, United States|Cleveland Clinic ( Site 0006), Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center ( Site 0015), Columbus, Ohio, United States|Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center ( Site 0009), Houston, Texas, United States",5972916.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CN(C)CCOC(c1ccccc1)c1ccccc1,"CARCINOMA, NON-SMALL-CELL LUNG",_DIPHENHYDRAMINE,NCT04165096,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona, United States|City of Hope ( Site 0014), Duarte, California, United States|University of Kentucky Markey Cancer Center ( Site 0019), Lexington, Kentucky, United States|MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland, United States|Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031), Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon, New Hampshire, United States|Cleveland Clinic ( Site 0006), Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center ( Site 0015), Columbus, Ohio, United States|Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center ( Site 0009), Houston, Texas, United States",8263647,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,NON SMALL CELL LUNG CANCER,_SELUMETINIB,NCT03392246,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Duke University, Durham, North Carolina, United States",7425637,C07D401/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,42.9084786135238,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,457.68,88.41,5.0,3.0,3.0,40.61,102.61,6.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,SMALL CELL LUNG CANCER,_ACETAZOLAMIDE,NCT03467360,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Antoine Lacassagne, Nice, France",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,LUNG CANCER,_ANLOTINIB,NCT03983928,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China",8148532,C07D239/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,LUNG NEOPLASMS,_ANLOTINIB,NCT03940404,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Observational Model: Case-Only|Time Perspective: Prospective,"First People's Hospital of Hangzhou, Hangzhou, Zhejiang, China",8148532,C07D239/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
Cn1nnc2c(C(N)=O)ncn2c1=O,SMALL CELL LUNG CANCER,_TEMOZOLOMIDE,NCT04400188,Phase 1|Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"West China Hospital of Sichuan University, Chengdu, Sichuan, China",5260291,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
N[C@@H](Cc1ccc(O)cc1)C(=O)O,"CARCINOMA, NON-SMALL-CELL LUNG",_TYROSINE,NCT03799094,Phase 1|Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Clifford Hospital, Guangzhou, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-2.4,181.1885,83.55,4.0,3.0,1.0,18.01,47.1,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
N[C@@H](Cc1ccc(O)cc1)C(=O)O,NSCLC,_TYROSINE,NCT04318938,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-2.4,181.1885,83.55,4.0,3.0,1.0,18.01,47.1,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,"CARCINOMA, NON-SMALL-CELL LUNG",_ZOLEDRONIC_ACID,NCT03958565,,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|NIH,Observational Model: Other|Time Perspective: Prospective,"University of Colorado Hospital, Aurora, Colorado, United States",4939130.0,C07F9/65031,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,LUNG CANCER,_AFATINIB,NCT01553942,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",6251912,C07D239/94,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,34.9247417811453,185.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.77,485.93800000000016,88.61,7.0,2.0,4.0,50.07,131.38,8.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,LUNG CANCER,_PEMETREXED,NCT01553942,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",5344932,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CN(C)C(=N)NC(=N)N,NON SMALL CELL LUNG CANCER,_METFORMIN,NCT03874000,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)N=C(N)N.Cl,NON SMALL CELL LUNG CANCER,_METFORMIN_HYDROCHLORIDE,NCT03874000,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,"CARCINOMA, NON-SMALL-CELL LUNG",_METFORMIN,NCT04170959,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Antwerp, Edegem, Antwerp, Belgium",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,NON-SMALL CELL LUNG CANCER METASTATIC,_PEMETREXED,NCT04163432,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States",5344932,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,LUNG NEOPLASMS,_PEMETREXED,NCT03380468,Phase 2|Phase 3,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fudan University Cancer Center, Shanghai, Shanghai, China",5344932,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,NON-SQUAMOUS NSCLC,_PEMETREXED,NCT03802240,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Shanghai Chest Hospital, Shanghai, China",5344932,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
O=c1[nH]cc(F)c(=O)[nH]1,HEAD AND NECK SQUAMOUS CELL CARCINOMA,_FLUOROURACIL,NCT03340896,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Bretonneau, Service CORad Pôle Henry S Kaplan, Tours, France",6670335,A61K8/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O,SMALL CELL LUNG CANCER,_IRINOTECAN_HYDROCHLORIDE,NCT04381910,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chinese Academy of Medical Sciences and Peking Union Medical College, Peking, Beijing, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,NON SMALL CELL LUNG CANCER,_CABOZANTINIB,NCT04131543,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OU di Oncologia Medica- Azienda ospedaliero-Universitaria S. Orsola Malpighi, Bologna, Italy|U.O di Oncologia Medica Policlinico V.Emanuele-G.Rodolico, Catania, Italy|Oncologia Medica 2 -Policlinico San Martino, Genova, Italy|S.S. di Oncologia Medica toraco-polmonare - Fondazione IRCCS - Istituto Nazionale Tumori, Milano, Italy|U.O.C Pneumologia ad Indirizzo Oncologico -AORN Ospedali dei Colli Monaldi-Cotugno-CTO, Napoli, Italy|UOC di Oncologia Medica 2 - IOV Istituto Oncologico Veneto, Padova, Italy|UOC di Oncologia Medica- Azienda Ospidaliero Universitaria di Parma, Parma, Italy|US di Oncologia Medica - A.O. di Perugia, Perugia, Italy|UO Pneumologia - A.O.U Pisana, Pisa, Italy|S.C. di Oncologia Medica - IFO - Istituto Regina Elena, Roma, Italy|UOC di Oncologia Medica - Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy",7579473,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,7.0,5.9138791350951685,14.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.01,501.514,98.78,5.0,2.0,5.0,51.49,136.12,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,"CARCINOMA, NON-SMALL-CELL LUNG",_CABOZANTINIB,NCT04471428,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology, Tucson, Arizona, United States|Stanford University, Palo Alto, California, United States|Kaiser Permanente - San Diego, San Diego, California, United States|Sansum Clinic, Santa Barbara, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Hartford Healthcare, Hartford, Connecticut, United States|Florida Hospital, Orlando, Florida, United States|Cancer Care Centers of Brevard, Rockledge, Florida, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Quincy Medical Group; Canc Ctr at Blessing Hosp, Quincy, Illinois, United States|Regional Cancer Care Associates, Bethesda, Maryland, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Minnesota Oncology Hematology, Minneapolis, Minnesota, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Oncology Associates of Oregon, P.C, Eugene, Oregon, United States|Consultants in Medical Oncology and Hematology, Broomall, Pennsylvania, United States|Charleston Oncology, P .A, Charleston, South Carolina, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States|Oncology and Hematology Associates of Southwest Virginia, Inc.,-Blacksburg, Blacksburg, Virginia, United States|Virginia Cancer Specialists (Fairfax) - USOR, Fairfax, Virginia, United States|Royal North Shore Hospital; Oncology, St. Leonards, New South Wales, Australia|Townsville Hospital, Townsville, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Austin Hospital Olivia Newton John Cancer Centre, Heidelberg, Victoria, Australia|Affinity Oncology, Nedlands, Western Australia, Australia|LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie, Graz, Austria|Ordensklinikum Linz Elisabethinen, Linz, Austria|Lhk Feldkirch; Interne Medizin Abt., Rankweil, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Wien, Austria|Institut Jules Bordet, Bruxelles, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Gent, Gent, Belgium|Clinique Ste-Elisabeth, Namur, Belgium|Clinique de l'Europe, Amiens, France|CHU Angers,Service de Pneumologie, Angers, France|CHU de Grenoble, Grenoble, France|Hopital Dupuytren; Pneumologie, Limoges, France|Hôpital Saint Joseph; Oncologie Medicale, Marseille, France|Centre Regional de Lutte contre le Cancer Val d Aurelle - Paul Lamarque; Service d oncologie, Montpellier, France|Centre Hospitalier de Mulhouse - Hopital Emile Muller, Mulhouse, France|Hopital Tenon;Pneumologie, Paris, France|Zentralklinik Bad Berka GmbH; Pneumologie, Bad Berka, Germany|Kliniken Essen Mitte Evang. Huyssens Stiftung/Knappschaft GmbH, Essen, Germany|Universitaetsklinikum Giessen und Marburg GmbH; Medizinische Klinik IV und V, Gießen, Germany|KRH Klinikum Siloah-Oststadt-Heidehaus, Hannover, Germany|Klinikum Koeln-Merheim; Lungenklinik, Köln, Germany|Uni. der Johannes Gutenberg-Universitaet Mainz; III. Medizinische Klinik und Poliklinik, Mainz, Germany|Universitaetsklinikum Giessen und Marburg, Marburg, Germany|Brüderkrankenhaus St. Josef Paderborn, Paderborn, Germany|Med. Versorgungszentrum Weiden, Abteilung für Onkologie, Weiden, Germany|Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine, Athens, Greece|Henri Dunant Hospital; Oncology Dept., Athens, Greece|Uoa Sotiria Hospital; Oncology, Athens, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|AORN Ospedali dei Colli Ospedale Monaldi; UOC Pneumologia ad indirizzo Oncologico, Napoli, Campania, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Emilia-Romagna, Italy|Ospedale Provinciale Santa Maria Delle Croci; Oncologia Medica, Ravenna, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy|Azienda Policlinico Umberto I, Roma, Lazio, Italy|IRCCS AOU San Martino - IST, Genova, Liguria, Italy|ASST Spedali Civili di Brescia, Brescia, Lombardia, Italy|Instituto Europeo di Oncologia, Milan, Lombardia, Italy|Istituto Clinico Humanitas, Rozzano (MI), Lombardia, Italy|Ospedale Vito Fazzi, Lecce, Puglia, Italy|A.O.U Careggi, Florence, Toscana, Italy|Hyogo Cancer Center, Hyogo, Japan|Sendai Kousei Hospital, Miyagi, Japan|Osaka International Cancer Institute, Osaka, Japan|Kinki-Chuo Chest Medical Center, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|National Health Insurance Service Ilsan Hospital, Gyeonggi-do, Korea, Republic of|St. Vincent's Hospital, Gyeonggi-do, Korea, Republic of|Ajou University Medical Center, Gyeonggi-do, Korea, Republic of|Samsung Changwon Hospital, Gyeongsangnam-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Ulsan University Hosiptal, Ulsan, Korea, Republic of|Centrum Onkologii im. Prof. Franciszka Łukaszczyka; Ambulatorium Chemioterapii, Bydgoszcz, Poland|SP ZOZ Wojewódzki Szpital Specjalistyczny nr 4; Oddzial Onkologii Klinicznej, Bytom, Poland|Centrum Onkologii w Gliwicach; II Klinika Radioterapii i Chemioterapii, Gliwice, Poland|Szpital Wojewódzki im. Mikołaja Kopernika; Oddział Dzienny Chemioterapii, Koszalin, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Hospital Pulido Valente; Servico de Pneumologia, Lisboa, Portugal|Hospital Pedro Hispano; Servico de Oncologia, Matosinhos, Portugal|Centro Hospitalar do Porto - Hospital de Santo António; Oncologia, Porto, Portugal|Hospital CUF Porto; Servico Pneumologia, Porto, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|CHVNG/E_Unidade 1; Servico de Pneumologia, Vila Nova De Gaia, Portugal|Regional Clinical Oncology Hospital, Yaroslavl, Jaroslavl, Russian Federation|MEDSI Clinical Hospital on Pyatnitsky Highway; Department of antitumor drug therapy, Moscow, Moskovskaja Oblast, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|GBUZ Leningradskaya state clinical hospital, St. Petersburg, Russian Federation|Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Oncologia, La Coruna, LA Coruña, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Univ. Nuestra Señora de Valme; Servicio de Oncologia, Sevilla, Spain|Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia, Valencia, Spain|Hospital Universitari i Politecnic La Fe; Oncologia, Valencia, Spain|Addenbrookes Hospital, Cambridge, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Castle Hill Hospital; The Queen's Centre for Oncology & Haematology, Hull, United Kingdom|Barts & London School of Med; Medical Oncology, London, United Kingdom|University College London Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Chelsea & Westminster Hospital, London, United Kingdom",7579473,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,5.9138791350951685,14.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.01,501.514,98.78,5.0,2.0,5.0,51.49,136.12,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0
CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,NON SMALL CELL LUNG CANCER,_VEMURAFENIB,NCT03178552,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Diego, La Jolla, California, United States|UC Davis; Comprehensive Cancer Center, Sacramento, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Eastern Connecticut Hematology and Oncology Associates; (ECHO), Norwich, Connecticut, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States|Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States|University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States|Illinois Cancer Care, Peoria, Illinois, United States|University of Kentucky; Markey Cancer Center, Lexington, Kentucky, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Health System; Hematology/Oncology, Detroit, Michigan, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cancer Inst. of New Jersey, New Brunswick, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Oregon HSU, Portland, Oregon, United States|St. Luke's University Health network, Bethlehem, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Tennessee Oncology PLLC - Nashville (20th Ave), Nashville, Tennessee, United States|Texas Oncology - South Austin, Austin, Texas, United States|Oncology Consultants PA, Houston, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Hospital Italiano, Buenos Aires, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Royal North Shore Hospital; Department of Medical Oncology, St Leonards, New South Wales, Australia|The Prince Charles Hospital; Oncology Dept., Chermside, Queensland, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|Austin Hospital; Medical Oncology, Heidelberg, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|UZ Brussel, Brussel, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Hospital de Caridade de Ijui; Oncologia, Ijui, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|CancerCare Manitoba; Department of Medical Oncology, Winnipeg, Manitoba, Canada|Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials, Barrie, Ontario, Canada|William Osler Health System Brampton Civic Hospital, Brampton, Ontario, Canada|London Health Sciences Centre · Victoria Hospital; Department of Medicine, London, Ontario, Canada|Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center, Oshawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|IUCPQ (Hôpital Laval), Quebec City, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas, Recoleta, Chile|Clinica CIMCA, San Jose, Costa Rica|Institut Bergonie CLCC Bordeaux, Bordeaux, France|Centre Francois Baclesse; Radiologie, Caen, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hopital Caremeau; Pneumologie, Nimes, France|Hopital Bichat Claude Bernard; Oncologie Serv., Paris, France|Hôpital Européen Georges Pompidou, Paris, France|Hopital Tenon; Oncologie Radiotherapie, Paris, France|CHU Poitiers, Poitiers, France|Hopital Pontchaillou, Rennes, France|CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse cedex 9, France|Hopital Bretonneau; Pneumologie Oncologie, Tours, France|Hopital Robert Schuman; Pneumologie, Vantoux, France|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Universitätsklinikum Düsseldorf; Klinik für Kardiologie, Pneumologie und Angiologie, Düsseldorf, Germany|Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen, Germany|Klinikum Esslingen; Klinik für Kardiologie, Angiologie und Pneumologie, Esslingen, Germany|Asklepios-Fachklinik Muenchen-Gauting; Klinik Für Pneumologie, Gauting, Germany|Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie, Gerlingen, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|HSK Dr.-Horst-Schmidt-Kliniken Klinik für Innere Medizin III Onkologie Hämatologie und Palliativmed, Wiesbaden, Germany|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Queen Mary Hospital; Medicine & Respiratory, Hong Kong, Hong Kong|Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong|Soroka Medical Center; Oncology Dept, Beer Sheva, Israel|Rambam Health Care Campus; Oncology, Haifa, Israel|Meir Medical Center; Oncology, Kfar-Saba, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Israel|Sourasky / Ichilov Hospital; Dept. of Oncology, Tel Aviv, Israel|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Lombardia, Italy|Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia, Milano, Lombardia, Italy|Asst Di Monza, Monza, Lombardia, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga; S.C.D.U. di Oncologia Toracica, Orbassano (TO), Piemonte, Italy|Fujita Health University Hospital, Aichi, Japan|National Cancer Center Hospital East, Chiba, Japan|Shikoku Cancer Center, Ehime, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kanazawa University Hospital, Ishikawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan|Kyoto University Hospital, Kyoto, Japan|Sendai Kousei Hospital, Miyagi, Japan|Tohoku University Hospital, Miyagi, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Kindai University Hospital, Osaka, Japan|Saga University Hospital, Saga, Japan|Shizuoka Cancer Center, Shizuoka, Japan|Juntendo University Hospital, Tokyo, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Kyorin University Hospital, Tokyo, Japan|Wakayama Medical University Hospital, Wakayama, Japan|National Hospital Organization Yamaguchi - Ube Medical Center, Yamaguchi, Japan|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Yonsei University Health System/Severance Hospital, Seoul, Korea, Republic of|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico|Oncologico Potosino, San Luis Potosí, SAN LUIS Potosi, Mexico|AVIX Investigación Clínica S.C, Monterrey, Mexico|Hospital Angeles Tijuana, Tijuana, Mexico|UMCG, NL -groningen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Auckland City Hospital, Auckland, New Zealand|Hemato Oncología de Panamá Especializada, Panama City, Panama|Hospital Nacional Edgardo Rebagliati Martins; Oncologia, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica Ricardo Palma, San Isidro, Peru|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, Poland|Krakowski Szpital Specjalistyczny im.Jana Pawla II, Krakow, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc; Oddzial V Chemioterapii Nowotworow Pluc, Olsztyn, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu, Poznan, Poland|Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad; Klinika Nowot.Pluca i Klatki Piers, Warszawa, Poland|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Principal Military Clinical Hospital n.a. N.N. Burdenko, Moscow, Moskovskaja Oblast, Russian Federation|FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF, Moscow, Russian Federation|Clinical Oncology Dispensary; Chemotherapy, Omsk, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary, St Petersburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia|Clinical Center Nis, NIS, Serbia|Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Insititut Catala D'Oncologia, Hospitalet de Llobregat, Barcelona, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital General Univ. de Alicante, Alicante, Spain|Hospital Universitari Vall d'Hebron; Oncology, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|ICO Badalona - Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal; Servicio de Oncología, Madrid, Spain|Hospital Quiron de Madrid; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clínico Universitario de Valencia; Servicio de Oncología, Valencia, Spain|Kaohsiung Chang Gung Memorial Hospital; Dept of Internal Medicine, Kaohsiung, Taiwan|National Taiwan Uni Hospital; Internal Medicine, Taipei, Taiwan|Taipei Veterans General Hospital; Chest Dept , Section of Thoracic Oncology, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou; Chest Dept, Taoyuan, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Prince of Songkla University; Division of Pulmonary Disease, Department of Medicine, Hat Yai, Thailand|Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology, Adana, Turkey|Akdeniz University Medical Faculty; Medical Oncology Department, Antalya, Turkey|Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department, Edirne, Turkey|Medipol University MF; Oncology Department, Istanbul, Turkey|Marmara Uni Faculty of Medicine; Medical Oncology, Istanbul, Turkey|Medikal Park Izmir Hospital, Karşıyaka, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey",7504509,C07D471/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,39.0,50.9579252140701,12.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.95,489.92199999999997,91.92,4.0,2.0,4.0,48.1,121.97,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,NON SMALL CELL LUNG CANCER,_COBIMETINIB,NCT03178552,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Diego, La Jolla, California, United States|UC Davis; Comprehensive Cancer Center, Sacramento, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Eastern Connecticut Hematology and Oncology Associates; (ECHO), Norwich, Connecticut, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States|Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States|University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States|Illinois Cancer Care, Peoria, Illinois, United States|University of Kentucky; Markey Cancer Center, Lexington, Kentucky, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Health System; Hematology/Oncology, Detroit, Michigan, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cancer Inst. of New Jersey, New Brunswick, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Oregon HSU, Portland, Oregon, United States|St. Luke's University Health network, Bethlehem, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Tennessee Oncology PLLC - Nashville (20th Ave), Nashville, Tennessee, United States|Texas Oncology - South Austin, Austin, Texas, United States|Oncology Consultants PA, Houston, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Hospital Italiano, Buenos Aires, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Royal North Shore Hospital; Department of Medical Oncology, St Leonards, New South Wales, Australia|The Prince Charles Hospital; Oncology Dept., Chermside, Queensland, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|Austin Hospital; Medical Oncology, Heidelberg, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|UZ Brussel, Brussel, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Hospital de Caridade de Ijui; Oncologia, Ijui, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|CancerCare Manitoba; Department of Medical Oncology, Winnipeg, Manitoba, Canada|Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials, Barrie, Ontario, Canada|William Osler Health System Brampton Civic Hospital, Brampton, Ontario, Canada|London Health Sciences Centre · Victoria Hospital; Department of Medicine, London, Ontario, Canada|Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center, Oshawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|IUCPQ (Hôpital Laval), Quebec City, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas, Recoleta, Chile|Clinica CIMCA, San Jose, Costa Rica|Institut Bergonie CLCC Bordeaux, Bordeaux, France|Centre Francois Baclesse; Radiologie, Caen, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hopital Caremeau; Pneumologie, Nimes, France|Hopital Bichat Claude Bernard; Oncologie Serv., Paris, France|Hôpital Européen Georges Pompidou, Paris, France|Hopital Tenon; Oncologie Radiotherapie, Paris, France|CHU Poitiers, Poitiers, France|Hopital Pontchaillou, Rennes, France|CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse cedex 9, France|Hopital Bretonneau; Pneumologie Oncologie, Tours, France|Hopital Robert Schuman; Pneumologie, Vantoux, France|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Universitätsklinikum Düsseldorf; Klinik für Kardiologie, Pneumologie und Angiologie, Düsseldorf, Germany|Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen, Germany|Klinikum Esslingen; Klinik für Kardiologie, Angiologie und Pneumologie, Esslingen, Germany|Asklepios-Fachklinik Muenchen-Gauting; Klinik Für Pneumologie, Gauting, Germany|Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie, Gerlingen, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|HSK Dr.-Horst-Schmidt-Kliniken Klinik für Innere Medizin III Onkologie Hämatologie und Palliativmed, Wiesbaden, Germany|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Queen Mary Hospital; Medicine & Respiratory, Hong Kong, Hong Kong|Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong|Soroka Medical Center; Oncology Dept, Beer Sheva, Israel|Rambam Health Care Campus; Oncology, Haifa, Israel|Meir Medical Center; Oncology, Kfar-Saba, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Israel|Sourasky / Ichilov Hospital; Dept. of Oncology, Tel Aviv, Israel|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Lombardia, Italy|Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia, Milano, Lombardia, Italy|Asst Di Monza, Monza, Lombardia, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga; S.C.D.U. di Oncologia Toracica, Orbassano (TO), Piemonte, Italy|Fujita Health University Hospital, Aichi, Japan|National Cancer Center Hospital East, Chiba, Japan|Shikoku Cancer Center, Ehime, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kanazawa University Hospital, Ishikawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan|Kyoto University Hospital, Kyoto, Japan|Sendai Kousei Hospital, Miyagi, Japan|Tohoku University Hospital, Miyagi, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Kindai University Hospital, Osaka, Japan|Saga University Hospital, Saga, Japan|Shizuoka Cancer Center, Shizuoka, Japan|Juntendo University Hospital, Tokyo, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Kyorin University Hospital, Tokyo, Japan|Wakayama Medical University Hospital, Wakayama, Japan|National Hospital Organization Yamaguchi - Ube Medical Center, Yamaguchi, Japan|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Yonsei University Health System/Severance Hospital, Seoul, Korea, Republic of|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico|Oncologico Potosino, San Luis Potosí, SAN LUIS Potosi, Mexico|AVIX Investigación Clínica S.C, Monterrey, Mexico|Hospital Angeles Tijuana, Tijuana, Mexico|UMCG, NL -groningen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Auckland City Hospital, Auckland, New Zealand|Hemato Oncología de Panamá Especializada, Panama City, Panama|Hospital Nacional Edgardo Rebagliati Martins; Oncologia, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica Ricardo Palma, San Isidro, Peru|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, Poland|Krakowski Szpital Specjalistyczny im.Jana Pawla II, Krakow, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc; Oddzial V Chemioterapii Nowotworow Pluc, Olsztyn, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu, Poznan, Poland|Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad; Klinika Nowot.Pluca i Klatki Piers, Warszawa, Poland|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Principal Military Clinical Hospital n.a. N.N. Burdenko, Moscow, Moskovskaja Oblast, Russian Federation|FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF, Moscow, Russian Federation|Clinical Oncology Dispensary; Chemotherapy, Omsk, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary, St Petersburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia|Clinical Center Nis, NIS, Serbia|Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Insititut Catala D'Oncologia, Hospitalet de Llobregat, Barcelona, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital General Univ. de Alicante, Alicante, Spain|Hospital Universitari Vall d'Hebron; Oncology, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|ICO Badalona - Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal; Servicio de Oncología, Madrid, Spain|Hospital Quiron de Madrid; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clínico Universitario de Valencia; Servicio de Oncología, Valencia, Spain|Kaohsiung Chang Gung Memorial Hospital; Dept of Internal Medicine, Kaohsiung, Taiwan|National Taiwan Uni Hospital; Internal Medicine, Taipei, Taiwan|Taipei Veterans General Hospital; Chest Dept , Section of Thoracic Oncology, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou; Chest Dept, Taoyuan, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Prince of Songkla University; Division of Pulmonary Disease, Department of Medicine, Hat Yai, Thailand|Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology, Adana, Turkey|Akdeniz University Medical Faculty; Medical Oncology Department, Antalya, Turkey|Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department, Edirne, Turkey|Medipol University MF; Oncology Department, Istanbul, Turkey|Marmara Uni Faculty of Medicine; Medical Oncology, Istanbul, Turkey|Medikal Park Izmir Hospital, Karşıyaka, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey",7803839,C07D401/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,68.0,47.7710014579354,17.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.35,531.318,64.6,4.0,3.0,4.0,44.75,115.85,4.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,NON SMALL CELL LUNG CANCER,_ENTRECTINIB,NCT03178552,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Diego, La Jolla, California, United States|UC Davis; Comprehensive Cancer Center, Sacramento, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Eastern Connecticut Hematology and Oncology Associates; (ECHO), Norwich, Connecticut, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States|Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States|University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States|Illinois Cancer Care, Peoria, Illinois, United States|University of Kentucky; Markey Cancer Center, Lexington, Kentucky, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Health System; Hematology/Oncology, Detroit, Michigan, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cancer Inst. of New Jersey, New Brunswick, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Oregon HSU, Portland, Oregon, United States|St. Luke's University Health network, Bethlehem, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Tennessee Oncology PLLC - Nashville (20th Ave), Nashville, Tennessee, United States|Texas Oncology - South Austin, Austin, Texas, United States|Oncology Consultants PA, Houston, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Hospital Italiano, Buenos Aires, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Royal North Shore Hospital; Department of Medical Oncology, St Leonards, New South Wales, Australia|The Prince Charles Hospital; Oncology Dept., Chermside, Queensland, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|Austin Hospital; Medical Oncology, Heidelberg, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|UZ Brussel, Brussel, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Hospital de Caridade de Ijui; Oncologia, Ijui, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|CancerCare Manitoba; Department of Medical Oncology, Winnipeg, Manitoba, Canada|Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials, Barrie, Ontario, Canada|William Osler Health System Brampton Civic Hospital, Brampton, Ontario, Canada|London Health Sciences Centre · Victoria Hospital; Department of Medicine, London, Ontario, Canada|Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center, Oshawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|IUCPQ (Hôpital Laval), Quebec City, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas, Recoleta, Chile|Clinica CIMCA, San Jose, Costa Rica|Institut Bergonie CLCC Bordeaux, Bordeaux, France|Centre Francois Baclesse; Radiologie, Caen, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hopital Caremeau; Pneumologie, Nimes, France|Hopital Bichat Claude Bernard; Oncologie Serv., Paris, France|Hôpital Européen Georges Pompidou, Paris, France|Hopital Tenon; Oncologie Radiotherapie, Paris, France|CHU Poitiers, Poitiers, France|Hopital Pontchaillou, Rennes, France|CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse cedex 9, France|Hopital Bretonneau; Pneumologie Oncologie, Tours, France|Hopital Robert Schuman; Pneumologie, Vantoux, France|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Universitätsklinikum Düsseldorf; Klinik für Kardiologie, Pneumologie und Angiologie, Düsseldorf, Germany|Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen, Germany|Klinikum Esslingen; Klinik für Kardiologie, Angiologie und Pneumologie, Esslingen, Germany|Asklepios-Fachklinik Muenchen-Gauting; Klinik Für Pneumologie, Gauting, Germany|Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie, Gerlingen, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|HSK Dr.-Horst-Schmidt-Kliniken Klinik für Innere Medizin III Onkologie Hämatologie und Palliativmed, Wiesbaden, Germany|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Queen Mary Hospital; Medicine & Respiratory, Hong Kong, Hong Kong|Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong|Soroka Medical Center; Oncology Dept, Beer Sheva, Israel|Rambam Health Care Campus; Oncology, Haifa, Israel|Meir Medical Center; Oncology, Kfar-Saba, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Israel|Sourasky / Ichilov Hospital; Dept. of Oncology, Tel Aviv, Israel|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Lombardia, Italy|Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia, Milano, Lombardia, Italy|Asst Di Monza, Monza, Lombardia, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga; S.C.D.U. di Oncologia Toracica, Orbassano (TO), Piemonte, Italy|Fujita Health University Hospital, Aichi, Japan|National Cancer Center Hospital East, Chiba, Japan|Shikoku Cancer Center, Ehime, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kanazawa University Hospital, Ishikawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan|Kyoto University Hospital, Kyoto, Japan|Sendai Kousei Hospital, Miyagi, Japan|Tohoku University Hospital, Miyagi, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Kindai University Hospital, Osaka, Japan|Saga University Hospital, Saga, Japan|Shizuoka Cancer Center, Shizuoka, Japan|Juntendo University Hospital, Tokyo, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Kyorin University Hospital, Tokyo, Japan|Wakayama Medical University Hospital, Wakayama, Japan|National Hospital Organization Yamaguchi - Ube Medical Center, Yamaguchi, Japan|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Yonsei University Health System/Severance Hospital, Seoul, Korea, Republic of|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico|Oncologico Potosino, San Luis Potosí, SAN LUIS Potosi, Mexico|AVIX Investigación Clínica S.C, Monterrey, Mexico|Hospital Angeles Tijuana, Tijuana, Mexico|UMCG, NL -groningen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Auckland City Hospital, Auckland, New Zealand|Hemato Oncología de Panamá Especializada, Panama City, Panama|Hospital Nacional Edgardo Rebagliati Martins; Oncologia, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica Ricardo Palma, San Isidro, Peru|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, Poland|Krakowski Szpital Specjalistyczny im.Jana Pawla II, Krakow, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc; Oddzial V Chemioterapii Nowotworow Pluc, Olsztyn, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu, Poznan, Poland|Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad; Klinika Nowot.Pluca i Klatki Piers, Warszawa, Poland|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Principal Military Clinical Hospital n.a. N.N. Burdenko, Moscow, Moskovskaja Oblast, Russian Federation|FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF, Moscow, Russian Federation|Clinical Oncology Dispensary; Chemotherapy, Omsk, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary, St Petersburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia|Clinical Center Nis, NIS, Serbia|Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Insititut Catala D'Oncologia, Hospitalet de Llobregat, Barcelona, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital General Univ. de Alicante, Alicante, Spain|Hospital Universitari Vall d'Hebron; Oncology, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|ICO Badalona - Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal; Servicio de Oncología, Madrid, Spain|Hospital Quiron de Madrid; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clínico Universitario de Valencia; Servicio de Oncología, Valencia, Spain|Kaohsiung Chang Gung Memorial Hospital; Dept of Internal Medicine, Kaohsiung, Taiwan|National Taiwan Uni Hospital; Internal Medicine, Taipei, Taiwan|Taipei Veterans General Hospital; Chest Dept , Section of Thoracic Oncology, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou; Chest Dept, Taoyuan, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Prince of Songkla University; Division of Pulmonary Disease, Department of Medicine, Hat Yai, Thailand|Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology, Adana, Turkey|Akdeniz University Medical Faculty; Medical Oncology Department, Antalya, Turkey|Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department, Edirne, Turkey|Medipol University MF; Oncology Department, Istanbul, Turkey|Marmara Uni Faculty of Medicine; Medical Oncology, Istanbul, Turkey|Medikal Park Izmir Hospital, Karşıyaka, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey",8299057,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,16.0,51.7464424320827,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.03,560.65,85.52,6.0,3.0,6.0,60.41,161.24,7.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,NON SMALL CELL LUNG CANCER,_TRAMETINIB,NCT03087448,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, Davis, Davis, California, United States|University of California, San Francisco, San Francisco, California, United States",7378423,C07C275/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
Cc1cc(Nc2ncc(Cl)c(=Nc3ccccc3S(=O)(=O)C(C)C)[nH]2)c(OC(C)C)cc1C1CCNCC1,NON SMALL CELL LUNG CANCER,_CERITINIB,NCT03087448,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, Davis, Davis, California, United States|University of California, San Francisco, San Francisco, California, United States",7153964,C07D239/48,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,12.0,69.9480482145424,14.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.23,558.135,105.24,8.0,3.0,4.0,61.33,153.86,9.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,"CARCINOMA, NON-SMALL-CELL LUNG",_TRAMETINIB,NCT04452877,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Harbin, Heilongjiang, China|Novartis Investigative Site, Jinan, Shandong, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Guangzhou, China|Novartis Investigative Site, Tianjin, China",7378423,C07C275/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,"CARCINOMA, NON-SMALL-CELL LUNG",_DABRAFENIB,NCT04452877,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Harbin, Heilongjiang, China|Novartis Investigative Site, Jinan, Shandong, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Guangzhou, China|Novartis Investigative Site, Tianjin, China",7994185,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,20.0,27.170989137353892,19.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.44,519.562,110.86,6.0,2.0,4.0,49.71,127.51,5.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,NON SMALL CELL LUNG CANCER,_LENVATINIB,NCT03829332,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alaska Clinical Research Center ( Site 0511), Anchorage, Alaska, United States|Ironwood Cancer & Research Centers ( Site 0541), Chandler, Arizona, United States|CBCC Global Research, Inc. ( Site 0532), Bakersfield, California, United States|Scripps Cancer Center ( Site 0521), La Jolla, California, United States|Florida Hospital ( Site 0526), Orlando, Florida, United States|Northwest Georgia Oncology Centers PC ( Site 0518), Marietta, Georgia, United States|Illinois Cancer Care, PC ( Site 0557), Peoria, Illinois, United States|Parkview Cancer Center ( Site 0542), Fort Wayne, Indiana, United States|University of Kentucky School of Medicine & Hospitals ( Site 0517), Lexington, Kentucky, United States|Anne Arundel Medical Center Oncology and Hematology ( Site 0514), Annapolis, Maryland, United States|Munson Medical Center ( Site 0512), Traverse City, Michigan, United States|Park Nicollet Frauenshuh Cancer Center ( Site 0554), Saint Louis Park, Minnesota, United States|University of Missouri Health Care ( Site 0555), Columbia, Missouri, United States|Billings Clinic Cancer Center ( Site 0508), Billings, Montana, United States|Cone Health Cancer Center at Alamance Regional ( Site 0527), Greensboro, North Carolina, United States|Genesis Cancer Care Center ( Site 0559), Zanesville, Ohio, United States|Oregon Health Sciences University ( Site 0544), Portland, Oregon, United States|Central Texas Veterans Healthcare System ( Site 0533), Temple, Texas, United States|Orange Health Services ( Site 0002), Orange, New South Wales, Australia|Wollongong Private Hospital ( Site 0005), Wollongong, New South Wales, Australia|The Prince Charles Hospital ( Site 0011), Chermside, Queensland, Australia|Ballarat Oncology and Haematology Services ( Site 0008), Wendouree, Victoria, Australia|St John of God Murdoch Medical Clinic ( Site 0001), Perth, Western Australia, Australia|Cross Cancer Institute ( Site 0400), Edmonton, Alberta, Canada|Lions Gate Hospital ( Site 0407), North Vancouver, British Columbia, Canada|William Osler Health System (Brampton Civic Hospital) ( Site 0402), Brampton, Ontario, Canada|Windsor Regional Cancer Program ( Site 0404), Windsor, Ontario, Canada|McGill University Health Centre ( Site 0418), Montreal, Quebec, Canada|Anhui Provincial Hospital ( Site 0108), Hefei, Anhui, China|The First Affiliated Hospital of Anhui Medical University ( Site 0113), Hefei, Anhui, China|Peking Union Medical College Hospital ( Site 0105), Beijing, Beijing, China|Beijing Cancer Hospital ( Site 0102), Beijing, Beijing, China|Beijing Chest Hospital Capital Medical University ( Site 0111), Beijing, Beijing, China|Xiangya Hospital of Central South University ( Site 0115), Changsha, Hunan, China|Hunan Cancer Hospital ( Site 0104), Changsha, Hunan, China|The First Hospital of Jilin University ( Site 0110), Chang chun, Jilin, China|Zhongshan Hospital Fudan University ( Site 0100), Shanghai, Shanghai, China|Shanghai Chest Hospital ( Site 0112), Shanghai, Shanghai, China|The First Affiliated Hospital Zhejiang University ( Site 0106), Hangzhou, Zhejiang, China|Hangzhou First People's Hospital ( Site 0109), Hangzhou, Zhejiang, China|2nd Affil Hosp of Zhejiang University College of Medicine ( Site 0114), Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital ( Site 0116), Hangzhou, Zhejiang, China|Fundacion Centro de Investigacion Clinica CIC ( Site 0366), Medellin, Antioquia, Colombia|Hospital General de Medellin Luz Castro de Gutierrez ( Site 0368), Medellin, Antioquia, Colombia|Biomelab S A S ( Site 0365), Barranquilla, Atlantico, Colombia|Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0374), Valledupar, Cesar, Colombia|Oncomedica S.A. ( Site 0372), Monteria, Cordoba, Colombia|Centro Medico Imbanaco de Cali S.A ( Site 0369), Cali, Valle Del Cauca, Colombia|AS Ida-Tallinna Keskhaigla ( Site 0161), Tallinn, Harjumaa, Estonia|SA Pohja-Eesti Regionaalhaigla ( Site 0162), Tallin, Harjumaa, Estonia|SA Tartu Ulikooli Kliinikum ( Site 0160), Tartu, Tartumaa, Estonia|CHU Jean Minjoz ( Site 0167), Besancon, Doubs, France|Institut Curie - Centre Rene Huguenin ( Site 0181), Saint-Cloud, Hauts-de-Seine, France|ICM Val D Auerelle ( Site 0177), Montpellier, Herault, France|CHU de Grenoble - Hopital Michallon ( Site 0169), La Tronche, Isere, France|Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 0185), Saint Herblain, Loire-Atlantique, France|Centre Hospitalier de la Cote Basque ( Site 0173), Bayonne, Pyrenees-Atlantiques, France|CHU de Rouen ( Site 0174), Rouen, Seine-Maritime, France|CHU Amiens Sud ( Site 0182), Amiens, Somme, France|Centre hospitalier Toulon Sainte-Musse ( Site 0172), Toulon, Var, France|Institut Curie ( Site 0166), Paris, France|Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 0207), Gyula, Bekes, Hungary|CRU Hungary KFT ( Site 0209), Miskolc, Borsod-Abauj-Zemplen, Hungary|Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz ( Site 0202), Miskolc, Borsod-Abaúj-Zemplén, Hungary|Petz Aladar Megyei Oktato Korhaz ( Site 0213), Gyor, Győr-Moson-Sopron, Hungary|Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0203), Szolnok, Jasz-Nagykun-Szolnok, Hungary|Tudogyogyintezet Torokbalint ( Site 0205), Torokbalint, Pest, Hungary|Semmelweis Egyetem ( Site 0210), Budapest, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 0217), Kaposvar, Hungary|Bnei Zion Medical Center ( Site 0227), Haifa, Heifa, Israel|Soroka Medical Center ( Site 0222), Beer Sheva, Southern, Israel|Sheba Medical Center ( Site 0220), Ramat Gan, Tel Aviv, Israel|Sourasky Medical Center ( Site 0225), Tel Aviv, Tell Abib, Israel|Rambam Medical Center ( Site 0223), Haifa, Israel|Meir Medical Center ( Site 0221), Kfar-Saba, Israel|Rabin Medical Center ( Site 0224), Petah Tikva, Israel|Barzilai Medical Center ( Site 0226), Ashkelon, Ḥeifā, Israel|Azienda Ospedaliera S. Giovanni Addolorata-Oncologia Medica ( Site 0233), Roma, Lazio, Italy|Presidio Ospedaliero San Vincenzo ( Site 0231), Taormina, Messina, Italy|Centro di Riferimento Oncologico CRO ( Site 0235), Aviano, Pordenone, Italy|Azienda Ospedaliera San Giuseppe Moscati ( Site 0234), Avellino, Italy|Universita Magna Grecia ( Site 0230), Catanzaro, Italy|A.O. Universitaria Careggi ( Site 0236), Firenze, Italy|Ospedale Santa Maria delle Croci ( Site 0232), Ravenna, Italy|Policlinico Gemelli di Roma ( Site 0237), Roma, Italy|Aichi Cancer Center Hospital ( Site 0018), Nagoya, Aichi, Japan|Kurume University Hospital ( Site 0025), Kurume, Fukuoka, Japan|Hyogo Cancer Center ( Site 0021), Akashi, Hyogo, Japan|Kanagawa Cardiovascular and Respiratory Center ( Site 0026), Yokohama, Kanagawa, Japan|Kanagawa Cancer Center ( Site 0023), Yokohama, Kanagawa, Japan|Miyagi Cancer Center ( Site 0028), Natori, Miyagi, Japan|Sendai Kousei Hospital ( Site 0022), Sendai, Miyagi, Japan|Kindai University Hospital ( Site 0017), Osakasayama, Osaka, Japan|National Hospital Organization Kinki-chuo Chest Medical Center ( Site 0027), Sakai, Osaka, Japan|National Hospital Organization Kyushu Medical Center ( Site 0015), Fukuoka, Japan|Kyushu University Hospital ( Site 0030), Fukuoka, Japan|Okayama University Hospital ( Site 0020), Okayama, Japan|Osaka International Cancer Institute ( Site 0019), Osaka, Japan|Toranomon Hospital ( Site 0016), Tokyo, Japan|Juntendo University Hospital ( Site 0029), Tokyo, Japan|Nippon Medical School Hospital ( Site 0024), Tokyo, Japan|Chungbuk National University Hospital ( Site 0079), Cheongju si, Chungbuk, Korea, Republic of|Seoul National University Bundang Hospital ( Site 0075), Seongnam-si, Kyonggi-do, Korea, Republic of|Ulsan University Hospital ( Site 0077), Ulsan, Ulsan-Kwangyokshi, Korea, Republic of|Asan Medical Center ( Site 0076), Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center ( Site 0078), Seoul, Korea, Republic of|Hospital Tengku Ampuan Afzan ( Site 0062), Kuantan, Pahang, Malaysia|Hospital Pulau Pinang. ( Site 0065), Georgetown, Pulau Pinang, Malaysia|Sarawak General Hospital ( Site 0064), Kuching, Sarawak, Malaysia|Beacon Hospital Sdn Bhd ( Site 0067), Petaling Jaya, Selangor, Malaysia|Institut Kanser Negara - National Cancer Institute ( Site 0063), Putrajaya, Wilayah Persekutuan Putrajaya, Malaysia|University Malaya Medical Centre ( Site 0061), Kuala Lumpur, Malaysia|Gleneagles Penang ( Site 0066), Pulau Pinang, Malaysia|Medica Sur S.A.B de C.V. ( Site 0384), Mexico City, Distrito Federal, Mexico|Consultorios de Medicina Especializada del Sector Privado ( Site 0388), Guadalajara, Jalisco, Mexico|Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 0381), Madero, Tamaulipas, Mexico|Instituto Nacional de Cancerologia. ( Site 0382), Mexico City, Mexico|Oaxaca Site Management Organization SC ( Site 0389), Oaxaca, Mexico|SPZOZ USK nr 1 im. Norberta Barlickiego UM w Lodzi ( Site 0256), Lodz, Lodzkie, Poland|Szpital Uniwersytecki im. Karola Marcinkowskiego ( Site 0247), Zielona Gora, Lubuskie, Poland|Krakowski Szpital Specjalistyczny im Jana Pawla II ( Site 0253), Krakow, Malopolskie, Poland|Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 0243), Krakow, Malopolskie, Poland|Centrum Medyczne Pratia Ostroleka ( Site 0242), Ostroleka, Mazowieckie, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0252), Warszawa, Mazowieckie, Poland|Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 0250), Przemysl, Podkarpackie, Poland|Ars Medical Sp. z o.o. ( Site 0254), Pila, Wielkopolskie, Poland|Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 0262), Ufa, Baskortostan, Respublika, Russian Federation|Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0266), Krasnoyarsk, Krasnoyarskiy Kray, Russian Federation|SBHI Samara Regional Clinical Oncology Dispensary ( Site 0265), Samara, Samarskaya Oblast, Russian Federation|SBHI Leningrad Regional Clinical Hospital ( Site 0263), Saint Petersburg, Sankt-Peterburg, Russian Federation|Railway Hospital of OJSC ( Site 0268), Saint Petersburg, Sankt-Peterburg, Russian Federation|City Clinical Oncology Center ( Site 0260), Saint Petersburg, Sankt-Peterburg, Russian Federation|National Taiwan University Hospital Hsin-Chu Branch ( Site 0087), Hsinchu, Taiwan|Taipei Medical University Shuang Ho Hospital ( Site 0090), New Taipei, Taiwan|National Cheng Kung University Hospital ( Site 0086), Tainan, Taiwan|National Taiwan University Hospital ( Site 0088), Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center ( Site 0091), Taipei, Taiwan|Taipei Veterans General Hospital ( Site 0089), Taipei, Taiwan|Necmettin Erbakan Universitesi Meram Tip Fakultesi ( Site 0321), Konya, Adana, Turkey|Gulhane Egitim ve Arastirma Hastanesi ( Site 0316), Ankara, Turkey|Abdurrahman Yurtaslan Onkoloji Hastanesi ( Site 0318), Ankara, Turkey|Baskent Universitesi Ankara Hastanesi ( Site 0319), Ankara, Turkey|Antalya Memorial Hospital Department of Medical Oncology ( Site 0324), Antalya, Turkey|Akdeniz Universitesi Tip Fakultesi ( Site 0322), Antalya, Turkey|Dokuz Eylul Universitesi Arastirma Uygulama Hastanesi ( Site 0314), Izmir, Turkey|Sakarya Universitesi Egitim ve Arastirma Hastanesi ( Site 0323), Sakarya, Turkey|Samsun Medical Park Hastanesi ( Site 0320), Samsun, Turkey|Cherkasy Regional Hospital ( Site 0336), Cherkasy, Cherkaska Oblast, Ukraine|City Clinical Hosp.4 of DCC ( Site 0338), Dnipro, Dnipropetrovska Oblast, Ukraine|MI Precarpathian Clinical Oncology Center ( Site 0346), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|Communal non profit enterprise Regional Clinical Oncology Center ( Site 0337), Kharkiv, Kharkivska Oblast, Ukraine|Ukranian Center of TomoTherapy ( Site 0344), Kropyvnytskiy, Kirovohradska Oblast, Ukraine|Medical Center Verum ( Site 0334), Kyiv, Kyivska Oblast, Ukraine|Kyiv City Clinical Oncology Centre ( Site 0339), Kyiv, Kyivska Oblast, Ukraine|Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 0331), Kyiv, Kyivska Oblast, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 0341), Lviv, Lvivska Oblast, Ukraine|MI Odessa Regional Oncological Centre ( Site 0333), Odesa, Odeska Oblast, Ukraine|Podillya Regional Center of Oncology ( Site 0343), Vinnytsia, Vinnytska Oblast, Ukraine",7253286,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,51.6478777798312,65.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.03,426.86,115.57,4.0,3.0,4.0,42.29,112.21,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,ADVANCED NON-SMALL CELL LUNG CANCER,_LENVATINIB,NCT03516981,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology Associates, PC- HAL ( Site 8001), Tempe, Arizona, United States|University of California Davis Comprehensive Cancer Center ( Site 0137), Sacramento, California, United States|University of California San Francisco ( Site 0111), San Francisco, California, United States|UCLA Hematology/Oncology -Santa Monica ( Site 0108), Santa Monica, California, United States|Yale University School of Medicine ( Site 0100), New Haven, Connecticut, United States|Mayo Clinic Florida ( Site 0115), Jacksonville, Florida, United States|University of Maryland ( Site 0136), Baltimore, Maryland, United States|Mayo Clinic Rochester - St. Mary's Hospital ( Site 0117), Rochester, Minnesota, United States|John Theurer Cancer Center ( Site 0112), Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center ( Site 0113), New York, New York, United States|Oncology Hematology Care ( Site 8005), Cincinnati, Ohio, United States|University of Pennsylvania ( Site 0132), Philadelphia, Pennsylvania, United States|UPMC Cancer Center/Hillman Cancer Center ( Site 0104), Pittsburgh, Pennsylvania, United States|Texas Oncology-Memorial City ( Site 8006), Houston, Texas, United States|Texas Oncology-Tyler ( Site 8003), Tyler, Texas, United States|Emily Couric Clinical Cancer Center ( Site 0134), Charlottesville, Virginia, United States|Northwest Cancer Specialists, P.C. ( Site 8000), Vancouver, Washington, United States|University of Wisconsin- Madison Carbone Cancer Center ( Site 0130), Madison, Wisconsin, United States|Blacktown Hospital Western Sydney Local Health District ( Site 0200), Blacktown, New South Wales, Australia|Greenslopes Private Hospital ( Site 0202), Greenslopes, Queensland, Australia|Fiona Stanley Hospital ( Site 0201), Murdoch, Western Australia, Australia|The Ottawa Hospital ( Site 0306), Ottawa, Ontario, Canada|Sunnybrook Health Science Centre ( Site 0304), Toronto, Ontario, Canada|Princess Margaret Cancer Centre ( Site 0309), Toronto, Ontario, Canada|CIUSSS du Saguenay-Lac-St-Jean ( Site 0305), Chicoutimi, Quebec, Canada|Jewish General Hospital ( Site 0307), Montreal, Quebec, Canada|Prince of Wales Hospital ( Site 1801), Hong Kong, Hong Kong|Queen Mary Hospital ( Site 1800), Hong Kong, Hong Kong|St James Hospital ( Site 2200), Dublin, Ireland|Mid Western Cancer Centre ( Site 2201), Limerick, Ireland|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0702), Meldola, Forli-Cesena, Italy|Istituto Clinico Humanitas Research Hospital ( Site 0700), Rozzano, Milano, Italy|AOU San Luigi Gonzaga di Orbassano ( Site 0707), Orbassano, Torino, Italy|AULSS21 Regione Veneto Ospedale Mater Salutis - Legnago ( Site 0701), Legnago, Verona, Italy|Azienda Ospedaliera Papardo ( Site 0706), Messina, Italy|Seconda Universita degli Studi di Napoli ( Site 0704), Napoli, Italy|Fondazione Policlinico Universitario A. Gemelli ( Site 0703), Roma, Italy|Azienda Ospedaliera Universitaria Senese ( Site 0705), Siena, Italy|National Cancer Center Hospital ( Site 2001), Tokyo, Japan|The Cancer Institute Hospital of JFCR ( Site 2000), Tokyo, Japan|Seoul National University Bundang Hospital ( Site 0803), Seongnam-si, Kyonggi-do, Korea, Republic of|Asan Medical Center ( Site 0801), Songpa-gu, Seoul, Korea, Republic of|Seoul National University Hospital ( Site 0800), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 0802), Seoul, Korea, Republic of|Samsung Medical Center ( Site 0805), Seoul, Korea, Republic of|Dolnoslaskie Centrum Onkologii. ( Site 0993), Wroclaw, Dolnoslaskie, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0910), Warszawa, Mazowieckie, Poland|MED-POLONIA Sp. z o.o. ( Site 0907), Poznan, Wielkopolskie, Poland|Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1003), Ufa, Baskortostan, Respublika, Russian Federation|The Loginov Moscow Clinical Scientific Center ( Site 1008), Moscow, Moskva, Russian Federation|N.N. Blokhin NMRCO ( Site 1000), Moscow, Moskva, Russian Federation|Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary-Chemotherapy #1 ( Site, Omsk, Omskaya Oblast, Russian Federation|SBHI Leningrad Regional Clinical Hospital ( Site 1001), Saint Petersburg, Sankt-Peterburg, Russian Federation|St Petersburg City Clinical Oncology Dispensary ( Site 1002), St. Petersburg, Sankt-Peterburg, Russian Federation|Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1005), Kazan, Tatarstan, Respublika, Russian Federation|National Cancer Centre Singapore ( Site 1900), Singapore, Central Singapore, Singapore|National University Hospital ( Site 1901), Singapore, Singapore|MPOC ( Site 2310), Groenkloof Pretoria, Gauteng, South Africa|Sandton Oncology Medical Group PTY LTD ( Site 2316), Johannesburg, Gauteng, South Africa|Wits Clinical Research ( Site 2313), Parktown-Johannesburg, Gauteng, South Africa|Univ. Pretoria and Steve Biko Academic Hospitals ( Site 2315), Pretoria, Gauteng, South Africa|Vaal Triangle Oncology Centre ( Site 2314), Vereeniging, Gauteng, South Africa|Umhlanga Oncolgy Center ( Site 2311), Umhlanga, Kwazulu-Natal, South Africa|Cape Town Oncology Trials Pty Ltd ( Site 2312), Kraaifontein, Western Cape, South Africa|Hospital General Universitari Vall d Hebron ( Site 1100), Barcelona, Spain|Hospital Universitario Ramon y Cajal ( Site 1101), Madrid, Spain|Hospital Universitario 12 de Octubre ( Site 1102), Madrid, Spain|Universitaetsspital Basel ( Site 2104), Basel, Basel-Stadt, Switzerland|Hopitaux Universitaires de Geneve HUG ( Site 2106), Geneva, Geneve, Switzerland|Kantonsspital Graubuenden ( Site 2103), Chur, Grisons, Switzerland|Kantonsspital St. Gallen ( Site 2102), St. Gallen, Sankt Gallen, Switzerland|Universitaetsspital Zuerich ( Site 2100), Zuerich, Zürich, Switzerland|Kaohsiung Chang Gung Memorial Hospital ( Site 1203), Kaohsiung, Taiwan|National Cheng Kung University Hospital ( Site 1202), Tainan, Taiwan|National Taiwan University Hospital ( Site 1200), Taipei, Taiwan|Taipei Veterans General Hospital ( Site 1204), Taipei, Taiwan|University College London Hospital NHS Foundation Trust ( Site 1308), London, London, City Of, United Kingdom|Cambridge University Hospitals NHS Trust ( Site 1306), Cambridge, United Kingdom|Derriford Hospital ( Site 1301), Plymouth, United Kingdom",7253286,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,51.6478777798312,65.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.03,426.86,115.57,4.0,3.0,4.0,42.29,112.21,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,NON SMALL CELL LUNG CANCER,_LORLATINIB,NCT02927340,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts general Hospital, Boston, Massachusetts, United States",8680111,C07D498/22,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,12.649130372286901,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.01,406.421,110.06,6.0,1.0,4.0,40.42,121.17,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,"CARCINOMA, NON-SMALL-CELL LUNG",_LORLATINIB,NCT03052608,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Florida Cancer Specialists, Altamonte Springs, Florida, United States|Florida Cancer Specialists, Brandon, Florida, United States|Florida Cancer Specialists, Clearwater, Florida, United States|Florida Cancer Specialists, Gainesville, Florida, United States|Florida Cancer Specialists, Largo, Florida, United States|Florida Cancer Specialists, Lecanto, Florida, United States|Florida Cancer Specialists, New Port Richey, Florida, United States|Florida Cancer Specialists, Ocala, Florida, United States|Florida Cancer Specialists, Orange City, Florida, United States|Florida Cancer Specialists, Orlando, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Spring Hill, Florida, United States|Florida Cancer Specialists, Tampa, Florida, United States|Florida Cancer Specialists, Tavares, Florida, United States|Florida Cancer Specialists, The Villages, Florida, United States|Florida Cancer Specialists, Winter Park, Florida, United States|Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Ophthalmic Consultants of Boston Inc, Boston, Massachusetts, United States|The William P. Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Sarah Cannon Research Institute., Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Shelbyville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|University of Washington Medical Center, Seattle, Washington, United States|Centro de Investigacion Pergamino SA, Pergamino, Buenos Aires, Argentina|Centro Medico Austral, Caba, Argentina|Bendigo Day Surgery Collection Centre and Laboratory, Bendigo, Victoria, Australia|Bendigo Medical Imaging, Bendigo Hospital, Bendigo, Victoria, Australia|Melbourne Pathology, Bendigo, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Grand Hopital de Charleroi - Site Notre Dame, Charleroi, Belgium|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|The Affiliated Hospital of Military Medical Sciences, Beijing, Beijing, China|Jilin Provincial Cancer Hospital, Changchun, Jilin, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Department of Respiratory,the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Beijing Cancer Hospital, Beijing, China|Guangdong General Hospital, Guangzhou, China|Fakultni nemocnice Olomouc, Klinika plicnich nemoci a tuberkulozy, Olomouc, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Hopital Haut-Léveque-Centre François Magendie, Pessac, Aquitaine, France|Hopital de Chevilly Larue, Chevilly Larue, France|Centre Hospitalier du Mans, Le Mans, France|Institut Paoli-Calmettes, Marseille cedex 09, France|Département d'Imagerie Médicale, Marseille cedex 20, France|Hôpital Nord, Marseille cedex 20, France|Service Ophtalmologie, Marseille cedex 20, France|Clinique Monticelli-Paradis-Dr Stephan Fauquier, Marseille, France|Groupe Hospitalier Bichat Claude Bernard, AP-HP, Paris, France|CHU de Rennes Hopital Pontchaillou, Rennes cedex 9, France|CHU de Rennes, Hopital Pontchaillou, Rennes cedex 9, France|Hopital Foch, Suresnes, France|Hopital Larrey, Toulouse Cedex 9, France|Hopital Pierre Paul Riquet, Toulouse cedex 9, France|Hôpital Larrey, Toulouse Cedex 9, France|Department d'imagerie medicale, Villejuif, France|Institut Gustave Roussy, Villejuif, France|Uberortliche Radiologische Gemeinschaftspraxis Dr. med. Marc Amler, Dresden, Germany|Technische Universitat Dresden , Medizinische Fakultat Carl Gustav Carus, Dresden, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Innere Medizin V, Homburg - Saar, Germany|Universitätsklinikum des Saarlandes, Homburg - Saar, Germany|Universitatsklinikum Regensburg, Institut fur Rontgendiagnostik, Regensburg, Germany|Universitatsklinikum Regensburg, Klinik und Poliklinik fur Innere Medizin II, Regensburg, Germany|The University of Hong Kong, Department of Clinical Oncology, Hong Kong, Hong Kong|The University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Artemis Hospital, Gurugram, Haryana, India|Manipal Hospital, Bangalore, Karnataka, India|Srinivasam Cancer Care Multispeciality Hospitals India Pvt Ltd, Bangalore, Karnataka, India|Sahyadri Clinical Research and Development Centre, Pune, Maharashtra, India|Sahyadri Specialty Hospital, Pune, Maharashtra, India|AOU Policlinico Vittorio Emanuele-P.O.G. Rodolico, Catania, CT, Italy|ASST Monza - A.O. San Gerardo, Monza, MB, Italy|IRCCS Ospedale San Raffaele, Milano, MI, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, MI, Italy|Istituto Europeo di Oncologia, Milano, MI, Italy|Istituto Clinico Humanitas, Rozzano, MI, Italy|Azienda Ospedaliera di Perugia - Ospedale S. M. Misericordia, Perugia, PG, Italy|Centro di Riferimento Oncologico-IRCCS, Pordenone, PN, Italy|Azienda Ospedaliero-Universitaria di Parma, Parma, PR, Italy|AUSL della Romagna - Ospedale degli infermi, Faenza, RA, Italy|AUSL della Romagna - Ospedale ""Umberto I"", Lugo, RA, Italy|UO Farmacia Oncologica, Ravenna, RA, Italy|Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy|Az.Osp.San Camillo-Forlanini, Roma, RM, Italy|Azienda Ospedaliera Dei Colli Ospedale Monaldi, Napoli, Italy|Istituto Nazionale Tumori di Napoli, Napoli, Italy|Ausl della Romagna- Ravenna, Ravenna, Italy|Aichi cancer center central hospital, Nagoya, Aichi, Japan|Nagoya University Hospital, Nagoya, Aichi, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Sendai Kousei Hospital, Sendai, Miyagi, Japan|Osaka International Cancer Institute, Osaka-shi, Osaka, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan|National Hospital Organization, Yamaguchi-Ube Medical Center, Ube, Yamaguchi, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka City General Hospital, Osaka, Japan|Tokushima University Hospital, Tokushima, Japan|Wakayama Medical University Department of Pulmonary Medicine and Oncology, Wakayama, Japan|The Catholic University of Korea, St. Vincents Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Division of Medical Oncology, Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Promotora Medica Aguascalientes SA de CV, Aguascalientes, Mexico|Instituto Nacional de Cancerologia, Distrito Federal, Mexico|Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Distrito Federal, Mexico|University Medical Center Groningen, Groningen, Netherlands|Klinika Onkologii i Radioterapii Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Med-Polonia Sp. z o.o., Poznan, Poland|Centrum Medyczne Dom Lekarski S.A., Szczecin, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy, Warszawa, Poland|RBHI Kursk Regional Clinical Oncology Dispensary, Kislino, Ryshkovsky Rural Council, Kursk Region, Russian Federation|Budgetary Healthcare Institution Omsk Region ""Clinical Oncological Dispensary"", Omsk, OMSK Region, Russian Federation|LEC at SBIH ""Saint-Petersburg Clinical Research Practical Center of specialized types of, Pesochniy Poselok, Saint-petersburg, Russian Federation|Private Medical Institution ""Euromedservice"", Pushkin, Saint-petersburg, Russian Federation|RBHI Kursk Regional Clinical Oncology Dispensary, Kursk, Russian Federation|FSBI ""N.N.Blokhin Medical Research Center of Oncology"", Moscow, Russian Federation|National University Hospital, Singapore, Singapore|Raffles Hospital, Singapore, Singapore|Institut Catala d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Canarias, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Complejo Hospitalario De Navarra, Pamplona, Navarra, Spain|Hospital Teresa Herrera C.H.U.A.C., A Coruna, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Institut Catala d'Oncologia Girona, Girona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario La Fe, Valencia, Spain|National Taiwan University Hospital, Taipei, Taiwan ROC, Taiwan|Chang Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Cukurova University Medical Faculty, Adana, Turkey|Istanbul University Oncology Institute, Istanbul, Turkey|Marmara Univ Pendik Training and Research Hospital, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|The Ipswich Hospital NHS Trust, Ipswich, Suffolk, United Kingdom|Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital, Birmingham, WEST Midlands, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom",8680111,C07D498/22,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,18.0,12.649130372286901,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.01,406.421,110.06,6.0,1.0,4.0,40.42,121.17,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,LUNG CANCER,_GEFITINIB,NCT03292133,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States",5457105.0,C07D239/94,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,29.0,14.2590196923961,1102.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,446.902,68.74,7.0,1.0,4.0,46.11,117.51,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,NSCLC,_GEFITINIB,NCT02856893,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institut Bergonie, Bordeaux, France|CHU de Brest, Brest, France|Centre Francois Baclesse, Caen, France|Centre Hopitalier Intercommunal De Creteil, Créteil, France|Assistance Publique - Hopitaux de Marseille - Hopital Nord, Marseille, France|Institut Paoli-Calmettes, Marseille, France|Centre Paul Strauss, Strasbourg, France|CHU Toulouse - Hopital Larrey, Toulouse, France|Institut de Cancerologie de Lorraine, Vandœuvre-lès-Nancy, France|Gustave Roussy, Villejuif, France|King Hussein Cancer Center, Amman, Jordan|Medical University of Gdansk, Gdansk, Poland|University Clinic Golnik, Golnik, Slovenia|The Institute Of Oncology, Ljubljana, Slovenia|Hospital Clinic Universitari de Barcelona, Barcelona, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Vall d'Hebron Institut d'Oncologia, Barcelona, Spain|University Hospital A Coruna-Hospital Teresa Herrera, Coruna, Spain|Hospital Universitario 12 De Octubre, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Institut Catala d'Oncologia - ICO Badalona - Hospital De Mataro, Mataró, Spain|Virgen del Rocio University Hospital, Sevilla, Spain",5457105.0,C07D239/94,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,29.0,14.2590196923961,1102.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,446.902,68.74,7.0,1.0,4.0,46.11,117.51,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,NSCLC,_OSIMERTINIB,NCT02856893,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institut Bergonie, Bordeaux, France|CHU de Brest, Brest, France|Centre Francois Baclesse, Caen, France|Centre Hopitalier Intercommunal De Creteil, Créteil, France|Assistance Publique - Hopitaux de Marseille - Hopital Nord, Marseille, France|Institut Paoli-Calmettes, Marseille, France|Centre Paul Strauss, Strasbourg, France|CHU Toulouse - Hopital Larrey, Toulouse, France|Institut de Cancerologie de Lorraine, Vandœuvre-lès-Nancy, France|Gustave Roussy, Villejuif, France|King Hussein Cancer Center, Amman, Jordan|Medical University of Gdansk, Gdansk, Poland|University Clinic Golnik, Golnik, Slovenia|The Institute Of Oncology, Ljubljana, Slovenia|Hospital Clinic Universitari de Barcelona, Barcelona, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Vall d'Hebron Institut d'Oncologia, Barcelona, Spain|University Hospital A Coruna-Hospital Teresa Herrera, Coruna, Spain|Hospital Universitario 12 De Octubre, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Institut Catala d'Oncologia - ICO Badalona - Hospital De Mataro, Mataró, Spain|Virgen del Rocio University Hospital, Sevilla, Spain",8946235,C07D401/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,12.0,30.325058009404696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.47,499.619,87.55,7.0,2.0,4.0,56.84,150.32,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,"CARCINOMA, NON-SMALL-CELL LUNG",_OSIMERTINIB,NCT03784599,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Maastricht UMC+, Maastricht, Limburg, Netherlands|VU medical center, Amsterdam, Noord Holland, Netherlands|Antoni van Leeuwenhoek ziekenhuis - Netherlands Cancer Institute, Amsterdam, Noord Holland, Netherlands|Erasmus MC, Rotterdam, Zuid Holland, Netherlands|Univercity Medical Center Groningen, Groningen, Netherlands",8946235,C07D401/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,12.0,30.325058009404696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.47,499.619,87.55,7.0,2.0,4.0,56.84,150.32,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,LUNG CANCER,_OSIMERTINIB,NCT03567642,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States",8946235,C07D401/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,30.325058009404696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.47,499.619,87.55,7.0,2.0,4.0,56.84,150.32,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,METASTATIC NON SMALL CELL LUNG CANCER,_OSIMERTINIB,NCT03497767,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Calvary Mater, Newcastle, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|St. Vincents Hospital, Sydney, New South Wales, Australia|Chris O'Brien Lifehouse, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Blacktown Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|ICON Cancer Centre Greenslopes, Brisbane, Queensland, Australia|Peter MacCallum Cancer Center, Melbourne, Victoria, Australia|Monash Health, Melbourne, Victoria, Australia|National University Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore",8946235,C07D401/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,30.325058009404696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.47,499.619,87.55,7.0,2.0,4.0,56.84,150.32,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,NON SMALL CELL LUNG CANCER,_CRIZOTINIB,NCT03375242,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Observational Model: Case-Only|Time Perspective: Prospective,"Pfizer local country office, Tokyo, Japan",7230098,C07D413/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,39.49157066880221,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.82,450.337,77.99,5.0,2.0,4.0,45.44,128.43,5.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,NON SMALL CELL LUNG CANCER,_APATINIB,NCT03267654,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Pulmonary Hospital;, Shanghai, Shanghai, China",US-20040259916-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,NSCLC,_APATINIB,NCT03801200,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hubei Cancer hospital, Wuhan, Hubei, China",US-20040259916-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21,NON SMALL CELL LUNG CANCER,_SAVOLITINIB,NCT03944772,Phase 2,Recruiting,All,"18 Years to 130 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Duarte, California, United States|Research Site, Los Angeles, California, United States|Research Site, Sacramento, California, United States|Research Site, Santa Monica, California, United States|Research Site, Santa Rosa, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Chicago, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Houston, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Herlev, Denmark|Research Site, Odense C, Denmark|Research Site, Vejle, Denmark|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Nagoya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Drammen, Norway|Research Site, Oslo, Norway|Research Site, Trondheim, Norway|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden",US-20140255428-A1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,16.0,15.8360541284215,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,345.37,91.61,6.0,0.0,5.0,35.72,119.06,3.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,NON SMALL CELL LUNG CANCER,_ALECTINIB,NCT03944772,Phase 2,Recruiting,All,"18 Years to 130 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Duarte, California, United States|Research Site, Los Angeles, California, United States|Research Site, Sacramento, California, United States|Research Site, Santa Monica, California, United States|Research Site, Santa Rosa, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Chicago, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Houston, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Herlev, Denmark|Research Site, Odense C, Denmark|Research Site, Vejle, Denmark|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Nagoya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Drammen, Norway|Research Site, Oslo, Norway|Research Site, Trondheim, Norway|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden",9126931,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,29.0,62.9828127887636,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.59,482.6166,72.36,5.0,1.0,6.0,56.56,155.11,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,LUNG CANCER,_ICOTINIB,NCT01996098,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China",US-20040048883-A1,A61P35/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,39.754409741473104,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.88,391.42699999999996,74.73,7.0,1.0,4.0,42.08,105.82,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,NON-SQUAMOUS NSCLC,_ICOTINIB,NCT03992885,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Pulmonary Medical Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China",US-20040048883-A1,A61P35/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,39.754409741473104,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.88,391.42699999999996,74.73,7.0,1.0,4.0,42.08,105.82,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,SMALL CELL LUNG CANCER,_TOPOTECAN,NCT03088813,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sutter Cancer Center, Sacramento, California, United States|National Jewish Health, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Florida Cancer Specialists (South Region), Fort Myers, Florida, United States|Adventist Health System/Sunbelt, Inc., Orlando, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, Marietta, Georgia, United States|Cancer Treatment Centers of America-Georgia, Newnan, Georgia, United States|Illinois Cancer Care, PC, Peoria, Illinois, United States|Southern Maine Health Care, Biddeford, Maine, United States|Maine Research Associates, Lewiston, Maine, United States|University of Maryland Medical Group, Baltimore, Maryland, United States|Reliant Medical Group, Inc., Worcester, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|North Shore Hematology Oncology Associates, PC, East Setauket, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Tri County Hematology & Oncology Associates, Inc, Massillon, Ohio, United States|OHSU Community Hematology Oncology, Portland, Oregon, United States|Charleston Hematology Oncology Associates, PA, Charleston, South Carolina, United States|Greenville Hospital System University Medical Center, Greenville, South Carolina, United States|Tennessee Oncology, Nashville, Tennessee, United States|MultiCare Health System Institute for Research and Innovation, Spokane, Washington, United States|Summit Cancer Treatment Center, Spokane, Washington, United States|Northwest Cancer Specialists, P.C.-Portland-West, Vancouver, Washington, United States|Border Medical Oncology Research Unit, Albury, New South Wales, Australia|Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia|South West Healthcare, Warrnambool, Victoria, Australia|Southern Medical Day Care Centre, Wollongong, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|AZ Klina, Brasschaat, Belgium|UZ Leuven, Leuven, Belgium|Centre Hospitalier de l'Ardenne, Libramont, Belgium|AZ Sint-Maarten, Mechelen, Belgium|Rua Antenor Duarte Villela, 1331, Barretos, Brazil|Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer, Curitiba, Brazil|Hospital de Caridade de Ijuí, Ijuí, Brazil|Oncobio Servicos de Saude, Nova Lima, Brazil|HGB - Hospital Giovanni Battista - Mãe de Deus Center, Porto Alegre, Brazil|Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil|INCA - Instituto Nacional de Câncer, Rio De Janeiro, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia, Santo André, Brazil|Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José Do Rio Preto, Brazil|Beijing Cancer Hospital, Beijing, China|The First Affiliated Hospital of Bengbu Medical College, Bengbu, China|Jilin Cancer Hospital, Changchun, China|The First Hospital of Jilin University, Changchun, China|West China Hospital, Sichuan University, Chengdu, China|Xinmin, Guangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Linyi Cancer Hospital, Linyi, China|Henan Cancer Hospital, Zhengzhou, China|Centre Francois Baclesse, Caen, Calvados, France|CHU Brest - Hôpital Morvan, Brest, France|Hopital Albert Calmette - CHU Lille, lille Cedex, France|Hôpital de la Timone, Marseille, France|Hôpital Nord - CHU Marseille, Marseille, France|Hôpital Saint-Louis, Paris, France|Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez, France|Centre Hospitalier de Saint-Quentin, Saint-Quentin, France|Hôpital d'Instruction des armées Sainte Anne, Toulon, France|Universitaetsklinikum Freiburg, Freiburg, Germany|Asklepios Klinik Harburg, Hamburg, Germany|Evangelisches Krankenhaus Hamm GmbH, Hamm, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|LMU-Campus Innenstadt, Muenchen, Germany|Pius-Hospital Oldenburg, Oldenburg, Germany|Semmelweis Egyetem, Budapest, Hungary|Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza, Gyula, Hungary|Petz Aladar Megyei Oktato Korhaz, Győr, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, Hungary|Tudogyogyintezet Torokbalint, Törökbálint, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Hungary|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Azienda Ospedaliera Universitaria- Università degli Studi della Campania ""Luigi Vanvitelli"", Napoli, Italy|Azienda Socio Sanitaria Territoriale Bergamo Ovest (Ospedale Treviglio Caravaggio di Treviglio), Treviglio, Italy|Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, St. Vincent's Hospital, Suwon, Korea, Republic of|KO-MED Centra Kliniczne Biala Podlaska, Biała Podlaska, Poland|Szpitale Pomorskie spółka z ograniczoną odpowiedzialnością, Gdynia, Poland|SP Zespol Gruzlicy i Chorob Pluc w Olsztynie, Olsztyn, Poland|Przychodnia Med-Polonia Sp. z o.o., Poznań, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznań, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warsaw, Poland|S.C Gral Medical S.R.L, Bucuresti, Romania|Institutul Oncologic ""Prof. Dr. Ion Chiricuta"" Cluj-Napoca, Cluj-Napoca, Romania|S.C Medisprof S.R.L, Cluj-Napoca, Romania|S.C Centrul de Oncologie Sf. Nectarie S.R.L, Craiova, Romania|S.C Radiotherapy Center Cluj S.R.L, Floreşti, Romania|S.C Oncocenter Oncologie Clinica S.R.L, Timisoara, Romania|Oncomed SRL, Timişoara, Romania|SBIH of Arkhangelsk region ""Arkhangelsk Clinical Oncological Dispensary"", Arkhangel'sk, Russian Federation|""VitaMed"" LLC, Moscow, Russian Federation|BHI of Omsk region ""Clinical Oncology Dispensary"", Omsk, Russian Federation|SBIH of Stavropol territory ""Pyatigorsk Oncological Dispensary"", Pyatigorsk, Russian Federation|SBHI of Kaluga Region ""Kaluga regional clinical oncology dispensary"", Saint Petersburg, Russian Federation|SPb SBIH ""City Clinical Oncological Dispensary"", Saint Petersburg, Russian Federation|SBIH ""Samara Regional Clinical Oncological Dispensary"", Samara, Russian Federation|SBIH of Yaroslavl region ""Regional Clinical Oncological Hospital"", Yaroslavl, Russian Federation|Clinical Center ""Bezanijska kosa"", Belgrade, Serbia|Oncomed System, Belgrade, Serbia|Military Medical Academy, Belgrad, Serbia|Clinical Center Kragujevac, Belgrad, Serbia|Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia|General Hospital Uzice, Užice, Serbia|Catalan Institute of Oncology, L'Hospitalet De Llobregat, Barcelona, Spain|ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Malaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan|Baskent University Adana Application and Research Center, Adana, Turkey|Trakya University Medical Faculty, Edirne, Turkey|Istanbul Medeniyet Uni Goztepe Training&Res Hosp, Istanbul, Turkey|Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Istanbul, Turkey|Inonu Uni. Med. Fac., Malatya, Turkey|Namik Kemal University, Tekirdağ, Turkey|CI Chernivtsi RC Oncological Dispensary, Chernivtsi, Ukraine|CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipro, Ukraine|Communal Non-profit Enterprise Regional Center of Oncology, Kharkiv, Ukraine|CI Kryvyi Rih Oncological Dispensary of DRC, Kryvyi Rih, Ukraine|Treatment and Diagnostic Center of LLC Specialized clinic Dobryi Prognoz, Kyiv, Ukraine|Treatment-Prevention Institution Volyn Regional Oncological Dispensary, Luts'k, Ukraine|Odesa Regional Oncologic Dispensary, Odesa, Ukraine|RCI Sumy Regional Clinical Oncological Dispensary, Sumy, Ukraine|CCCH City Oncological Center SHEI Uzhgorod NU, Uzhgorod, Ukraine|Medical Clinic Innovacia, LLC, Vyshhorod, Ukraine",5004758,C07D491/22,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,NON SMALL CELL LUNG CANCER,_APREPITANT,NCT02646020,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Cancer Center of Sun-Yat Sen University (CCSYSU), GuangZhou, Guangdong, China",5145684,B82Y5/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,11.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.44,534.4267,75.19,5.0,2.0,4.0,45.56,116.93,8.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,NON SMALL CELL LUNG CANCER,_DESLORATADINE,NCT02646020,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Cancer Center of Sun-Yat Sen University (CCSYSU), GuangZhou, Guangdong, China",5178878,A61K9/0056,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.48,310.821,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1,"CARCINOMA, NON-SMALL-CELL LUNG",_MOCETINOSTAT,NCT02954991,Phase 2,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yuma Regional Medical Center, Yuma, Arizona, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|City of Hope National Medical Center, Duarte, California, United States|University of California San Diego, La Jolla, California, United States|University of California San Francisco Comprehensive Cancer Center, San Francisco, California, United States|University of California Los Angeles - Torrance - Community Cancer Care, Santa Clarita, California, United States|Rocky Mountain Cancer Centers - Denver - Midtown, Denver, Colorado, United States|Baptist Health, Louisville, Kentucky, United States|Henry Ford Hospital, Detroit, Michigan, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States|Saint Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Oncology Hematology Care-Blue Ash, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Hematology Oncology Associates - Barnett Office, Medford, Oregon, United States|Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States|Vanderbilt University, Nashville, Tennessee, United States|Texas Oncology - South Austin, Austin, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|USOR - Texas Oncology - Sherman, Sherman, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|Virginia Cancer Specialist, Fairfax, Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States",US-20090131367-A1,A61K38/07 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,23.0,32.7488,14.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.01,396.454,105.82,6.0,3.0,4.0,42.56,120.32,6.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1,LUNG CANCER,_MOCETINOSTAT,NCT03220477,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"John Hopkins Medical Center, Baltimore, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",US-20090131367-A1,A61K38/07 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,23.0,32.7488,14.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.01,396.454,105.82,6.0,3.0,4.0,42.56,120.32,6.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+],NON SMALL CELL LUNG CANCER,_PEMETREXED_DISODIUM,NCT04379635,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Anhui Provincial Hospital, Hefei, Anhui, China|The First Affiliated Hospital Of Anhui Medical University, Hefei, Anhui, China|Beijing Cancer Hospital, Beijing, Beijing, China|Beijing Hospital, Beijing, Beijing, China|Peking Union Medical College Hospital - Oncology, Beijing, Beijing, China|Capital Medical University Xuanwu Hospital, Beijing, Beijing, China|Peking University Pepole's Hospital, Beijing, Beijing, China|Fujian Medical university union hospital, Fuzhou, Fujian, China|Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China|Quanzhou First Hospital of Fujian Province, Quanzhou, Fujian, China|First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China|Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, China|Guangxi Medical University Affiliated Tumor Hospital& Oncology Medical College, Nanning, Guangxi, China|Hainan Cancer Hospital, Haikou, Hainan, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Luoyang Central Hospital, Luoyang, Henan, China|The second affiliated hospital of Zhengzhou University, Zhengzhou, Henan, China|Hubei Cancer Hospital, Wuhan, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|General Hospital of Eastern Theater Command, Nanjing, Jiangshu, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|The First affiliated hospital of Nanchang University, Nanchang, Jiangxi, China|Jilin Cancer Hospital, Changchun, Jilin, China|Jilin Province People's Hospital, Changchun, Jilin, China|The First Affilliated Hospital of Jilin University, Changchun, Jilin, China|Liaoning Cancer Hospital, Shenyang, Liaoning, China|General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|Jinan Central Hospital, Jinan, Shandong, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, China|Fudan University Affiliated Zhongshan Hospital, Shanghai, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|West China Hospital ,Sichuan University, Chengdu, Sichuan, China|Sichuan Cancer Hospital, Chengdu, Sichuan, China|General Hospital of Tianjin Medical University, Tianjin, Tianjin, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China|Yunnan Cancer Hospital, Kunming, Yunnan, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|Ningbo No.2 Hospital, Ningbo, Zhejiang, China|Sun Yat-sen University - Cancer Center (SYSUCC), Guangzhou, China",WO-2001062760-A2,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,11.0,32.7488,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,LUNG CANCER,_ITRACONAZOLE,NCT03664115,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"oncology department Ain shams university, Cairo, Egypt",6407079,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1346.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.48,705.633,100.79,9.0,0.0,7.0,74.71,200.4,11.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
NS(=O)(=O)OC[C@@H]1C[C@@H](n2ccc3c(N[C@H]4CCc5ccccc54)ncnc32)C[C@@H]1O,NON SMALL CELL LUNG CANCER,_PEVONEDISTAT,NCT03228186,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States",8207177,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,64.8226862974599,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.18,443.519,132.36,7.0,3.0,5.0,46.22,117.23,6.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O,NON SMALL CELL LUNG CANCER,_PLINABULIN,NCT02504489,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Ironwood Cancer & Research Centers, Chandler, Arizona, United States|Pacific Cancer Medical Center, Inc., Anaheim, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Memorial Health Care System, Colorado Springs, Colorado, United States|Cancer Center of Central Connecticut, Plainville, Connecticut, United States|Peachtree Hematoloy-Oncology Consultants, PC, Atlanta, Georgia, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Kansas University Medical Center, Westwood, Kansas, United States|University of Louisville-Brown Cancer Center, Louisville, Kentucky, United States|Henry Ford Hospital, Detroit, Michigan, United States|Michigan Center of Medical Research, Farmington Hills, Michigan, United States|Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, United States|Central Care Cancer Center, Bolivar, Missouri, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Toledo Cancer Center, Toledo, Ohio, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Cookeville Regional Medical Center Cancer Center, Cookeville, Tennessee, United States|Blacktown Cancer Centre, Blacktown, New South Wales, Australia|Border Medical Oncology Research Unit, East Albury, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Adult Mater Hospital, South Brisbane, Queensland, Australia|Peninsula and South East Oncology, Melbourne, Victoria, Australia|Epworth Hospital, Richmond, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Perth Oncology/Mount Hospital, Perth, Western Australia, Australia|St John of God Hospital, Subiaco, Subiaco, Western Australia, Australia|Anhui Provincial Hospital, Hefei, Anhui, China|Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China|The PLA General Hospital, Beijing, Beijing, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China|Zhongshan Hospital Xiamen University, Xiamen, Fujian, China|Guizhou Provincial Hospital, Guiyang, Guizhou, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Affiliated Cancer Hospital of Harbin Medical Unive, Ha'erbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|The Second Xiangya Hospital of Central South Unive, Changsha, Hunan, China|Jiangyin People's Hospital, Jiangyin, Jiangsu, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|Nantong Tumor Hospital, Nantong, Jiangsu, China|Jiangxi Provincial Tumor Hospital, Nanchang, Jiangxi, China|Jilin Province Cancer Hospital, Changchun, Jilin, China|Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China|The First Affiliated Hospital of Xi'an Jiaotong U, Xi'an, Shaanxi, China|Shandong Cancer Hospital, Jinan, Shangdong, China|527-Linyi Cancer Hospital, Linyi, Shangdong, China|Yantai Yuhuangding Hospital, Yantai, Shangdong, China|Shanghai Chest Hospital, Shanghai Jiaotong Univers, Shanghai, Shanghai, China|The Fifth People's Hospital of Shanghai, Shanghai, Shanghai, China|West China Hospital of Sichuan University, Chendu, Sichuan, China|Tianjin People's Hospital, Tianjin, Tianjin, China|Affiliated Tumor Hospital of Xinjiang Medical Univ, Ürümqi, Xinjiang, China|Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|The First Affiliated Hospital, Zhejiang University, Hanzhou, Zhejiang, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,3.12,336.395,86.88,3.0,3.0,3.0,37.16,98.02,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O,NON-SMALL CELL LUNG CANCER METASTATIC,_PLINABULIN,NCT02812667,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UC San Diego Moores Cancer Center, La Jolla, California, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,3.12,336.395,86.88,3.0,3.0,3.0,37.16,98.02,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,NON SMALL CELL LUNG CANCER,_INDOCYANINE_GREEN,NCT02570815,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",6915154,A61B5/0261,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,11.0,58.7773876260292,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.26,753.99,114.99,7.0,2.0,6.0,87.2,231.13,14.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,LUNG CANCER,_INDOCYANINE_GREEN,NCT04182152,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Shanghai Chest Hospital, Shanghai, Shanghai, China",6915154,A61B5/0261,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,58.7773876260292,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.26,753.99,114.99,7.0,2.0,6.0,87.2,231.13,14.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,URINARY RETENTION,_TAMSULOSIN,NCT03609580,Phase 1|Phase 2,Recruiting,Male,65 Years and older   (Older Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"HackensackUMC, Hackensack, New Jersey, United States",4703063,C07D203/10,0.0,0.0,1.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,27.3024086736894,325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.05,408.51199999999994,99.88,6.0,2.0,2.0,43.95,108.86,11.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,NON SMALL CELL LUNG CANCER,_MIFEPRISTONE,NCT02642939,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cooper Institute for Reproductive Hormonal Disorders, Melrose Park, Pennsylvania, United States",10500216,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,4.0,85.0,242.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.33,429.5937,40.54,3.0,1.0,5.0,50.69,132.58,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,NON SMALL CELL LUNG CANCER,_CAPMATINIB,NCT04139317,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sarah Cannon Research Institute, Nashville, Tennessee, United States|Novartis Investigative Site, Wollongong, New South Wales, Australia|Novartis Investigative Site, Shepparton, Victoria, Australia|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Ostrava Vitkovice, Czechia|Novartis Investigative Site, LILLE Cédex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Shatin, New Territories, Hong Kong|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Kuching, Sarawak, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand",WO-2008064157-A1,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,72.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.04,412.42800000000005,85.07,5.0,1.0,5.0,42.1,125.27,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,"CARCINOMA, NON-SMALL-CELL LUNG",_CAPMATINIB,NCT04427072,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Torokbalint, Pest, Hungary",WO-2008064157-A1,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,72.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.04,412.42800000000005,85.07,5.0,1.0,5.0,42.1,125.27,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C,NON SMALL CELL LUNG CANCER,_TIPIFARNIB,NCT03496766,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, A Coruña, Spain|Hospital Virgen de los Lirios, Alcoy, Alicante, Spain|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Central de Asturias, Oviedo, Asturias, Spain|ICO-Badalona, Badalona, Barcelona, Spain|ICO-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Provincial de Castellón, Castelló de la Plana, Castelló, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Universitario de la Arrixaca, El Palmar, Murcia, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Sant Joan de Reus, Reus, Tarragona, Spain|H. Universitario de Canarias, La Laguna, Tenerife, Spain|H.U.Vall D´Hebrón, Barcelona, Spain|H. Clinic i Provincial, Barcelona, Spain|Hospital de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitario de Ciudad Real, Ciudad Real, Spain|ICO Girona -H. Dr. Josep Trueta, Girona, Spain|Hospital de Jaén, Jaén, Spain|Hospital Lucus Agustí, Lugo, Spain|Hospital La Princesa, Madrid, Spain|Hospital Puerta de Hierro, Madrid, Spain|H. 12 de Octubre, Madrid, Spain|H. Carlos Haya, Málaga, Spain|H. Son Llàtzer, Palma de Mallorca, Spain|Hospital Clinico de Salamanca, Salamanca, Spain|Hospital Virgen de La Macrena, Sevilla, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|H. General U. de Valencia, Valencia, Spain|Hospital La Fe, Valencia, Spain",6545020,A61K41/0038,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,27.105279369186203,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.77,489.39599999999996,64.15,3.0,1.0,5.0,50.16,148.2,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0
C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1,NSCLC,_POZIOTINIB,NCT04402008,Phase 1|Phase 2,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Cancer Center East, Kashiwa, Chiba, Japan|Osaka City General Hospital, Miyakojima-ku, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan",WO-2008150118-A2,A61P35/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.93,491.34,76.58,6.0,1.0,4.0,48.59,124.72,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
C[S@@](=O)CCCCN=C=S,LUNG CANCER,_SULFORAPHANE,NCT03232138,Phase 2,Recruiting,All,"55 Years to 75 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States",5411986,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,14.0,25.659664469496196,283.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.24,177.28,29.43,2.0,0.0,0.0,19.12,49.57,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,NON SMALL CELL LUNG CANCER,_ENCORAFENIB,NCT03915951,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA - Westwood, Los Angeles, California, United States|UCLA Hematology/Oncology, Santa Monica, California, United States|Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, United States|The William W. Backus Hospital, Norwich, Connecticut, United States|Day Kimball Healthcare, Putnam, Connecticut, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States|Florida Cancer Specialist, Lady Lake, Florida, United States|Florida Cancer Specialists NORTH - SCRI - PPDS, Saint Petersburg, Florida, United States|Florida Cancer Specialists PAN - SCRI - PPDS, Tallahassee, Florida, United States|SCRI Florida Cancer Specialists South, Venice, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Menorah Medical Center Laboratory, Overland Park, Kansas, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Tufts University School of Medicne New England Eye Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Ophthalmic Consultants of Boston Inc, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Comprehensive Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center/East, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General/Chelsea HealthCare Center, Chelsea, Massachusetts, United States|North Shore Cancer Center, Danvers, Massachusetts, United States|Quest Diagnostics Massachusetts LLC, Marlborough, Massachusetts, United States|Tufts Medical Center at Stoneham, Stoneham, Massachusetts, United States|Tufts University School of Medicne New England Eye Center, Stoneham, Massachusetts, United States|Mass General Hospital West, Waltham, Massachusetts, United States|Centerpoint Medical Center, Independence, Missouri, United States|Sarah Cannon Cancer Center Laboratory at Centerpoint Medical Center, Independence, Missouri, United States|HCA Midwest Health - SCRI - PPDS, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center - Basking Ridge, Basking Ridge, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center - Bergen, Montvale, New Jersey, United States|Montefiore Einstein Cancer Center, Bronx, New York, United States|Montefiore Medical Center - Moses Pharmacy, Bronx, New York, United States|Motefiore Medical Center, Bronx, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering, New York, New York, United States|Weill Cornell Eye Associates, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavilion, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Ohio State University Wexner Medical Center Clinical Laboratories, Columbus, Ohio, United States|Providence Oncology and Hematology Care Clinic - Southeast, Clackamas, Oregon, United States|Providence Cancer Center Oncology and Hematology Care - Newberg, Newberg, Oregon, United States|Providence Cancer Institute, Franz Clinic, Portland, Oregon, United States|Providence Oncology and Hematology Care Clinic - Westside, Portland, Oregon, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|UPMC Eye Center, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Shadyside Hospital, Pittsburgh, Pennsylvania, United States|Weaver Eye Associates, York, Pennsylvania, United States|WellSpan Oncology Research, York, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|SCRI Tennessee Oncology- Chattanooga, Chattanooga, Tennessee, United States|Tennessee Oncology Hendersonville, Hendersonville, Tennessee, United States|Tennessee Oncology NASH - SCRI - PPDS, Nashville, Tennessee, United States|Houston Eye Associates - Gramercy Location, Houston, Texas, United States|Millennium Oncology, Houston, Texas, United States|Millenium Oncology, Shenandoah, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Ospedale di Faenza, Faenza, Emilia-romagna, Italy|Ospedale Civile Umberto I, Lugo, Emilia-romagna, Italy|Laboratorio a risposta rapida AUSL della Romagna - Ravenna, Ravenna, Emilia-romagna, Italy|Ospedale S.Maria delle Croci, Ravenna, Emilia-romagna, Italy|Ausl della Romagna Ospedale degli Infermi, Rimini, Emilia-romagna, Italy|Istituto Nazionale Dei Tumori, Milano, Lombardia, Italy|Ospedale San Raffaele S.r.l. - PPDS, Milano, Lombardia, Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale, Napoli, Naples, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Ospedale Cervesi di Cattolica, Cattolica, Rimini, Italy|Azienda Sanitaria Ospedaliera S. Luigi Gonzaga, Orbassano, Torino, Italy|Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi, Bologna, Italy|Ospedale San Raffaele S.r.l. - PPDS, Milano, Italy|Azienda Ospedale Policlinico Federico II di Napoli, Naples, Italy|National Cancer Center Clinical Pharmacy, Goyang-si, Gyeonggido, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeonnam, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center - PPDS, Seoul, Korea, Republic of|Samsung Medical Center - PPDS, Seoul, Korea, Republic of|Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Noord-holland, Netherlands|Netherlands Cancer Institute, Amsterdam, Noord-holland, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Hospital Universitario Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Madrid, Spain|Hospital Regional Universitario de Malaga - Hospital General, Malaga, Málaga, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario Vall d'Hebrón - PPDS, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|C.H. Regional Reina Sofia - PPDS, Córdoba, Spain|ICO l'Hospitalet - Hospital Duran i Reynals, Hospitalet de Llobregat, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocio - PPDS, Sevilla, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,22.0,15.310375983079734,13.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.16,540.01,140.13,7.0,3.0,3.0,54.11,145.6,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,NON SMALL CELL LUNG CANCER,_BINIMETINIB,NCT03915951,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA - Westwood, Los Angeles, California, United States|UCLA Hematology/Oncology, Santa Monica, California, United States|Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, United States|The William W. Backus Hospital, Norwich, Connecticut, United States|Day Kimball Healthcare, Putnam, Connecticut, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States|Florida Cancer Specialist, Lady Lake, Florida, United States|Florida Cancer Specialists NORTH - SCRI - PPDS, Saint Petersburg, Florida, United States|Florida Cancer Specialists PAN - SCRI - PPDS, Tallahassee, Florida, United States|SCRI Florida Cancer Specialists South, Venice, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Menorah Medical Center Laboratory, Overland Park, Kansas, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Tufts University School of Medicne New England Eye Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Ophthalmic Consultants of Boston Inc, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Comprehensive Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center/East, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General/Chelsea HealthCare Center, Chelsea, Massachusetts, United States|North Shore Cancer Center, Danvers, Massachusetts, United States|Quest Diagnostics Massachusetts LLC, Marlborough, Massachusetts, United States|Tufts Medical Center at Stoneham, Stoneham, Massachusetts, United States|Tufts University School of Medicne New England Eye Center, Stoneham, Massachusetts, United States|Mass General Hospital West, Waltham, Massachusetts, United States|Centerpoint Medical Center, Independence, Missouri, United States|Sarah Cannon Cancer Center Laboratory at Centerpoint Medical Center, Independence, Missouri, United States|HCA Midwest Health - SCRI - PPDS, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center - Basking Ridge, Basking Ridge, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center - Bergen, Montvale, New Jersey, United States|Montefiore Einstein Cancer Center, Bronx, New York, United States|Montefiore Medical Center - Moses Pharmacy, Bronx, New York, United States|Motefiore Medical Center, Bronx, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering, New York, New York, United States|Weill Cornell Eye Associates, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavilion, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Ohio State University Wexner Medical Center Clinical Laboratories, Columbus, Ohio, United States|Providence Oncology and Hematology Care Clinic - Southeast, Clackamas, Oregon, United States|Providence Cancer Center Oncology and Hematology Care - Newberg, Newberg, Oregon, United States|Providence Cancer Institute, Franz Clinic, Portland, Oregon, United States|Providence Oncology and Hematology Care Clinic - Westside, Portland, Oregon, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|UPMC Eye Center, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Shadyside Hospital, Pittsburgh, Pennsylvania, United States|Weaver Eye Associates, York, Pennsylvania, United States|WellSpan Oncology Research, York, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|SCRI Tennessee Oncology- Chattanooga, Chattanooga, Tennessee, United States|Tennessee Oncology Hendersonville, Hendersonville, Tennessee, United States|Tennessee Oncology NASH - SCRI - PPDS, Nashville, Tennessee, United States|Houston Eye Associates - Gramercy Location, Houston, Texas, United States|Millennium Oncology, Houston, Texas, United States|Millenium Oncology, Shenandoah, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Ospedale di Faenza, Faenza, Emilia-romagna, Italy|Ospedale Civile Umberto I, Lugo, Emilia-romagna, Italy|Laboratorio a risposta rapida AUSL della Romagna - Ravenna, Ravenna, Emilia-romagna, Italy|Ospedale S.Maria delle Croci, Ravenna, Emilia-romagna, Italy|Ausl della Romagna Ospedale degli Infermi, Rimini, Emilia-romagna, Italy|Istituto Nazionale Dei Tumori, Milano, Lombardia, Italy|Ospedale San Raffaele S.r.l. - PPDS, Milano, Lombardia, Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale, Napoli, Naples, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Ospedale Cervesi di Cattolica, Cattolica, Rimini, Italy|Azienda Sanitaria Ospedaliera S. Luigi Gonzaga, Orbassano, Torino, Italy|Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi, Bologna, Italy|Ospedale San Raffaele S.r.l. - PPDS, Milano, Italy|Azienda Ospedale Policlinico Federico II di Napoli, Naples, Italy|National Cancer Center Clinical Pharmacy, Goyang-si, Gyeonggido, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeonnam, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center - PPDS, Seoul, Korea, Republic of|Samsung Medical Center - PPDS, Seoul, Korea, Republic of|Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Noord-holland, Netherlands|Netherlands Cancer Institute, Amsterdam, Noord-holland, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Hospital Universitario Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Madrid, Spain|Hospital Regional Universitario de Malaga - Hospital General, Malaga, Málaga, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario Vall d'Hebrón - PPDS, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|C.H. Regional Reina Sofia - PPDS, Córdoba, Spain|ICO l'Hospitalet - Hospital Duran i Reynals, Hospitalet de Llobregat, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocio - PPDS, Sevilla, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain",7777050,C07D235/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,28.9780077619663,11.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,441.233,88.41,5.0,3.0,3.0,38.55,98.02,6.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,AIRWAY INFLAMMATION,_PREDNISONE,NCT03861390,Phase 1|Phase 2,Recruiting,All,18 Years to 45 Years   (Adult),Other|U.S. Fed,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Center for Environmental Medicine, Asthma and Lung Biology at UNC Chapel Hill, Chapel Hill, North Carolina, United States",6488960,5,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,PULMONARY ARTERIAL HYPERTENSION,_ANASTROZOLE,NCT03229499,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Stanford University, Stanford, California, United States|University of Colorado - Denver, Aurora, Colorado, United States|Johns Hopkins University, Baltimore, Maryland, United States|Washington University, Saint Louis, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, East Providence, Rhode Island, United States|Vanderbilt University, Nashville, Tennessee, United States",RE36617,C07D239/26,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,10.0,47.3438879648452,907.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.31,293.3663,78.29,4.0,0.0,2.0,31.97,97.47,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,PULMONARY ARTERIAL HYPERTENSION,_OLAPARIB,NCT03782818,Phase 1|Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alberta Hospital, Edmonton, Alberta, Canada|UHN-Toronto General Hospital, Toronto, Ontario, Canada|IUCPQ-UL, Quebec City, Quebec, Canada",7151102,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,"HYPOXIA, ALTITUDE",_ACETAZOLAMIDE,NCT04251364,Not Applicable,Recruiting,Male,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Association EXALT, UM Sport Pathologies, Hôpital Sud, Avenue Kimberley, Échirolles, France",,,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,"HYPOXIA, ALTITUDE",_ATORVASTATIN,NCT04251364,Not Applicable,Recruiting,Male,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Association EXALT, UM Sport Pathologies, Hôpital Sud, Avenue Kimberley, Échirolles, France",4681893,C07D405/06,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,"HYPERTENSION, PULMONARY",_ACETAZOLAMIDE,NCT02755298,Phase 2|Phase 3,Recruiting,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University Hospital Zurich, Zurich, Switzerland",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,NON SMALL CELL LUNG CANCER,_BRIGATINIB,NCT04074993,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of",9012462,C07F9/65717,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,72.0,70.99940450522591,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.11,584.1,85.86,9.0,2.0,5.0,64.1,164.77,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(=O)N[C@@H](CS)C(=O)O,IDIOPATHIC PULMONARY FIBROSIS,_ACETYLCYSTEINE,NCT04312594,Phase 2,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Peking Union Medical College Hospital, Beijing, Beijing, China",8148356,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,14.0,79.3116901784431,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.03,163.195,66.4,3.0,3.0,0.0,15.34,37.67,3.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
[C-]#[O+],ACUTE RESPIRATORY DISTRESS SYNDROME,_CARBON_MONOXIDE,NCT03799874,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Weill Cornell Medical College, New York, New York, United States|Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,SMALL CELL LUNG CANCER,_VENETOCLAX,NCT04422210,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|John Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Duke Cancer Institute, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|UZ Antwerpen, Edegem, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Rigshospitalet; Onkologisk Klinik, København Ø, Denmark|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|ICO I Hospitalet Hospital Duran i Reynals Instituto Catalan de Oncologia de Hospitalet ICO, L'Hospitalet de Llobregat, Barcelona, Spain|START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain",8546399,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,NON SMALL CELL LUNG CANCER,_SELINEXOR,NCT03095612,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado Cancer Center, Aurora, Colorado, United States|University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|University of Vanderbilt Medical Center-Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",9079865,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,CORONAVIRUS INFECTION,_SELINEXOR,NCT04349098,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"UCLA, Los Angeles, California, United States|Kaiser Permanente Oakland, Oakland, California, United States|UC Davis Health, Sacramento, California, United States|Kaiser Permanente Sacramento, Sacramento, California, United States|Kaiser Permanente San Francisco, San Francisco, California, United States|Miami Cancer Institute at Baptist Health, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Norton Healthcare, Louisville, Kentucky, United States|Boston Medical Center, Boston, Massachusetts, United States|Karmanos, Detroit, Michigan, United States|Michigan Center of Medical Research, Farmington Hills, Michigan, United States|Michigan Center of Medical Research, Royal Oak, Michigan, United States|Columbia University, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute-Atrium Health University City, Charlotte, North Carolina, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Baylor Scott & White Dallas, Dallas, Texas, United States|MultiCare Institute for Research & Innovation (Puget Sound), Tacoma, Washington, United States|Hospital Hietzing, 2. Medical department - Center for Diagnosis and Therapy of Rheumatic Diseases, Vienna, Austria|CHU Bordeaux, Bordeaux, France|CHU Lyon, Lyon, France|CHU Nantes, Nantes, France|Hadassah MC, Jerusalem, Israel|Hasharon Medical Center, Petah Tiqva, Israel|Sheba Medical Center, Tel HaShomer, Israel|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Servicio de Medicina Interna, Hospital Universitario de Salamanca, Universidad de Salamanca, Salamanca, Spain|Princess Royal University Hospital, Kent, United Kingdom|Kings College Hospital, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom",9079865,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,BRONCHOPULMONARY DYSPLASIA,_SILDENAFIL,NCT03142568,Phase 2,Recruiting,All,up to 28 Days   (Child),Other|NIH|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States|Wesley Medical Center, Wichita, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Ochsner Baptist Medical Center, New Orleans, Louisiana, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Children's Hospital of Nevada at UMC, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Kings County Hospital Center, Brooklyn, New York, United States|Cohen Children's Medical Center of NY, New Hyde Park, New York, United States|Golisano Children's Hospital - University of Rochester Medical Center, Rochester, New York, United States|WakeMed Health and Hospitals, Raleigh, North Carolina, United States|New Hanover Regional Medical Center, Wilmington, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States",5250534.0,C07D487/04,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,474.576,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
[Cl-].[Na+],ALLERGIC ASTHMA,_SODIUM_CHLORIDE,NCT04035109,Phase 1|Phase 2,Enrolling by invitation,All,18 Years to 45 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UNC Center for Environmental Medicine, Asthma and Lung Biology, Chapel Hill, North Carolina, United States",6248726,7,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,PULMONARY HYPERTENSION,_ALBUTEROL,NCT03270332,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pulmonary Human Research Laboratory, University of Miami, Miller School of Medicine, Miami, Florida, United States",5775321,B65D83/54,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,SMALL CELL LUNG CANCER,_RUCAPARIB,NCT03958045,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States",6495541,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,35.2204357379001,20.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.39,323.371,56.92,2.0,3.0,4.0,35.19,92.91,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,"RESPIRATORY DISTRESS SYNDROME, ADULT",_ILOPROST,NCT03111212,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Tuebingen, Tuebingen, Germany",EP-1089970-B1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,57.5289020308425,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.22,360.494,77.76,4.0,3.0,2.0,42.68,105.18,9.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.O=S(=O)(O)O,ASTHMA,_ALBUTEROL_SULFATE,NCT03847896,Phase 3,Recruiting,All,"4 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Mobile, Alabama, United States|Research Site, Costa Mesa, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, Palmdale, California, United States|Research Site, Roseville, California, United States|Research Site, Sacramento, California, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Aventura, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Green Acres, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Palmetto Bay, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, White Marsh, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, North Dartmouth, Massachusetts, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Rochester Hills, Michigan, United States|Research Site, Woodbury, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Bellevue, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Toms River, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, Monroe, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Gaffney, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Boerne, Texas, United States|Research Site, Corsicana, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sherman, Texas, United States|Research Site, Greenfield, Wisconsin, United States|Research Site, Buenos Aires, Argentina|Research Site, Tucumán, Argentina|Research Site, Brandýs Nad Labem, Czechia|Research Site, Kralupy Nad Vltavou, Czechia|Research Site, Lovosice, Czechia|Research Site, Neratovice, Czechia|Research Site, Praha, Czechia|Research Site, Rokycany, Czechia|Research Site, Varnsdorf, Czechia|Research Site, Berlin, Germany|Research Site, Dortmund, Germany|Research Site, Frankfurt am main, Germany|Research Site, Halle, Germany|Research Site, Hamburg, Germany|Research Site, Hessen, Germany|Research Site, Leipzig, Germany|Research Site, Lübeck, Germany|Research Site, Marburg, Germany|Research Site, Munich, Germany|Research Site, Neu Isenburg, Germany|Research Site, Sachsen, Germany|Research Site, Schleswig, Germany|Research Site, Wiesbaden, Germany|Research Site, Witten, Germany|Research Site, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Sremska Kamenica, Serbia|Research Site, Valjevo, Serbia|Research Site, Košice, Slovakia|Research Site, Žilina, Slovakia|Research Site, Cherkasy, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivs'k, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kherson, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Luts'k, Ukraine|Research Site, Vinnytsia, Ukraine",4409237,3,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,12.0,29.6679603277274,338.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1,"HYPERTENSION, PULMONARY",_SELEXIPAG,NCT04175600,Phase 3,Recruiting,All,2 Years to 17 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UCLA Medical Center, Los Angeles, California, United States|UCSF, San Francisco, California, United States|Childrens Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Congenital Heart Center of the University of Florida, Gainesville, Florida, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Detroit Medical Center, Detroit, Michigan, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Virginia Division of Pediatric Cardiology, Charlottesville, Virginia, United States|Queensland CHILDREN'S HOSPITAL, South Brisbane, Australia|State Institution Republican Scientific And Practical Center For Pediatric Surgery, Minsk, Belarus|Health Institution 4Th City Children'S Clinical Hospital, Minsk, Belarus|ULB Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|Complexo de Prevencao,Diagnostico,Terapia e Reabilitacao Respiratoria LTDA Hospital Dia do Pulmao, Blumenau, Brazil|Hospital Pequeno Principe, Curitiba, Brazil|Hospital de Messejana dr. Carlos Alberto Studart Gomes, Fortaleza, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Irmandade Da Santa Casa de Misericordia de Sao Paulo, Sao Paulo, Brazil|Hospital São Paulo-UNIFESP, Sao Paulo, Brazil|Multiprofile Hospital For Active Treatment National Cardiology Hospital, Ead, Sofia, Bulgaria|Hospital For Sick Children, Toronto, Ontario, Canada|Stollery Children's Hospital, Edmonton, Canada|Centre Hospitalier Sainte Justine, Montreal, Canada|Beijing Anzhen Hospital, Beijing, China|Guangdong Provincial People's Hospital, Guangzhou, China|Guangzhou Women And Children's Medical Center, Guangzhou, China|Shanghai Children's Medical Center, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China|Children's Hospital of Fudan University, Shanghai, China|The General Hospital of Northern Theater Command, Shenyang, China|Wuhan Asia Heart Hospital, Wuhan, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'An, China|Clinica San Rafael, Bogota, Colombia|Fundacion Neumologica Colombiana, Bogota, Colombia|Fundacion Santa Fe de Bogota, Bogota, Colombia|Centro Medico Imbanaco de Cali S.A., Cali, Colombia|Fundacion Cardiovascular de Colombia, Floridablanca, Colombia|Clinica Vascular las Americas, Medellin, Colombia|Hospital Universidad del Norte, Soledad, Colombia|Rigshospitalet, Copenhagen Ø, Denmark|New Children's Hospital of the Helsinki University Hospital (HUS), Helsinki, Finland|Hôpital Cardiologique - Chru Lille, Lille Cedex, France|Hopital de la Timone, Marseille Cedex 5, France|CHU Arnaud de Villeneuve, Montpellier Cedex 5, France|Hôpital Necker - Enfants Malades, Paris, France|Hôpital Cardiologique Du Haut-Lévêque, Pessac, France|Chu Hopital Des Enfants, Toulouse Cedex 9, France|Universitätsklinikum Freiburg Zentrum, Freiburg, Germany|Universitäres Herzzentrum Hamburg, Hamburg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Herzzentrum Leipzig GmbH, Leipzig, Germany|Gottsegen György Országos Kardiológiai Intézet, Budapest, Hungary|Rambam Medical Center, Haifa, Israel|Sheba Medical Center, Ramat Gan, Israel|Azienda Ospedaliera Policlinico S. Orsola-Malpighi, Bologna, Italy|Universtà Degli Studi Di Padova, Padova, Italy|Ospedale Pediatrico Bambin Gesù, Roma, Italy|AOU Città della Salute e della Scienza di Torino, Presidio Ospedale Infantile Regina Margherita, Torino, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of|Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania|National Heart Institute, Kuala Lumpur, Malaysia|CICUM San Miguel, Guadalajara, Mexico|Operadora de Hospitales Angeles SA de CV Hospital Angeles Lomas, Mexico, Mexico|Unidad de Investigacion Clinica en Medicina S.C. (UDICEM), Monterrey, Mexico|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Uniwersytecki Szpital Dzieciecy w Krakowie, Kraków, Poland|Wojewodzki Szpital Specjalistyczny we Wroclawiu, Wroclaw, Poland|Slaskie Centrum Chorob Serca, Zabrze, Poland|Hospital De Santa Marta, Lisboa, Portugal|Centro Hospitalar de São João, EPE, Porto, Portugal|Kazan State Medical University, Kazan, Russian Federation|Cardiovascular Pathology Research Institute of Siberian Branch of RAMS, Kemerovo, Russian Federation|Children's City Clinical Hospital n.a. Baslyaeva, Moscow, Russian Federation|Veltischev Research and Clinical Institute for Pediatrics of the Pirogov RNRMU, Moscow, Russian Federation|National medical Research Center n.a. V.A.Almazov of MoH of Russian Federation, Saint-Petersburg, Russian Federation|Samara Regional Clinical Cardiological Dispensary, Samara, Russian Federation|Tyumen Regional Hospital #1, Tyumen, Russian Federation|Univerzitetska Dečja Klinika, Belgrade, Serbia|Hosp. Univ. A Coruña, A Coruña, Spain|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Sant Joan de Deu, Esplugues de Llobregat, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Hosp. Virgen Del Rocio, Sevilla, Spain|Drottning Silvias barn- och ungdomssjukhus, Gothenburg, Sweden|Skanes universitetssjukhus, Lund, Sweden|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chiang Mai University Hospital, Chiang Mai, Thailand|Cukurova Balcali Hospital Application and Research Center, Adana, Turkey|Hacettepe University Medical Faculty, Ankara, Turkey|CAPA Istanbul University Medical Faculty, Istanbul, Turkey|Mehmet Akif Ersoy Training and Research Hospital, Istanbul, Turkey|Behcet Uz Pediatric Diseases and Surgery Training and Research Hospital, Izmir, Turkey|Izmir Tepecik Training and Research Hospital, Izmir, Turkey|Dnipropetrovsk clinical medical center of Mother and Child after prof. Rudnev, Dnipro, Ukraine|MI 'Dnipropetrovsk Regional Clinical Center of Cardiology and Cardiac Surgery', Dnipro, Ukraine|Scientific Practical Medical Center for Pediatric Cardiology and Cardio Surgery of the MOH, Kyiv, Ukraine|Communal Non-commercial Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital', Lviv, Ukraine|MI Zaporizhzhia Regional Clinical Children's Hospital of Zaporizhzhia Regional Council, Zaporizhzhya, Ukraine|Hanoi Medical University Hospital, Hanoi, Vietnam|Tam Duc Cardiology Hospital, Ho Chi Minh, Vietnam|Children's Hospital 1, Ho Chi Minh, Vietnam",7205302,5,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,59.7301792644612,38.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.4,496.63,101.49,7.0,1.0,3.0,54.98,136.81,11.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,RENAL INSUFFICIENCY,_APIXABAN,NCT02664155,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CH ARRAS, Arras, Boulevard Georges Besnier, France|Chu Tours, Tours, Hôpital Trousseau, France|CH d'Agen-Nérac, Agen, France|Chu Amiens, Amiens 1, France|Chu Angers, Angers 9, France|CH Besançon, Besancon, France|CHU de Bordeaux, Bordeaux, France|CHU La Cavale Blanche Brest, Brest, France|HIA de Brest, Brest, France|CHU Castelnau-le-Lez, Castelnau Le Lez, France|CH Louis Pasteur - Chartres, Chartres, France|Chu Clermont-Ferrand, Clermont-Ferrand, France|CHU Dijon, Dijon, France|Hôpital La Tronche Grenoble, Grenoble 9, France|Hôpital Charles Foix - APHP Ivry sur Seine, Ivry sur Seine, France|Chu Limoges, Limoges, France|CHU Lyon, Lyon, France|HCL - Hôpital Edouard Herriot, Lyon, France|Chu Montpellier, Montpellier 5, France|CHU de Nantes - Hôpital Bellier, Nantes, France|CHU de Nantes - Hôpital Hôtel Dieu, Nantes, France|CHU Nice, Nice, France|HEGP - APHP Paris, Paris, France|Hôpital Louis Mourier- APHP Paris, Paris, France|CHU de Rouen, Rouen, France|Chu Saint Etienne, Saint Etienne, France|Chu Strasbourg, Strasbourg, France|CH Toulon, Toulon, France|HIA de Toulon, Toulon, France|CHU Toulouse, Toulouse 9, France|CH de Valenciennes, Valenciennes, France",6413980,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,78.0,30.325058009404696,179.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.22,459.4971,110.76,5.0,1.0,5.0,49.62,126.9,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,RENAL INSUFFICIENCY,_RIVAROXABAN,NCT02664155,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CH ARRAS, Arras, Boulevard Georges Besnier, France|Chu Tours, Tours, Hôpital Trousseau, France|CH d'Agen-Nérac, Agen, France|Chu Amiens, Amiens 1, France|Chu Angers, Angers 9, France|CH Besançon, Besancon, France|CHU de Bordeaux, Bordeaux, France|CHU La Cavale Blanche Brest, Brest, France|HIA de Brest, Brest, France|CHU Castelnau-le-Lez, Castelnau Le Lez, France|CH Louis Pasteur - Chartres, Chartres, France|Chu Clermont-Ferrand, Clermont-Ferrand, France|CHU Dijon, Dijon, France|Hôpital La Tronche Grenoble, Grenoble 9, France|Hôpital Charles Foix - APHP Ivry sur Seine, Ivry sur Seine, France|Chu Limoges, Limoges, France|CHU Lyon, Lyon, France|HCL - Hôpital Edouard Herriot, Lyon, France|Chu Montpellier, Montpellier 5, France|CHU de Nantes - Hôpital Bellier, Nantes, France|CHU de Nantes - Hôpital Hôtel Dieu, Nantes, France|CHU Nice, Nice, France|HEGP - APHP Paris, Paris, France|Hôpital Louis Mourier- APHP Paris, Paris, France|CHU de Rouen, Rouen, France|Chu Saint Etienne, Saint Etienne, France|Chu Strasbourg, Strasbourg, France|CH Toulon, Toulon, France|HIA de Toulon, Toulon, France|CHU Toulouse, Toulouse 9, France|CH de Valenciennes, Valenciennes, France",7157456,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
O=C([O-])c1ccccc1-c1c2cc(Br)c(=O)c(Br)c-2oc2c(Br)c([O-])c(Br)cc12.[Na+].[Na+],CHRONIC OBSTRUCTIVE PULMONARY DISEASE,_EOSIN,NCT04008017,,Recruiting,All,"Child, Adult, Older Adult",Other,Observational Model: Other|Time Perspective: Cross-Sectional,"Assiut Faculty of Medicine, Assiut, Egypt",3932356,C08F2/46,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,37.4217129715189,1701.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.12,691.8589999999997,89.49,5.0,0.0,4.0,46.14,155.26,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,ACUTE ASTHMA,_BUDESONIDE,NCT04016220,Phase 1,Recruiting,All,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Monastir, Monastir, Tunisia",6123924,A61K9/008,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0
[C-]#[O+],SMOKING CESSATION,_CARBON_MONOXIDE,NCT03059940,Early Phase 1,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1,HEART FAILURE|CARDIOMYOPATHY,_MILRINONE,NCT02077010,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Kansas Medical Center, Kansas City, Kansas, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",4313951.0,C07D213/75,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,15.4417955194151,576.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.04,211.2194,65.78,3.0,1.0,2.0,21.46,61.14,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
FCOC(C(F)(F)F)C(F)(F)F,HEART DISEASE,_SEVOFLURANE,NCT03569085,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States",5990176,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
FC(F)OC(Cl)C(F)(F)F,HEART DISEASE,_ISOFLURANE,NCT03569085,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.3,184.49200000000002,9.23,1.0,0.0,0.0,9.73,23.04,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,NASAL POLYPS,_FUROSEMIDE,NCT03362515,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Thomas Jefferson University Department of Otolaryngology, Philadelphia, Pennsylvania, United States",3939713,G01N30/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,11.8606131542742,1299.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.71,330.744,122.63,5.0,3.0,2.0,30.55,77.47,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],PULMONARY EMBOLISM,_FERUMOXYTOL,NCT03173066,Phase 1,Enrolling by invitation,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Brigham and Women's Hospital, Boston, Massachusetts, United States",6599498,B82Y5/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0
[133Xe],CHRONIC OBSTRUCTIVE PULMONARY DISEASE,_XENON-133,NCT03331302,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Virginia Health System, Charlottesville, Virginia, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,132.9059,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CNCC[C@@H](Oc1ccccc1C)c1ccccc1,SLEEP APNEA,_ATOMOXETINE,NCT03919955,Phase 1|Phase 2,Recruiting,All,"21 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Brigham and Women's Hospital, Boston, Massachusetts, United States",5658590.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,31.2449947637528,104.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.95,255.3547,21.26,2.0,1.0,2.0,29.79,79.44,6.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1,SLEEP APNEA,_OXYBUTYNIN,NCT03919955,Phase 1|Phase 2,Recruiting,All,"21 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Brigham and Women's Hospital, Boston, Massachusetts, United States",5164190,A61K9/7061,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,22.0,23.228403047290502,333.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.36,357.4864,49.77,3.0,1.0,2.0,41.25,105.26,10.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,"SLEEP APNEA, OBSTRUCTIVE",_ATORVASTATIN,NCT03308578,Phase 1|Phase 2,Enrolling by invitation,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Mayo Clinic in Rochester, Rochester, Minnesota, United States",4681893,C07D405/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,OBSTRUCTIVE SLEEP APNEA OF ADULT,_ATORVASTATIN,NCT03122639,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Columbia University Medical Center, New York, New York, United States",4681893,C07D405/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,"SLEEP APNEA, OBSTRUCTIVE",_MONTELUKAST,NCT03545997,Phase 3,Recruiting,All,"45 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Hospital, Bron, France|Métropole Savoie Hospital, Chambéry, France|University Hospital, Clermont-Ferrand, France|University Hospital Grenoble, Grenoble, France|University Hospital, Grenoble, France|Annecy Genevois Hospital, Metz-Tessy, France|University Hospital, Pierre-Bénite, France|University Hospital, Saint-Étienne, France",8007830.0,A61K9/1623,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,CANCER,_ERLOTINIB,NCT02714530,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oslo University Hospital, Oslo, International/Other, Norway|St Olavs Hospital, Trondheim, Norway",5747498,C07D491/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CN[C@]1(c2ccccc2Cl)CCCCC1=O,BIPOLAR DEPRESSION,_ESKETAMINE,NCT03965871,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Wojewodzki Szpital im. Jana Pawła II, Belchatow, Poland|Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych, Boleslawiec, Poland|Samodzielny Publiczny Psychiatryczny Zaklad Opieki Zdrowotnej, Choroszcz, Poland|Szpital Miejski, Elblag, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Gornoslaskie Centrum Medyczne, Katowice, Poland|Specjalistyczny Psychiatryczny Zespol Opieki Zdrowotnej, Lodz, Poland|Podhalanski Szpital Specjalistyczny im. Jana Pawła II, Nowy Targ, Poland|Pabianickie Centrum Medyczne, Pabianice, Poland|Mazowieckie Specjalistyczne Centrum Zdrowia, Pruszkow, Poland|Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych, Swiecie, Poland|Mazowiecki Szpital i Centrum Diagnostyczne Allenort, Warsaw, Poland|Uniwersytecki Szpital Kliniczny, Wroclaw, Poland",8785500,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,18.0,88.08394422883421,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.73,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,SLEEP APNEA,_OXYTOCIN,NCT02564068,Early Phase 1,Enrolling by invitation,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GW-Medical Faculty Associates, Washington, District of Columbia, United States",3943246,A61K38/095,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,18.3658802028789,1710.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,CANCER,_GEFITINIB,NCT02929693,Phase 3,Enrolling by invitation,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,5457105.0,C07D239/94,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,14.2590196923961,1102.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,446.902,68.74,7.0,1.0,4.0,46.11,117.51,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1,PSYCHOMOTOR AGITATION,_LOXAPINE,NCT03513549,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Observational Model: Cohort|Time Perspective: Prospective,"Pharmaceutical Research Associates, Inc, Raleigh, North Carolina, United States",7537009.0,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,33.0,84.4370520955255,687.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.18,327.80800000000005,28.07,3.0,0.0,4.0,34.99,95.11,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CCN(CC)CC(=O)Nc1c(C)cccc1C,COUGH,_LIDOCAINE,NCT03805282,Phase 3,Recruiting,All,"18 Years to 120 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Hospital Universitario de Brasilia, Brasília, Distrito Federal, Brazil",5234957.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O,COUGH,_ATP,NCT03722849,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"The University of Melbourne, Parkville, Victoria, Australia",3933594.0,G01N33/525,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,17.150249491775998,2074.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.84,507.181,279.13,14.0,7.0,3.0,38.92,95.81,8.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,COUGH,_CAPSAICIN,NCT03722849,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"The University of Melbourne, Parkville, Victoria, Australia",6239180,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,COUGH,_ADENOSINE,NCT03722849,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"The University of Melbourne, Parkville, Victoria, Australia",5731296,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,60.2887122938869,1415.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.2,267.2413,139.54,8.0,4.0,3.0,25.28,63.2,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,COVID-19,_DAPAGLIFLOZIN,NCT04350593,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Heart Group of the Eastern Shore, Fairhope, Alabama, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Loyola University, Maywood, Illinois, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Mid America Heart Institute, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Jacobi Medical Center, Bronx, New York, United States|St. Francis Hospital, Roslyn, New York, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Sentara Healthcare, Norfolk, Virginia, United States|Centro de Pesquisa Dr. Marco Mota, Maceió, Alagoas, Brazil|Hospital Cárdio Pulmonar, Salvador, Bahia, Brazil|Hospital de Messejana dr Carlos Alberto Studart Gomes, Fortaleza, Ceará, Brazil|Hospital Coração do Brasil, Brasília, Distrito Federal, Brazil|Hospital Estadual Jayme dos Santos Neves, Serra, Espírito Santo, Brazil|Santa Casa de Misericórdia de Passos, Passos, Minas Gerais, Brazil|PROCAPE, Recife, Pernambuco, Brazil|Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, Rio Grande Do Sul, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, Santa Catarina, Brazil|Centro de Pesquisa Clínica do Coração, Aracaju, Sergipe, Brazil|Faculdade de Medicina de Botucatu, UNESP, Botucatu, São Paulo, Brazil|Instituto de Pesquisa Clínica de Campinas, Campinas, São Paulo, Brazil|Centro Integrado de Pesquisas, São José do Rio Preto, São Paulo, Brazil|Fundação Pio XII, Barretos, Brazil|Hospital Moriah, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil",6956026,A61K47/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O,COUGH,_GEFAPIXANT,NCT04193176,Phase 3,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Center for Clinical Trials, LLC ( Site 0021), Paramount, California, United States|Health Awareness, Inc. ( Site 0038), Jupiter, Florida, United States|Well Pharma Medical Research, Corp. ( Site 0040), Miami, Florida, United States|Lenus Research & Medical Group Llc ( Site 0007), Sweetwater, Florida, United States|Florida Pulmonary Research Institute, LLC ( Site 0008), Winter Park, Florida, United States|Paul A. Shapero, MD ( Site 0037), Bangor, Maine, United States|Chesapeake Clinical Research, Inc ( Site 0022), White Marsh, Maryland, United States|University of Missouri ENT & Allergy Center ( Site 0010), Columbia, Missouri, United States|Alliance for Multispecialty Reseach, LLC ( Site 0035), Las Vegas, Nevada, United States|Albuquerque Clinical Trials ( Site 0019), Albuquerque, New Mexico, United States|American Health Research ( Site 0027), Charlotte, North Carolina, United States|Clinical Research of Gastonia ( Site 0016), Gastonia, North Carolina, United States|PMG Research of Wilmington ( Site 0004), Wilmington, North Carolina, United States|Temple University ( Site 0003), Philadelphia, Pennsylvania, United States|AAPRI Clinical Research Institute ( Site 0031), Warwick, Rhode Island, United States|Diagnostics Research Group ( Site 0013), San Antonio, Texas, United States|TPMG Clinical Research ( Site 0025), Newport News, Virginia, United States|Tidewater Physician Multispecialty Group, PC ( Site 0028), Williamsburg, Virginia, United States|Bellingham Asthma & Allergy ( Site 0006), Bellingham, Washington, United States|Centro Medico Dra De Salvo ( Site 0300), Buenos Aires, Argentina|Investigaciones en Patologias Respiratorias ( Site 0302), Tucuman, Argentina|Fundacion Centro de Investigacion Clinica CIC ( Site 0401), Medellin, Antioquia, Colombia|Universidad Pontificia Bolivariana - Clinica Universitaria Bolivariana ( Site 0408), Medellin, Antioquia, Colombia|Medplus Medicina Prepagada ( Site 0402), Bogota, Distrito Capital De Bogota, Colombia|Praxis Dr. Wehgartner-Winkler ( Site 0906), Augsburg, Bayern, Germany|Zentrum fuer ambulante pneumologische Forschung Marburg GbR ( Site 0900), Marburg, Hessen, Germany|Ballenberger Freytag Wenisch Institut fuer klinische Forschung GmbH ( Site 0905), Neu-Isenburg, Hessen, Germany|Pneumologicum im Suedstadtforum ( Site 0908), Hannover, Niedersachsen, Germany|Bethel Soluciones Medicas S.A. ( Site 0506), Guatemala, Guatemala|Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0500), Guatemala, Guatemala|Clinica Medica Especializada en Neumologia y Tisiologia ( Site 0504), Guatemala, Guatemala|Clinica Medica Especializada en Neumologia ( Site 0502), Guatemala, Guatemala|Private Clinic ( Site 0505), Guatemala, Guatemala|Clinica Privada Dr. Jose Francisco Flores Lopez ( Site 0503), Guatemala, Guatemala|Kaplan Medical Center ( Site 1103), Rehovot, HaMerkaz, Israel|Chaim Sheba Medical Center ( Site 1101), Ramat Gan, Tel Aviv, Israel|Sourasky Medical Center ( Site 1100), Tel-Aviv, Tell Abib, Israel|Shaare Zedek Medical Center ( Site 1107), Jerusalem, Yerushalayim, Israel|Hadassah Ein Karem Jerusalem ( Site 1108), Jerusalem, Yerushalayim, Israel|Rabin Medical Center ( Site 1102), Petah Tikva, Israel|Carmel Medical Center ( Site 1104), Haifa, Ḥeifā, Israel|Chonbuk National University Hospital ( Site 1507), Jeonju-si, Jeonrabugdo, Korea, Republic of|Wonju Severance Christian Hospital ( Site 1502), Wonju-si, Kang-won-do, Korea, Republic of|The Catholic University of Korea Eunpyeong St Mary s Hospital ( Site 1506), Seoul, Korea, Republic of|Konkuk University Medical Center ( Site 1504), Seoul, Korea, Republic of|Asan Medical Center ( Site 1505), Seoul, Korea, Republic of|Clinica Ricardo Palma ( Site 0601), San Isidro, Lima, Peru|Asociacion Civil por la Salud ( Site 0602), Lima, Peru|Hospital Nacional Arzobispo Loayza ( Site 0607), Lima, Peru|Clinica Belen ( Site 0604), Piura, Peru|RSBHI Belgorod regional clinical hospital of Prelate Ioasafa ( Site 1416), Belgorod, Belgorodskaya Oblast, Russian Federation|GBUZ Regional Clinical Hospital 3 ( Site 1420), Chelyabinsk, Chelyabinskaya Oblast, Russian Federation|City Clinical Hospital No. 3 them. M. A. Podgorbunskogo ( Site 1400), Kemerovo, Kemerovskaya Oblast, Russian Federation|Clinic of FSBEI HE OmSMU of Minzdrav ( Site 1438), Omsk, Omskaya Oblast, Russian Federation|Perm Clinical Center of the Federal Medical and Biological Agency ( Site 1450), Perm, Permskiy Kray, Russian Federation|SEIHPE Saint Petersburg SMU ( Site 1434), Saint Petersburg, Sankt-Peterburg, Russian Federation|Limited Liability Company Kurator ( Site 1424), St. Petersburg, Sankt-Peterburg, Russian Federation|Saratov City Clinical Hospital 2 n.a. V.I. Razumovsky ( Site 1452), Saratov, Saratovskaya Oblast, Russian Federation|State health Agency Ulyanovsk regional clinical hospital ( Site 1414), Ulyanovsk, Ul Yanovskaya Oblast, Russian Federation|Voronezh Regional Clinical Hospital #1 ( Site 1440), Voronezh, Voronezskaja Oblast, Russian Federation|SBCIH of the Yaroslavl region Central city hospital ( Site 1428), Yaroslavl, Yaroslavskaya Oblast, Russian Federation|Hospital Clinico Universitario de Santiago ( Site 1805), Santiago de Compostela, La Coruna, Spain|Hospital General Universitario Gregorio Maranon ( Site 1808), Madrid, Madrid, Comunidad De, Spain|SE Road Clinical Hospital 2 of Kyiv station ( Site 2812), Kyiv, Kyivska Oblast, Ukraine|F.G.Yanovskyy Institute of Phthisiology and Pulmonology ( Site 2808), Kyiv, Kyivska Oblast, Ukraine|F.G.Yanovskyy Institute of Phthisiology and Pulmonology ( Site 2819), Kyiv, Kyivska Oblast, Ukraine|Odesa regional clinical hospital ( Site 2804), Odesa, Odeska Oblast, Ukraine|City Polyclinic N20 ( Site 2806), Odesa, Odeska Oblast, Ukraine|Poltava City Clinical Hospital -1 ( Site 2813), Poltava, Poltavska Oblast, Ukraine|Private Small-Scale Enterprise Medical Centre ""Pulse"" ( Site 2809), Vinnytsya, Vinnytska Oblast, Ukraine|Volyn Regional Clinical Hospital ( Site 2816), Lutsk, Volynska Oblast, Ukraine|Medical Center of LLC Medical Clinic Blahomed ( Site 2815), Kyiv, Ukraine|Medinova North London Dedicated Research Centre ( Site 2705), Northwood, England, United Kingdom|GP Direct ( Site 2714), Harrow, London, City Of, United Kingdom|Medinova Lakeside Dedicated Research Centre ( Site 2712), Corby, Northamptonshire, United Kingdom|West Walk Surgery ( Site 2700), Yate, South Gloucestershire, United Kingdom|Kings College Hospital NHS Foundation Trust ( Site 2702), London, Southwark, United Kingdom|Medinova Warwickshire Dedicated Research Centre ( Site 2715), Kenilworth, Warwickshire, United Kingdom",7858632,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,30.0,69.8494835622907,7.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.87,353.4,156.44,7.0,3.0,2.0,34.62,91.44,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0
COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O,CHRONIC COUGH,_GEFAPIXANT,NCT04525885,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","The First Affiliated Hospital of Fujian Medical University ( Site 5017), Fuzhou, Fujian, China|The First Affiliated Hospital of Guangzhou Medical University ( Site 5000), Guangzhou, Guangdong, China|Inner Mongolia Autonomous Region Hospital ( Site 5018), Hohhot, Inner Mongolia, China|The First Affiliated Hospital of Nanchang University ( Site 5012), Nanchang, Jiangxi, China|ShengJing Hospital of China Medical University ( Site 5024), Shenyang, Liaoning, China|Shanghai General Hospital ( Site 5010), Shanghai, Shanghai, China|The First Affiliated Hospital of Zhejiang University ( Site 5014), Hangzhou, Zhejiang, China|Peking University Third Hospital ( Site 5005), Beijing, China",7858632,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,30.0,69.8494835622907,7.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.87,353.4,156.44,7.0,3.0,2.0,34.62,91.44,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0
